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ABSTRACT 
 
Cell culture of chondrocytes, either in an experimental or industrial setting, typically 
rely on an invariant feeding strategy. The contribution of each component of the total 
expansion regime to the behaviour of the cells been expanded are not fully understood. It can 
be argued that to fully realise the potential of cell-based therapies, the exact contribution of 
the various expansion parameters to growth rate, metabolic behaviour and cell phenotype 
need to be intimately understood. 
 The studies in this thesis aim to better inform the nutritional aspects of future cell 
manufacturing strategy by; uncovering the contribution of critical culture parameters to 
growth rate and phenotype, understanding the relationship of any interactions that may exist 
between components and how these components may influence the culture as a function of 
time. 
 Results from the various studies demonstrated that an isolated subpopulation of 
chondrocytes can be sustained under serum-free conditions that promote SOX-9 transcript 
expression while returning growth rates similar to that found using serum-based medium. The 
contribution of the medium components, seed density and adhesion protein concentration to 
growth rate, metabolic behaviour and SOX-9,6 & 5 transcript expression were quantified 
using a statistically designed experiment. Two factors from the experiment, EGF and FGF-2, 
were taken forward and their effects on growth rate and gene expression as a function of time 
were investigated. The findings revealed that the exact timing of the introduction of the 
proteins into the culture medium had a marked impact on cell growth and gene expression.  
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INTRODUCTION 
 
Injuries to articular cartilage are a particular nuisance due to the tissue’s extremely 
limited capacity for self-repair. Acute injury to the cartilage can result in poor mechanical 
function of the affected joint and be the starting point for a progressive deterioration that can 
result in osteoarthritis. Osteoarthritis (OA) can be characterised by the gradual loss of hyaline 
cartilage from the joint surface, which exposes the underlying bone resulting in poor joint 
function and chronic pain. The occurrence of OA correlates with age (Arden and Newitt, 
2006, A S Anderson and R F Loeser, 2010). From a health economics standpoint, this 
correlation is of grave concern as today's increasingly ageing demographic means the 
prospective number of people that may require an intervention has yet to reach its peak (P M 
Brooks, 2002). It is envisaged that OA will contribute a considerable burden to national 
GDPs and as such, there is an economic precedent for a sustained research effort into 
improving existing treatments and the inception of novel strategies that can effectively 
remedy significant cartilage injuries and arthritic joints. 
 
A strong evidence base exists that demonstrates the role transplanted articular 
chondrocytes, the cells responsible for producing cartilage matrix; play in the regeneration of 
articular cartilage (Brittberg et al., 1994, T Minas, 2005). Cell therapies based on the concept 
of autologous chondrocyte implantation (ACI) are an established practice for the treatment of 
chondral injuries. Further value of chondrocytes lies in their ability to produce tissue 
engineered constructs (Yu Liu et al., 2017). Engineered cartilage may be of high value not 
just in the direct treatment of cartilage injury but also in providing a realistic animal model 
alternative for the testing of future repair strategies. Strengthening the value proposition 
presented by chondrocyte based cell therapies is the notion that chondrocytes may possess, to 
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some extent, an immune privileged status. Uncertainty remains over whether chondrocytes 
are immune privileged on a cellular level or rather just that the cellular immunological 
features are shielded by the formation of a matrix  (S. Gortz and W.D Bugbee 2006., S 
Moskalewski et al., 2002 and A Poggi et al., 2016). In any case, the door to a new generation 
of allogeneic chondrocyte based treatments, be it cellular or tissue engineered, remains open 
and offers one such avenue for future joint care strategies.   
 
  One major problem that hampers the full potential of ACI and tissue engineered 
cartilage is that chondrocytes rapidly lose their phenotype during ex vivo expansion.  To date, 
the ex vivo expansion conditions used to culture chondrocytes is heavily reliant on fetal calf 
serum. Fetal calf serum is a cocktail of proteins that includes Fibronectin, TGFβ1, FGF, IGF-
1 in lot dependent concentrations (Zheng et al., 2006). The use of serum is at odds, due to its 
variable nature, with the demand for a highly characterised and controlled manufacturing 
process that is required for the delivery of large volumes of “quality” cells. Quality in relation 
to therapeutic cells is, arguably, an abstract concept. One facet of quality specific to 
chondrocyte expansion might be broadly summarised as the preservation of key 
chondrogenic genes that allow the cell to efficiently produce the cartilage matrix. Expansion 
of chondrocytes in serum and on tissue culture plastic leads to a dedifferentiated gene 
expression profile (P D Benya et al., 1982) that cannot support the production of matrix 
appropriate to its physiological task. Work has been done to address this by promoting 
chondrocyte growth and critical gene maintenance with serum-free medium formulations 
(Malpeli et al., 2004, P Giannoni et al., 2005). However, serum-free medium do not appear to 
feature routinely in experimental or clinical expansion protocols. Speculatively, this is due to 
the large cost associated with using a defined medium. The general approach to limit the loss 
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of phenotype is to either limit the expansion stage or to include a redifferentiation step in the 
form of pellet or scaffold culture after a period of expansion in serum-based medium. 
 
To fully realise the potential of the role of chondrocytes in cartilage repair, be it as 
part of a cell-based intervention or as a tissue engineered construct, large numbers of 
phenotypically desirable cells that can be delivered cost-effectively is required. To achieve 
this elucidation of the key parameters in the nutritional regime that impact the phenotype 
during the ex vivo expansion are required and will be investigated in this thesis. Of key 
interest is how the time-modulated delivery of components may influence the phenotype and 
rate of proliferation while offering up the opportunity to utilise expensive recombinant 
medium components more cost-effectively.  
It is envisaged that the findings presented here will contribute the creation of a time-
resolved operating space that would be under the tight control of the user. In turn, this 
endeavour could augment established cell therapy processes that utilise viable chondrocytes, 
aid in the development of tissue-engineered constructs and inform novel and efficient 
methods of cell expansion in the future. 
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CHAPTER A: BACKGROUND 
 
1.0 Cartilage 
 
 Hyaline cartilage is a tissue that covers a number of joint interface surfaces and is 
histologically distinct from the two other forms of cartilage – Fibrocartilage, a tough fibrous 
tissue found in knee joint menisci and intervertebral discs (M Benjamin and E J Evans, 1990) 
and elastic cartilage which contains a elastin giving it a flexible property (R W Cox and M A 
Peacock, 1977). Hyaline cartilage has a glassy blue appearance when fresh and is, in essence, 
a biphasic material - a porous structure with an interstitial fluid that gives it an elastic sponge-
like property. These intrinsic properties make the tissue well adapted to handling the 
compressive loading and shear stresses that are felt at the joint interfaces. Furthermore, the 
biphasic nature of hyaline cartilage also contributes to the near frictionless movement 
between articulating surfaces (J Buckwalter et al., 1997). The work herein is concerned with 
hyaline cartilage of the articular zones and as such the term “cartilage” will refer solely to the 
hyaline variant unless otherwise stated. The resistance of hyaline cartilage to wear incurred in 
daily life is quite remarkable, especially when considering man-made biomaterials used in 
total arthroplasty (joint replacement) typically start to fail after ten years (D W Murry et al., 
1993). This remarkable resistance profile is marred only by the tissues extremely limited 
capacity to regenerate from injury. This ultimately means that what starts as a minor acute 
cartilage injury can in some instances slowly progress towards more serious levels of 
degeneration which can bring with it life-changing implications (Caldwell and Wang, 2015). 
          Cartilage is composed mainly of water, somewhere between 60-80%, with the rest of 
the matrix accounted for by the extracellular matrix (ECM) - a mix of proteoglycans, link 
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proteins, type II collagen and other more negligible, but perhaps not insignificant components 
(P A Torzilli, 1985). The finer details of these components are outlined in Table 1. The 
dominating proteoglycan of hyaline cartilage is aggrecan, a large aggregating glycoprotein 
that contains within its superstructure regions of negatively charged glycosaminoglycans 
(GAGs) (Fig.1). These GAGs serve to attract physiological cations to the anionic regions in 
order to negate any net charge. In doing so a large osmotic gradient is created, allowing the 
movement of water into the matrix. The collagen fibres give a degree of support to the 
cartilage matrix, resisting the swell pressure created by the water content (Riesle et al., 1998, 
E Han et al., 2011). The collagen fibril network serves to keep the negative charges of the 
GAGs at a fixed distance apart. The absence of collagen would mean the electron-electron 
repulsion would alter the fixed charge density and ultimately alter the physical properties of 
the cartilage.  The intricate organisation of the collagen fibrils differs by zones (Fig.2) and 
adds a depth of architectural complexity to the tissue (N Cohen et al., 1998). The exact 
composition as outlined in table 1 reportedly differs slightly between species, for example, 
unpublished data by J Rieppo and colleagues suggested bovine cartilage has a slightly lower 
total proteoglycan content when compared to a human. 
 
 
 
 
 
 
 
Matrix Component Contribution 
Water ~60-85% 
Collagen II ~10-30% 
I,III,VI,IX,X 
,XI 
*** < 5% 
cumulative 
 
 
Proteoglycan  
 
 
 
Aggrecan 3-10% 
Versican  
 
*** < 5% 
cumulative 
Decorin 
Lumican 
Fibromodulin 
Biglycan 
Link Protein Negligible 
Hyaluronan (HA) Negligible 
COMP Negligible 
 
Table 1. General Composition of Cartilage  
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Figure 2. General superstructure and organisation of cartilage. The absolute thickness of the cartilage is related to 
the joint of which it belongs and can vary between 1 and 6mm (D Shepherd and B Seedhom, 1999). Image taken 
from C V N Pullicino and J B Richardson, Basic Science for FRCS. p95) 
Figure 1. The chemical structures of the two glycosaminoglycans present in the proteoglycan aggrecan: 
chondroitin-6-sulphate (left) and keratin sulphate (right). Represented bottom is a section of an aggrecan chain that 
depicts the role of other molecules such as hyaluronic acid 
 
 7 
 
The cartilaginous matrix is maintained by the chondrocyte.  The chondrocyte is 
responsible for producing the components outlined in Table 1 as well as catabolic proteins 
that regulate normal matrix turnover (B J Rose and D L Kooyman, 2016). Although the 
chondrocyte is often regarded as the sole cell type present in cartilage, it should be noted that 
the cell fulfils different functions based on the region of cartilage it resides in. In recent years, 
a growing evidence base indicates that there is a distinct progenitor subpopulation present in 
the cartilage with more mesenchymal-like properties (G P Dowthwaite et al., 2004., R 
Williams et al., 2010., DD Campbell and M Pei, 2012). It is suggested that these progenitors 
reside in the top resting layer of cartilage (“STZ," fig.1). Below the top superficial zone is the 
midzone that contains rounded proliferating chondrocytes that organise into columns. The 
proliferating column chondrocytes give way to the pre-hypertrophic and hypertrophic 
chondrocytes of the deep zone. The fully differentiated hypertrophic chondrocytes have a 
markedly different gene expression profile to that of resting and proliferating chondrocytes. 
Terminally differentiated chondrocytes create a pro bone forming environment which results 
in the calcified cartilage region denoted by the “tidemark” (L Yang et al. 2014). The 
contribution of chondrocytes from these different regions to the success of ACI interventions 
is not yet clear, but further research will likely aid in informing future cartilage repair 
therapies (C R Chu and N Friel, 2012).  
The matrix environment where the chondrocyte resides is avascular and so nutritional 
sustenance is thought to be provided largely by diffusion from the surrounding synovial fluid. 
Subsequently, chondrocytes are thought accustomed to a low oxygen environment of between 
0.5 and 5 % (C T Brighton and R B Heppenstall, 1978). This correlates with a relatively low 
base rate of metabolism. For example, complete collagen II matrix turnover in humans is 
thought to take approximately four hundred years which explains in part why the tissue has 
extremely limited capacity to recover from injury (A Maroudas, 1979).  With this stated it is 
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perhaps unclear why chondrocyte implantation is sometimes successful in regenerating 
hyaline-like cartilage as the technique does not typically stimulate a significant bleed or 
access the mesenchymal niche of the subchondral bone which are thought to be factors in 
traditional wound regeneration. 
 
2.0 Chondral Disorders  
 
2.1 Osteoarthritis: 
 
 Osteoarthritis (OA) is a disease that afflicts the articulating joints of a range of 
species. It can be broadly characterised by the progressive degeneration of the hyaline 
cartilage that covers the joint ends combined with the general narrowing of joint spaces and 
the formation of small boney growths known as osteophytes (JH Kellgren and J S Lawrence, 
1954). Associated with the above radiological characteristics is the manifestation and 
emergence of the clinical symptoms; chronic pain reduced joint mobility and an overall 
reduction in quality of life (J W P Michael et al., 2010). The risk factors that determine the 
likelihood of developing OA are not entirely clear but thought to be the result of the 
convergence of several factors that include genetic predisposition, lifestyle, and gait 
alteration (V N P Cassar and J B Richardson, 2004).  The occurrence of OA generally 
correlates with age, although OA is not exclusive to the elderly (NICE, 2008). From a health 
economics standpoint, this correlation is compounded by an increasingly ageing demographic 
which ultimately means the prospective number of people that will require treatment has yet 
to peak. Current available estimates put the cost of OA in the UK at 1% of GDP (NICE, 
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2008) and it is envisaged that OA will contribute a considerable burden to national GDPs 
worldwide and as such, there is an economic precedent for a sustained research effort.   
 To date, there is little in the way of effective treatment for OA, with current strategies 
either based around palliative management or arthroplasty (joint replacement or 
resurfacement). The success in improving quality of life with joint replacement surgery is 
contradicted in part by the high cost, demand for expert professionals and the limited half-life 
of the implants. The lifespan of implants is a particularly troubling factor for younger patients 
requiring total arthroplasty as each successive revision increases the incidence of 
complication (K L Ong et al., 2010). These drawbacks ultimately raise questions over the 
sustainability of conventional OA treatment strategy as demand rises. With the 
acknowledgement that OA is a condition that presents without a single exclusive pathology, it 
is perhaps conceivable that its effective alleviation or indeed prevention may arrive in the 
form of a combination treatment (P Sarzi-Puttini et al., 2005). Effective treatment regimes 
that address pathologies relating to altered gait, muscular atrophy, bone changes, hyperplasia 
of the synovial membrane, morphological changes to the joint capsule and degradation of the 
hyaline cartilage will all likely to play a part in the restoration of normal joint function. 
Arguably, the role of cartilage in OA is the most scrutinised and the depth of literature in the 
field will aid in the development of strategies and interventions aimed at reversing localised 
chondral injuries. 
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2.2 Cartilage lesions and Osteochondritis dissecans (OCD) of the knee 
 
 Defects of the knee joint that can contribute to the development of OA, as eluded to 
earlier, are numerous and subject to debate. Events such as ligament tears, particularly 
damage to the anterior cruciate ligament and fractures of the surrounding bone, damage to the 
meniscal cartilage (M Englund et al., 2009) can lead to abnormal gait. Alterations to the 
normal pattern of movement are thought to be a possible contributor to early-stage OA ( M 
Henriksen et al., 2010). The mechanism for this is not immediately clear, but one train of 
thought is that areas of cartilage experience compression and sheer from loading they have 
not been conditioned to. Changes to natural gait undoubtedly play a significant role in disease 
progression and as such comprehensive treatment packages may need to address a certain 
biomechanical component rather than be solely focused on treatment of the hyaline and bone 
surfaces. 
  A second recognised contributing factor is direct tissue injury to the cartilaginous 
surface, either acutely or through an underlying pathology. Injuries of this nature can broadly 
be separated into OCD or cartilage lesions with the latter being the more common. 
Classification of cartilage lesions and OCD are outlined in Figure 4, A and B, respectively. A 
cartilage lesion is an area that presents itself as abnormal upon arthroscopic investigation or 
MRI. OCD is a pathologically distinct occurrence where the articular cartilage and 
subchondral bone separate from the surface of the joint. The condition is thought to be caused 
by avascular necrosis of the underlying subchondral bone which in turn disrupts the articular 
cartilage (L Peterson et al., 2003). Both articular cartilage lesions and OCD are good 
candidates for cell-based therapies, and such practices already form part of adopted practices.  
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3.0 Efficacy Endpoints  
 
Fundamental to evaluating an intervention is the recognition of appropriate 
measurement systems that are capable of quantifying efficacy. Historically this has been 
accomplished using clinical examination, imaging scans and biopsy analysis. While these 
measurements are still of great significance, they do not always correlate with the patient's 
perception of the outcome. As a result, there has been a shift to patient administered reporter 
systems. These systems are concerned with comparing aspects such as perception of pain, 
Figure 4. (A) ICRS Grade 1: Superficial lesions. Soft indentation (A) and/or superficial fissures and cracks 
(B), ICRS Grade 2: Lesions extending down to less than 50% of cartilage dept., ICRS Grade 3. Cartilage 
defects down to greater than 50% of cartilage depth (A) as well as down to the calcified layer (B) and 
down but not through the subchondral bone (C)., Blisters (D)., ICRS Grade 4. Penetration of subchondral 
bone (A & B). (B) OCD I. Stable, continuity: Softened area covered by intact cartilage. OCD II. Partial 
discontinuity, stable on probing. OCD III. Complete discontinuity, “dead in situ”, not dislocated. OCD IV. 
Dislocated fragment, loose within bed or empty defect. Images replicated from ICRS evaluation form 
without permission. 
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joint function and quality of life preoperatively versus postoperatively / follow up.  The 
grading systems allow for a useful basis to establish a baseline from which interventions can 
be evaluated for efficacy. Advocates of such systems point out that they are less prone to 
potential systematic bias that can creep in if the administration is dealt with exclusively on 
the clinical end (M E Roos et al., 1998).  
 The International Cartilage Repair Society (ICRS) is a forum that brings together 
practising clinicians, research clinicians and research scientists who are involved in cartilage 
research and repair. The combined expert input to the forum has perhaps, not surprisingly, 
yielded numerous useful outputs. One such output is the appointment of a widely adopted 
evaluation system for grading defects of the knee and evaluating post-operative repair 
success. This is known as the ICRS cartilage injury evaluation package (Table 2) and 
includes both subjective patient self-assessment forms and an objective professional 
assessment (H Hauselmann et al., 2000). The patient administered section, however, is not 
universally employed and there are numerous other subjective measurement systems for 
assessing injury and evaluating outcome cited in the literature. The IKDC (International Knee 
Documentation Committee) evaluation package, the KOOS (Knee injury and Osteoarthritis 
Score) system, the modified Cincinnati Knee Rating System and The SF (short form)-36 are 
examples of perhaps the most commonly employed patient administered reported systems. 
The patient assessment forms tend to follow a similar formula, posing a range of questions 
relating to function, pain and quality of life which is then manipulated into score. Higher 
scores converge on normal joint function; with lower scores indicative of a greater level of 
symptom. The administering clinicians appear to have their preferences on which self-
assessment form to employ although it is not uncommon to see a single study employ 
multiple subjective measures. All subjective evaluation systems have various mooted 
advantages and disadvantages and the chosen assessment used will likely fall to preference. 
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Numerous more exist and the goal is not to pragmatically debate the relative merits but rather 
illuminate the diversity in evaluating the efficacy of treatments in the field. There are a few 
studies offering insight into which objective based methods are most appropriate (K Hambly 
and K Griva, 2008., J Agel and R F LaPrade, 2009) 
 Ultimately, evaluating the intervention choice often comes down to comparing the 
improvement in post-operative score to the baseline score. The ICRS propose an objective 
surgical assessment that generates a score based on three categories (fill depth or graft 
survival, integration to border and macroscopic appearance). Interestingly there is a biopsy 
option for histological analysis but the result does not appear to contribute to the final score 
which ties into the earlier point made that to date, no study has been able to conclusively 
correlate a successful histological or radiological outcome with patient clinical outcome.   
 
Part A: Patient administered Part B: Clinician administered 
 ICRS Injury Questionnaire  ICRS Knee Surgery History 
Registration 
 The IKDC Subjective Knee Evaluation 
Form-2000 
 IKDC Knee Examination Form 2000 
  ICRS-Articular Cartilage Injury 
Mapping System 
  ICRS-Articular Cartilage Injury 
Classification System 
  ICRS-Osteochondritis Dissecans (OCD) 
Classification System 
  ICRS-Cartilage Repair Assessment 
System 
 
Table 2. The two parts, A and B, to the ICRS knee evaluation package 
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4.0 Current Standards of Care  
 
 The current standard of care for treating chondral injury is evaluated on a patient-
specific basis and considers factors including the nature of the lesion (ICRS/OCD grade1-4), 
size, location and any previous interventions. Established therapies can be broadly 
categorised into palliative, reparative, and restorative techniques 
 
4.1 Palliative Treatment  
 
Debridement and Lavage 
 
 Debridement (removal of dead or damaged tissue) and lavage (wash out) are suitable 
for candidates who present with small lesions typically less than 2-3cm2 and complain of 
predominantly mechanical type symptoms such as “catching” or locking sensations. The 
procedure is reported to alleviate mechanical symptoms in the short term but ultimately is 
palliative in nature as no attempt to repair the injury is the made (K Strachan, 1992). 
Advocates also recommend the strategy for OA lesions as the washing out of inflammatory 
mediators and calcium phosphate crystals is thought to be beneficial although this remains 
controversial (D T Felson and J Buckwalter, 2002).  
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4.2 Restorative Techniques 
 
Mosaicplasty, formally known as Osteochondral Cylinder Transplantation (OCT) is a 
technique that requires the harvest of either an allogeneic or autologous cartilage sample 
(sometimes referred to as osteochondral autograft transfer or OAT) “plug” which can then be 
transplanted directly into the injury site. There is an obvious limitation in using autogenic 
material in the sense there is a limit on the amount of material that can be harvested from the 
condyle margins or trochlea groove, typically 1-4cm2 ( L Hangody and P Füles, 2003). As 
with the majority of autograft procedures, donor site morbidity is a primary concern.  Using 
allogeneic grafts circumnavigates this problem although more fundamental limitations such 
as physically accessing harvest/defect site and achieving a smooth convex finish are 
sustained. Allografts inevitably introduce new problems such as adventitious agents, 
availability of donors and potential immunogenic side effects. 
 The principal advantages of OCT is that the procedure can be performed in one step 
and achieves instant defect fill although lateral integration of graft and host matrix is 
reportedly rare and can lead to subsequent post-operative complications. A prospective, 
randomised study conducted by Bentely et al. (2002) reported that after a mean follow up 
time of nineteen months, the reparative practice of ACI placed 88% of patients in the good to 
excellent category (modified Cincinnati and Stanmore scores). In comparison, the OCT group 
placed 69% within the same classification. Arthroscopic evaluation revealed good to 
excellent repair in 82% of ACI cases as oppose to 34% after OCT and further reported 100% 
failure of grafts performed in the patellar region. The authors questioned the contribution 
OCT will make to the field of chondral defect repair in the future.    
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4.3 Reparative Techniques 
 
4.3.1 Marrow Stimulating Techniques  
  
 Abrasion arthroplasty, subchondral drilling and microfracture are a series of related 
techniques whose restorative mode of action lies in the formation of a clot, achieved by 
accessing the mesenchymal niche beneath the subchondral plate ( M R Steinwachs et al., 
2008). Abrasion arthroplasty involves the initial debridement of the cartilage lesion followed 
by subsequent debridement of subchondral bone in order to achieve a bleed ( L L Johnson, 
2001). Subchondral drilling and microfracture are in principle the same technique – a method 
of breaching the subchondral bone to induce the formation of a clot. The key difference being 
the drilling technique, as the name suggests the use of a high-speed drill achieves the breach 
(M Hamanishi et al., 2013), whereas microfracture employs an arthroscopic awl (Y M Yen et 
al., 2008). Microfracture offers a few advantages of subchondral drilling; firstly, clinical 
outcome is observed to be higher than drilling. It is theorised that this is maybe due to the 
manual awl avoiding thermal necrosis of adjacent tissue created by the drill and the rougher 
surface created from the awl puncture helps facilitate clot adherence. From a practical point 
of view, some clinicians also find it easier to employ an arthroscopic awl. Microfracture 
generally has a favourable short-term outcome (K Mithoefer et al., 2009) combined with the 
fact the procedure is technically less demanding and relatively cheap to employ arguably 
gives microfracture its “gold standard” status for repair of full-thickness defects (ICRS grades 
3-4) less than 3-4cm2. Most products in development are compared against microfracture as a 
means of evaluating efficacy. 
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  A few notable drawbacks, however, are that results histologically show that repairs 
are predominately fibrocartilage. The fibrocartilage repair does not have the same long-term 
resistance as hyaline cartilage and is thought to wear faster which draws questions over 
microfractures ability to affect long-term repair ( A Gobbi et al., 2014., R M Frank et al., 
2017). Immediately after the procedure the newly formed clot is considered extremely fragile 
and can be easily dislodged, to avoid this a high level of patient compliance is required 
postoperatively.  An extrapolation of the microfracture approach termed autologous matrix-
induced chondrogenesis (AMIC) sought to enhance the outcome by providing a collagen 
scaffold that aids clot formation and provides a structure to guide repair tissue formation 
(Behrens et al., 2004). This, in turn, allows larger size defects to be treated with this 
procedure. Short-term and mid-term results suggest an improvement in patient-reported 
outcome, however, the paucity of long-term data and variation in how the procedure is 
executed clouds overall efficacy (A Fontana., 2017, N Shaikh et al., 2017).  
   
4.3.2 Autologous chondrocyte implantation (ACI) 
 
 Autologous chondrocyte implantation or ACI is a technique first conceived in the late 
1980s, with first in man studies following in 1994 ACI is a two-step procedure that 
repopulates a lesion with the patient’s own ex vivo expanded chondrocytes (M Brittberg et 
al., 1994). The first stage of ACI involves inspection of the legion and a cartilage biopsy 
taken from a non-weight bearing region of the afflicted joint. In the instance of the knee 
(where ACI is employed more routinely than hip or ankle), this would typically be the 
peripherals of the femoral condyles or the trochlea groove. The tissue explant is processed to 
release the chondrocytes in a GMP certified lab and the cells expanded in monolayer over a 
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number of weeks in the patient’s own serum. After the expansion period the cells are 
suspended in the patient’s serum ready for implantation in a second round of surgery. The 
clinician will typically prepare the lesion with an initial debridement to remove unstable 
tissue. To secure the transplanted chondrocytes, a periosteal flap is manufactured from an 
area of periosteum harvested from the patients proximal tibia. The flap is sutured in place and 
the cells injected under the patch. The post-operative care procedure is similar to that of 
microfracture as the repair site is fragile until cell adherence takes place. 
 
 Long-term (ten year) data is now becoming available, and the results largely ratify 
ACI as a viable treatment option. Two follow-up studies published 2014 both indicate 
satisfactory results although the authors acknowledged the procedure ultimately fails to 
achieve full tissue restoration and joint function (K Zaslav et al., 2009., P Niemeyer et al., 
2014., S Z Nawaz et al., 2014). Transplant survival beyond ten years was assessed to be 
approximately 50% although the observers commented that younger patients were far more 
likely to have prolonged graft survival, the reasons for which are explored below. At the 
conception of the studies, there was little in the way of candidate screening which ultimately 
masks the overall potential of the procedure. For example, patients who have undergone 
previous marrow stimulating techniques are significantly more likely to fail an ACI 
procedure (T Minas et al., 2009). Incidentally, a 2004 study comparing ACI and 
microfracture at two year follow up reported no significant difference in outcome (R Jones et 
al., 2004)  
There are a few practical drawbacks to ACI, an obvious limitation being the 
requirement for access to a GMP facility to expand the chondrocytes and secondly, the need 
for two separate sessions in theatre. This arguably has a sizable impact on the health 
economics front when compared to conceptually simpler acellular techniques like 
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microfracture. The national institute for health and care excellence (NICE) in the UK outlined 
the cost for material acquisition per patient from various sources (Table 3). 
 
Source Cost (2005) Inflation-adjusted  estimate cost for 2018 
Genzyme Ltd UK £4000-£5000 £5792-£7240 
BBraun/TeTec AG £4000 £5792 
Verigen UK £3200 £4634 
Geistlich Biomaterials £3500 £5068 
Robert Jones and Agnes 
Hunt Orthopaedic Hospital 
 
£2000 
  
£2896 
 
 Further to the practical technicalities, there are a few commonly cited clinical complications 
arising from ACI. These include hypertrophic growth (most commonly associated with use of 
periosteum), delamination and total graft failure (P Niemeyer et al., 2008). By nature of being 
an autologous treatment, a biopsy of the patient’s cartilage tissue is required. Herein lay 
several points of notable concern. Firstly, the issue of donor site morbidity. The biopsy itself 
creates a new chondral injury, although there is no clear consensus that this causes a direct 
problem (G Matricali et al., 2010). The risk is mitigated by taking the biopsy from a non-load 
bearing area; however this in itself creates a paradoxical situation as the chondral population 
of non-weight bearing areas are thought not to be adapted to compressive and shear forces (B. 
Vanwanseele et al., 2002). Further to this, any underlying pathology may predispose the 
chondrocyte population to adoption of an undesirable phenotype. The chondrogenic potential 
Table 3. Figures from a 2005 NICE Appraisal Determination for the use of autologous chondrocyte implantation 
for the treatment of cartilage defects in knee joints. The cited cost was adjusted for inflation based on an average 
inflation rate of 2.89% per year obtained from the office for national statistics composite price index. 
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of the patient’s own cells is a source of potential variation that may influence outcome, which 
is an unavoidable part of autologous treatments. Indeed the expanded chondrocytes are not 
vetted for any markers of potency or quality, which remains an undefined term in itself. The 
biological phenomenon of senescence also limits the candidate base for ACI with the 
procedure generally not offered to people over fifty-five. Ultimately senescence of the 
chondrocyte population leads to decline in the chondrogenic potential meaning an 
intervention of this approach is less likely to have a successful outcome (J A Martin and J A 
Buckwalter, 2003). Somewhat ironically the demand for treatment may well be highest in the 
> fifty-five group. Interestingly though, two recent studies found the contribution of patient-
specific variability and age do not correlate with the clinical outcome (O A Behery et al., 
2013 and G D Smith et al., 2018). Arguably, another significant component of ACI that has 
the potential to affect the outcome is the conditions in which the cells are expanded ( P 
Giannoni et al., 2005). The fine control of the expansion conditions represents an area that 
could yield further improvements in outcome. 
 
4.3.3 ACI 2.0 & 3.0 
 
 Since the introduction of ACI, a host of extensions of the original procedure have 
been developed. The augmentations are predominantly based on the inclusion of a scaffold 
matrix to which the autologous chondrocytes are seeded before fitting to the lesion with a 
bioadhesive, typically fibrin glue.  The inclusion of a matrix substrate has the practical 
advantage of negating the need for periosteal harvest which is beneficial for the patient, 
reduces surgery time and may affect outcome by bypassing hypertrophic growth associated 
with its use. The original extension of ACI, known as Matrix-Induced Chondrocyte 
Implantation, or MACI, seeds expanded chondrocytes on a porcine collagen membrane (P 
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Cherubino et al., 2003). The inclusion of the membrane is thought to help circumnavigate 
some complications encountered with periosteal ACI such as hypertrophic growth and 
delamination. The absolute efficacy of MACI is controversial however with studies reporting 
contradictory outcomes (P Niemeyer et al., 2014,). Again the outcome is likely obscured by 
large range of variables including patient age, underlying pathology, lesion size and location, 
ICRS grade, expansion conditions, efficacy endpoint measure and study design. Despite the 
uncertainty in effectiveness a whole industry has developed offering a wide range of “ACI 
3.0” options and expansion services. Products under this umbrella are sometimes referred to 
as MACT or “Matrix-Associated Chondrocyte Transplantation”. While the results are 
expected to be superior to the original ACI procedure there is a lack of evaluation studies to 
date.  
 
 
Product Company Description Efficacy Evidence 
Base 
Development 
Stage 
 
 
 
 
 
Hyalograft C 
 
 
 
 
Anika 
Therapeutics 
 
 
 
Monolayer 
expanded 
chondrocytes 
seeded on a 
synthetic scaffold 
made of a 
hyaluronic acid 
derivative 
Study conducted 2005 
showed 91.5% patients 
showed statistically 
significant improvement in 
IKDC subjective score at 
short-term follow up after 
intervention for grade III/IV 
chondral lesions (average 38 
months). Submitted biopsy 
samples were predominately 
hyaline-like. Further study 
by Brix et al. (2014) 
reported similar results and 
this concluded this MACT 
approach was associated 
with excellent outcome 
except patient cases deemed 
as “salvage”. 
 
 
Application for 
centralised 
marketing 
authorisation to the 
EMA withdrawn as 
of 2013. Thought to 
be manufacturing 
related. Product 
future not yet 
known. 
Table 4. Overview of MACT products in various stages of development 
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BioCart II 
 
Originally 
Procon 
Biotech. 
Acquisition 
by 
Histogenics 
2011 
 
Cells expanded in 
monolayer with a 
proprietary FGF 
variant and then 
seeded onto a 
human fibrin and 
hyaluronic acid 
scaffold, freeze-
dried to produce a 
porous sponge-
like scaffold. 
 
Results from a limited eight 
patient cohort for phase I 
study showed statistically 
significant increase in IKDC 
and Lysholm score from 
baseline at 6 and 12 months 
following intervention for 
grade III/IV chondral 
lesions. MRI finding 
showed between a 75% to 
100% defect fill. (S E 
Donmayer. et al., 2010) 
 
 
Thought to be at 
stage II currently, 
however, 
acquisition by 
Histogenics may 
lead to development 
mothball in favour 
of perusing 
Neocart. 
 
 
 
 
 
 
 
Bioseed C 
 
 
 
 
 
 
BioTissue 
Technologies 
GmbH 
 
 
 
 
 
Synthetic scaffold 
composed of 
fibrin glue and 
PGA, PLA, PDS 
copolymer seeded 
with autologous 
chondrocytes 
expanded in 
monolayer 
Assessment at 4 year follow 
up of a 52 patient (Grade 
III/IV chondral lesions) 
cohort showed statically 
significant in t outcome 
scores postoperatively 
(IKDC) in 50 patients, (2 
failures). Detailed MRI 
analysis at 4 years in 44 
patients revealed 32 with 
complete defect fill, 11 with 
>50% and 1 <50% fill. MRI 
signal indicated normal 
tissue in 26 patients, small 
alteration in 15 and 
hyperintense in 3. Authors 
concluded Bioseed C 
represented a plausible 
treatment option for the 
future. (P C Kreuz. et al., 
2009) 
 
 
 
 
 
 
Phase III trial 
currently on going 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neocart 
 
 
 
 
 
 
 
 
Histogenics  
Implant of 
patients own 
Neocartilage. The 
process initially 
expands 
autologous 
chondrocytes in 
monolayer before 
seeding onto a 
type 1 collagen 
matrix. The 
seeded 
chondrocytes are 
matured in a force 
bio reactor (which 
includes control 
over oxygen 
tension) for ~2 
A randomized phase II 
study involving 30 patients 
given neocart or “next best” 
– microfracture) in a ratio of 
2:1. Study concluded 2012 
reported superior outcome 
in: 
 
 KOOS pain (at 
6,12&24 months) 
 KOOS symptoms 
(6 months) 
 IKDC, KOOS 
sports and VAS (12 
& 24 months) 
 KOOS QoL (24 
months) 
 
 
 
 
 
 
 
 
Phase III FDA trial 
currently on going  
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weeks before 
further in 
maturation in 
static 3D culture. 
The maturation 
process stimulates 
Neocartilage 
formation which 
is subsequently 
transplanted. 
With respect to 
microfracture for the 
treatment of III/IV chondral 
lesions. The encouraging 
results are dampened by 
limited cohort size and 
variation in patient group 
baseline statistics. No 
supplementary MRI or 
histological analysis (D C 
Crawford et al., 2009) 
 
 
 
 
Cartipatch 
 
 
 
 
TBF Tissue 
Engineering  
 
Monolayer 
expanded 
chondrocytes 
(autologous 
serum) seeded on 
and matured on a 
synthetic argrose-
alginate scaffold. 
A randomised multicentre 
controlled study comparing 
Cartipatch to Mosaicplasty 
for isolated focal 
osteochondral defects of the 
knee. The study concluded, 
at two year follow up, that 
Mosaicplasty returned 
superior IKDC scores and 
that functional outcome was 
worse in the Cartipatch 
group. ( A Clave et al, 2015) 
 
 
 
 
Product appears to 
have been dropped 
 
 
 
 
 
 
Chondroselect 
 
 
 
 
 
 
 
 
 
Tigenix 
 
Autologous 
expanded 
chondrocytes with 
attention to 
manufacturing 
variability. 
Product vetted for 
“quality.” Product 
/ Procedure 
referred to as 
characterised 
chondrocyte 
implantation  
(CCI) 
 
Clinical outcome at thirty-
six months in a randomised 
trial vs microfracture 
showed CCI superior in the 
KOOS at endpoint with a 
greater number of treatment 
responders. The study also 
indicated subchondral bone 
reaction worsened 
significantly in the 
microfracture group ca. 
CCI. Interestingly the 
authors argued chondrocyte 
quality affected outcome. (D 
B F Saris et al., 2009) 
 
 
 
 
First cell-based 
product registered 
as an ATMP with 
European market 
approval. 
 
                  
Table 4 gives a brief account of some of the MACT related strategies in the 
development pipeline. The long-term trial data of the individual approaches will undoubtedly 
be highly anticipated by the cartilage community so the next generation of treatments can be 
appropriately informed. Of equal significance is how the respective enterprises deal with 
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evolving regulatory requirements as well as reduce manufacturing overheads as health 
providers push for ever more efficient cost/benefit profiles. For example, Johnson & Johnson 
sought to address the drawback of a two-stage process with a point of care system in the form 
of a proprietary cartilage autograft system (CAIS). Briefly, the procedure involves harvest of 
autogenic material in a similar fashion to ACI. The harvested material is manually minced 
and then secured in place with a resorbable polymer scaffold and staples (J B Cole et al., 
2011). Early clinical reports demonstrated safety and the phase III trial was due to conclude 
December 2014, however, the trial was halted after concerns relating to the cost of market 
entrance versus market worth were raised. It is tempting to speculate that halt was also due to 
the emerging technologies that avoid the need for an autograft and can access the over sixty 
patient demographic that is restricted in the instance of autologous approaches. One path that 
represents itself as a major possible augmentation is the introduction of an allogeneic cell 
source to MACT like products. Whilst this would introduce some new hurdles it would, like 
the CAIS approach, negate the need for two procedures. Moreover, an “off the shelf” product 
with a verified level of quality may assist in achieving a more consistent patient outcome as 
well as offering the chance of identifying any underlying patient pathologies that predispose 
an undesirable outcome. This, in turn, would allow clinicians to make more informed 
decisions regarding best course of patient care. 
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5.0 Allogeneic Solutions  
 
5.1 Biocartilage, DeNovo NT and Revaflex  
 
Biocartilage (Arthrex) is an “off the shelf” dehydrated allogeneic minced cartilage 
formulation to be used in conjunction with microfracture and platelet-rich plasma (PRP) (G D 
Abrams et al., 2013). There is evidence to suggest PRP has mesenchymal chemoattractant 
and mitogenic properties which encourage migration of the multipotent stem cells from the 
subchondral bone to the defect site (E Rubio-Azpeitia and I Andia, 2014). The minced 
allogeneic cartilage offers a pseudo-scaffold to aid in clot stabilisation and subsequent 
chondrogenesis. Clinical data is as of yet unavailable but is expected to be superior to 
microfracture. Two other products in the development pipeline of note are DeNovo Natural 
Tissue (NT) and Revaflex, formally DeNovo Engineered Tissue (ISTO / Zimmer). These 
products stand out for a number of reasons, firstly the allogeneic sources are viable and 
secondly, the products use “juvenile” (classified as from a donor in the ≤13 years) 
chondrocytes. DeNovo NT is a minced allogeneic cartilage product similar to in concept to 
CAIS and the established OAT procedures. The product is shipped in blister products 
containing nutrient medium. DeNovo NT uses juvenile chondrocytes as opposed to mature on 
the reported basis of the significantly increased metabolic features such as collagen II and 
GAG expression (D H Adkisson et al., 2010). To date, there are only a few studies evaluating 
the short-term efficacy of DeNovo NT (J A Buckwalter et al., 2014., Y H Stevens et al., 
2014) and none have published long-term follow-ups. Further, no comparator studies to 
microfracture are currently available, so the efficacy of the treatment remains as of yet, 
unknown. Revaflex (formerly DeNovo ET) is a living tissue engineered construct that drives 
cultured juvenile chondrocytes to form a Neocartilage matrix which is subsequently 
 26 
 
implanted into patients. Revaflex is thought to be currently in the middle of a phase III trial 
after phase II showed statistically significant outcomes and no immunological response (J D 
Harris et al., 2013) 
 
 
6.0 The Immunogenicity of Chondrocytes  
 
               An important question that arises from the emergence of commercialised allogeneic 
products is the immunogenic profile of the viable chondrocytes. The long-established 
procedure of allogeneic osteochondral grafting leads to an intuitive belief that chondrocytes 
are immune privileged to an extent. A body of evidence exists that demonstrates that 
chondrocytes can and do express both MHC I and MHC II antigens and do provoke T-Cell 
proliferation (C M Revell and K Athanasiou., 2009). Additionally in vivo immunological 
responses were observed in rabbits transplanted with allogeneic chondrocytes, which 
ultimately lead to graft rejection (S Moskalewski et al., 2002). These observations are not 
consistent with adopted practices of allogeneic cartilage grafts which have no significant 
incidence of immune rejection. This lead to the generally accepted hypothesis that the 
avascular nature of cartilage tissue and the isolated pericellular environment of the 
chondrocytes probably play a significant role in shielding immunological features from the 
host immunocompetent cells. The established paradigm is one of evasion rather than 
“invisibility”, however, a growing evidence base poses to re-ignite the debate.  A 
contradictory study involving HACs have shown no presence of MHCII, CD80 and 86 
antigens by flow cytometry and subsequently failed to stimulate T-cell proliferation in in 
vitro models (D J Huey et al., 2012). Further to this, a 2010 study on juvenile HACs showed 
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they actively suppressed T-cell proliferation in a contact-dependent fashion (D H Adkisson et 
al. 2010). The literature appears divided on whether chondrocytes or their tissue engineered 
products are immunogenic or not and Table 5 illustrates the division.  
 
 
Isolated or Matrix 
Bound Chondrocytes 
Species Immune Reaction?   Reference 
Isolated Rabbit Yes S Moskalewski et 
al, 2002 
Both Rabbit No PJ Chesterman et 
al, 1968 
Matrix Bound Rabbit Mixed B Arzi et al, 2015 
Isolated Human No P Jobanputra et al, 
1992 
Isolated              Human No 
 
DH Adkisson et al, 
2010 
Isolated        Human into Pig Yes Niemietz et al, 
2014 
Isolated                Rat Yes A Romaniuk et al, 
1995 
 
 
 
Table 5. Overview of  outcomes from studies addressing the immunogenicity question 
 28 
 
 
 The exact nature by which isolated chondrocytes and matrix bound chondrocytes 
sometimes achieve their apparent immune privileged status is not fully agreed upon but 
seems to be the result of a combination of factors. Factors including, heterogeneity in 
chondrocyte immune profiles, dense ECM shielding of chondrocyte immune features and 
generally low T-cell infiltration into the ECM and synovial fluid. Further to this, a 2015 study 
concluded that the survival of a tissue engineered construct in rabbits was a function of not 
only the donor source but also the lesion location. Xenogeneic material was strongly rejected 
at all implant sites however allogenic material implanted survived in the trochlea but elicited 
a notable immune response in the patella.(B Arzi et al, 2015). The authors hypothesised the 
difference could be due to proximity of the implant site to the synovium. This discovery may 
explain the earlier Moskalewski study, which was also performed with rabbit recipients. 
Unfortunately, though the earlier study used free chondrocytes and not construct bound 
chondrocytes which makes direct comparison difficult. The question of lesion site adds an 
additional dimension of complexity to the immunological conundrum. Ultimately, the most 
important question that arises from the discussion takes the form of ‘is any detectable sign of 
immune response clinically relevant?’ The current body of evidence cannot definitely answer 
such a question and any answer may be dependent on multiple conditions been met.   
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7.0 Cell Sources for ACI or tissue engineered constructs  
 
Treatment technology using viable cells can broadly be divided into four categories; 
Autologous, allogenic, xenogeneic and syngeneic. Autologous and syngeneic (genetically 
identical donor) cells, as already been touched upon, are patient derived.  The primary 
advantage of autologous cells is that the immunological question of host-graft rejection is 
side stepped (Z Chen et al, 2008). From an industry perspective, the use of autologous cells is 
mixed. Regulatory restrictions are more relaxed surrounding the use of autologous cells while 
they remain classed as “minimally manipulated” and so the route to early clinical trials is less 
obstructive. This is reflected by the general observation that the literature reports a far greater 
proportion of trials using autologous cells.  On the other hand, there are a few drawbacks to 
autologous cell therapies from a commercial perspective. Clinicians can prepare autologous 
cells on site without the need for commercial support. The nature of autologous cells means 
that any commercial outfit will face an almost insurmountable challenge of intimately 
characterising cell quality and understanding failure modes.  The most notable disadvantage 
of autologous cells is the limited amount of material that can be harvested which can be 
problematic in the instance where a lot of tissue or cells are required in order to affect a 
treatment or the cells are required in a time critical scenario.  
  Allogenic, from a different individual but same species or Xenogeneic, different 
species are an attractive option due to the availability of material.  The allure of such cell 
sources is increased by the notion that a “universal” cell line could be established to provide a 
platform for a more quality assured product. A scaled up or scaled out allogenic-based 
product more readily lends itself to economically efficient quality testing due to the fact the 
testing could be done on large batches. Additionally, and assuming the end product lends 
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itself to storage, the possibility of stock piling remains open which may be advantageous for 
products intended for medical emergencies. The major roadblock for allogenic and 
xenogeneic-based treatments is the immunological question. It is accepted that introducing 
immunologically incompatible material into the body will result in host-graft rejection which 
means allogenic cell therapies will require strategies to avoid this such as HLA matching, 
host immune suppression or immune evasion. 
Outside of the direct question of allogenic or autologous the important consideration 
of the source tissue of the cell and the type of cell. Chondrocytes could be derived directly 
from cartilage such as the case with autologous chondrocyte implantation however this is not 
the only option. Chondrocyte progenitors can be harvested and insolated from the full 
thickness population present in hyaline cartilage (C Archer et al, 2004). Chondrocytes or 
chondrocyte progenitors can be obtained from the differentiation of mesenchymal, embryonic 
or induced pluripotent stem cells (A Cheng et al, 2014 and RM Guzzo et al, 2014). To add 
the complexity mesenchymal stem cells can be isolated from a number of different tissue 
sources such as bone marrow, dental pulp and adipose ( P Stanko et al, 2014). In spite of the 
variety of potential sources on offer, an argument, based on intuition would say that the best 
source for a producing chondrocytes capable of supporting a permanent cartilage matrix 
would be one derived from the in vivo niche. To this end, chondroprogenitor isolated from 
full thickness cartilage are an attractive candidate for manufacturing studies that would 
circumnavigate the need for additional, potentially expensive, differentiation steps necessary 
when starting with non-committed stem cells. 
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  7.1 Culture Conditions and Explant Procedure  
 
Chondrocytes expanded for both clinical and research application are typically 
cultured using serum. The former typically employs autologous serum obtained from the 
patient’s blood, whereas the latter uses commercially available animal serum. Chondrocytes 
are an anchorage-dependent cell line and are typically expanded on tissue culture plastic in 
the form of T-flasks or carrier beads. A commonly cited problem with the culture of 
chondrocytes is the rapid loss of the in vivo phenotype which can be characterised by the loss 
of transcript expression of the master chondrogenic gene SOX-9 and the SOX-9 support 
genes SOX-6 and 5, this, in turn, leads to the loss of cartilage-specific markers. SOX-9 is a 
transcription factor expressed in differentiated chondrocytes but not in hypertrophic 
chondrocytes ( Zhao et al. 1997). Studies have determined that it plays a central role in 
activating downstream cartilage-specific markers Col2a1, Col1a2, and aggrecan (Bi et al. 
1999). SOX-9 is also thought to play a role in modulating the rate at which proliferating 
column chondrocytes convert to hypertrophic chondrocytes by mediating the function of 
parathyroid hormone-related protein (PTHrP) (W Huang et al. 2001). PTHrP forms part of a 
negative feedback loop with Indian hedgehog (Ihh) (H M Kronenberg et al. 2001., H 
Akiyama et al., 2002). Indian hedgehog protein is an activator of PTHrP. Activated PTHrP, 
in turn, is thought to prevent the proliferating chondrocytes which express Ihh from 
progressing to hypertrophic chondrocytes directly. In addition, SOX-9 is thought to be a 
target of PTHrP, which results in enhanced transcript expression.  This intricate cascade is 
represented in the diagram in figure 5.  
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How exactly SOX-9 contributes to maintaining the stability of the proliferating and 
pre-hypertrophic chondrocytes is unclear but investigators observed that SOX-9 knockout 
mice exhibit enlarged prehypertrophic zones.   The loss of the PTHrP-Ihh feedback loop 
promotes the emergence of hypertrophic chondrocytes, and the emergence of hypertrophy 
markers; collagen X expression, matrix metalloprotease-13, alkaline phosphatase and 
vascular endothelial growth factor (M B Goldring et al., 2006). SOX-6 and SOX-5 are co-
expressed with SOX-9 in differentiated chondrocytes and work cooperatively to activate the 
Col2a1 gene. It was demonstrated that SOX-6 and 5 were required to achieve collagen 
expression levels consistent with that of mature cartilage (Smits et al., 2001). 
 
Figure 5. Diagram showing the PTHrP-IHH negative feedback look taken from H M Kronenberg (2003). (1) 
PTHrP is secreted from chondroblasts and chondrocytes and acts on the proliferating column chondrocytes to 
sustain proliferation and delay IHH production. (2) IHH is produced as the PTHrP signal dimishes. (3) IHH 
production stimulates production of more PTHrP at th top of the proliferating chondrocytes. (4) IHH further 
promotes osteogenesis by directing perichondroal mesenchymal cells down the osteoblast lineage   
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 Loss of SOX signalling in chondrocytes leads to dedifferentiation and is thought to 
be instigated, at least in part, by changes to the cytoskeleton that are the result of culturing on 
tissue culture plastic (A woods et al., 2005). Dedifferentiation of chondrocytes can be 
reversed, to an extent, by employing “three-dimensional” culture methods such as pellet or 
incorporation of cells into gels (P.D. Benya, J.D. Shaffer, 1982). It would be advantageous, 
however, purely from an economic standpoint, to avoid the need for such methods by 
preserving the phenotype during the expansion.  
 
7.2 Chondrocyte Culture Survey 
In order to gauge the degree of variability between culture practices typically 
employed and to inform the proposed experimental work a brief exploration of explant and 
expansion protocols described in the literature was undertaken.  
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Reference Cell 
 Source 
Harvest Method Expansion Conditions 
 
 
 
 
 
 
Van Susante, J. L. et al. 
Culture of 
chondrocytes in 
alginate and collagen 
carrier gels. Acta 
Orthop. Scand. 66, 
549–56 (1995). 
 
 
 
 
 
 
 
 
Bovine 
Metacarpophalangeal Joints 
 
 
 
1) 2h incubation in RPMI DM 
Culture medium, pyruvate 
(1mM), gentamycin (1.2%)  
and Pronase E (0.2%) 
2) Overnight incubation with 
collagenase B (0.1%), culture 
medium. 37oC. Air (95%), 
CO2 (5%). 
3) Cells washed 3 times by 
centrifugation and 
resuspended in RPMI DM 
(30mL)  
Collagen Gel Alginate Gel 
Cells Dispersed in: 
 7 volumes of Collagen 
solution (8mg /ml in acetic 
acid (0.05%) UV sterilised 
 2 volumes of 3xconcentrated 
DMEM 
 1 volume Hepes (0.2M) to a 
concentration of 2 x 106 
cells / mL 
 24 well plates precoated with 
0.3mL gel and slabs of DMB 
on the bottom were prepared 
 Samples containing 
Chondrocytes placed on top 
and allowed to gel at 37oC 
 Gels overlaid with RPMI 
DM (2mL) w/ 10% FCS. 
 Medium Changed every 
other day 
 Low Viscosity Alginate dissolved in 
physiological saline and autoclaved 
for 20m. 
 Pelleted Chondrocytes suspended in 
the alginate solution and sampled as 
for collagen. 
 Gelled by addition of Ca2+ 
 Gel washed 4 times with saline. 
 Addition of culture medium (DME / 
Ham’s F12 w/ 10% FCS). 
 
 
Flannery, C. R., Little, 
C. B., Caterson, B. & 
Hughes, C. E. Effects 
of culture conditions 
and exposure to 
catabolic stimulators on 
the expression (MMPs) 
and disintegrin 
metalloproteinases 
 
 Human Articular 
Chondrocytes (68-79-
year-old patients 
suffering advanced OA 
of the knee) 
 Bovine from 
Metacarpophalangeal 
Joints (1-2 week old 
calves) 
 
 
1) 0.1% Pronase in DMEM 
containing 5% FBS for 1 h at 
37oC with agitation.  
2) 0.04% collagenase in 
DMEM w/ 5% FBS 
overnight 378C with 
 
Monolayer and Agarose (same conditions): 
 
 Seed density : 1x106 cm2 
 DMEM 
 10ng/ml IL-1β (recombinant) or 1mM trans-Retinoic Acid  
 Maintained for 4 days  
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(ADAMs) by articular 
cartilage chondrocytes. 
Matrix Biol. 18, 225–
37 (1999). 
 Porcine from 
Metacarpophalangeal 
Joints(3-6-month-old) 
agitation. Cells were filtered 
washed and counted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fragonas, E. et al. 
Articular cartilage 
repair in rabbits by 
using suspensions of 
allogenic chondrocytes 
in alginate. 
Biomaterials 21, 795–
801 (2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rabbit Articular 
Chondrocytes 
 
 
1) Immediately after harvest 
sample immersed in PBS 
2) Minced and digested at 37oC 
with collagenase  (125 U ml-
1) for 3-5h under constant 
oscillation in DMEM 
supplemented with  2% FCS, 
glutamine (2mM), Penicillin 
(500 U ml-1), Streptomycin 
(500 µg ml-1) and Hepes-
NaOH (10mM) – pH 7.4  
3) Solution was filtered and 
diluted with KRH (Krebs-
Ringers Henseleit)  solution 
(NaCl (110mM), KCl 
(10mM), MgCl2 (1mM),  
CaCl2 (1mM), Hepes 
(30mM) 
4) Cells pelleted by 
centrifugation at 600xg for 
10m 
5) Washed in the KRH and 
suspended in a solution of 
sodium to give 1x106 ml-1 
chondrocytes in alginate( 
0.75% w/v ) 
 
 
 
 
 
 
 
 
 
Alginate Gel Culture: 
 
 One mL aliquots of cell suspension plated on 35mm Petri dishes and 
gelled by addition of 2mL of CaCl2 (50mM), NaCl (0.1mM), (10mM) 
Hepes (10mM). After gelation excess, CaCl2 was removed by washing 
with an excess of KRH solution 
 
 1.5mL of media  placed into each dish 
 
 Media: DMEM supplemented with FCS (10% v/v), penicillin (500 U ml-
1), streptomycin (500 µg ml-1), Glutamine (2mM) and ascorbate (50 µg 
ml-1) 
 
 Cells cultured for one week at 37oC at 5% CO2 with medium change 
every two days. 
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De Bari, C., 
Dell’Accio, F. & 
Luyten, F. P. Human 
periosteum-derived 
cells maintain 
phenotypic stability and 
chondrogenic potential 
throughout expansion 
regardless of donor age. 
Arthritis Rheum. 44, 
85–95 (2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mix of cadaveric (12 hours 
post-mortem) and live 
biopsy (knee replacement 
surgery) periosteum-derived 
cells (mean age 57 years) 
 
1) Samples rinsed twice with 
balanced salt solution and 
supplemented with  penicillin 
(100 units/ml), streptomycin 
(100 units/ml), amphotericin 
(0.25 mg/ml) 
2) Samples minced and digested 
with collagenase (0.2%) in 
high glucose DMEM w/ FBS 
(10%) 
3) Overnight incubation at 
37oC then collected by 
centrifugation, twice washed 
and resuspended in high 
glucose DBEM w/ FBS 
(10%) and antibiotics. 
4) Plated in T25 culture flask 
and allowed to attach for 4 
days 
5) Non-adherent cells removed 
by medium change. 
 
 
Monolayer Culture: 
 
• Growth medium (implies the same mixture as before) at 37oC and 5% 
CO2 
• Medium change every 3 days 
• After 10-20 days of primary culture (confluence) the cells were washed 
with PBS and harvested with trypsin-EDTA (0.25% trypsin, 1mM 
EDTA) and repeated at 1:4 dilution. 
• Cell passages were continued in the same way (1:4 dilution) every 6-12 
days (at confluence)    
 
 
Growth Factor Treatment:  
 
• Recombinant BMP-2, BMP-4, BMP-7, GDF-5, CDMP-1 were 
dissolved in 45% acetonitrile and 0.1% TFA and added to the culture 
medium at final concentrations of 100-300 ng/mL 
Recombinant TGF-β1 was dissolved in HCI (4mM), BSA ( 1mg/mL) 
and added at a final concentration of 10ng/ml 
 
 
 
 
 
 
 
 
 
Jakob, M. et al. 
Specific growth factors 
during the expansion 
 
 
 
 
 
 
 
 
 
 
Human Articular 
Chondrocytes from hip or 
 
 
 
 
 
 
 
 
 
Samples incubated at 37oC in 
type II collagenase (0.15%) and 
resuspended in DMEM 
 
Initial Monolayer Expansion: 
 
 Cells plated in flasks at approximately 104 cells/cm2 and cultured in an 
incubator at 37oC and 5% CO2 
 At approximately 10 days (sub-confluent) first passage cells were 
detached using trypsin (0.25%) and EDTA (1mM) 
 After 10 days P2 cells were detached in the same manner and cultured in 
pellets with the addition of various growth factors to the control medium 
 Growth Factor Concentrations: 
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and redifferentiation of 
adult human articular 
chondrocytes enhance 
chondrogenesis and 
cartilaginous tissue 
formation in vitro. J. 
Cell. Biochem. 81, 
368–77 (2001) 
 
 
 
ankle joint (mean age 57.5) 
of 4 patients not presenting 
with joint disease following 
joint replacement (femoral 
neck fracture) or foot 
amputation (tumour 
resection) 
containing FBS (10%, d-glucose 
(4.5 mg/mL), non-essential 
amino acids (0.1 mM), sodium 
pyruvate (1mM), HEPES buffer 
(100mM), penicillin (100 
U/mL), streptomycin (µg/mL) 
and l-glutamine (0.29 mg/mL) 
 
 FGF-2 (5 ng/mL) 
 EGF (10 ng/mL) 
 PDGFbb (1 ng/mL) 
 TGF-β (1 ng/mL) 
 All used with control medium (left) to study population doublings during 
P1 
 
Pellet Culture: 
 
 Both serum free (SFM) and serum supplemented formulations employed. 
 SFM: DMEM with ITS+1 (sigma), ascorbic acid 2-phosphate (0.1mM) and 
HSA (1.25 mg/mL) 
 Serum supplemented medium was control medium(left) with insulin (10 
mg/mL) and ascorbic acid 2-phosphate (0.1mM) (concentration was of 
insulin was to substitute requirement for IGF-I (Yaeger et al., 1997) 
 Aliquots of 5x105 in medium (0.5mL) were centrifuged at 7500 rpm (15s) 
in polypropylene conical tubes to form spherical pellets. 
 Pellets were placed onto a 3D orbital shaker at 30 rpm in an incubator 
humidified at 37oC under 5% CO2 
 Pullets were cultured in 4 different mediums (0.5mL) :Serum 
supplemented, Serum-free(SF),SF with TGF-β (10ng/mL) and SF with 
TGF-β and dexamethasone (10-7 M) 
 
 
Kolettas, E., Muir, H. 
I., Barrett, J. C. & 
Hardingham, T. E. 
Chondrocyte phenotype 
and cell survival are 
regulated by culture 
conditions and by 
specific cytokines 
through the expression 
of Sox-9 transcription 
 
 
 
 
 
DES4 supB+ and 10W sup 
B+ clone 1. ( Carcinogen-
immortalized, non-
tumorigenic Syrian hamster 
embryonic chondrocyte-like 
cells) 
 
 
 
 
 
 
 
                         N/A 
 
 Cells were cultured as monolayers in MEM with FCS (10%), non-
essential amino acids (1% v/v), L-glutamine (1.4mM), penicillin (100 
units/ml) and streptomycin (100 µg/ml) at 37oC under 5% CO2 
 Early passage cells were split 1:16 and expanded in the above medium for 
3 days (50-60% confluent) or 4-5 days for fully confluent. 
 The medium was changed either with the same control medium or a 
serum-free growth medium with or without human recombinant IL-1α 
(5ng/mL) or IGF-1 (50ng/mL), or both together. 
 A selection of early passage cells grown either in the default or serum-free 
medium were treated with 5-azacytidine (4.10 µM) 
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factor. Rheumatology 
(Oxford). 40, 1146–56 
(2001). 
 
 
 
 
 
 
 
 
 
Mandl, E. W., van der 
Veen, S. W., Verhaar, 
J. a N. & van Osch, G. 
J. V. M. Serum-free 
medium supplemented 
with high-concentration 
FGF2 for cell 
expansion culture of 
human ear 
chondrocytes promotes 
redifferentiation 
capacity. Tissue Eng. 8, 
573–80 (2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human Ear Cartilage from 
three children (5-10yrs) 
during ear correction 
surgery 
 
 
 
 
 
 
1) The perichondrium was 
dissected from the cartilage. 
The cartilage was sliced into 
small pieces and washed 
several times in physiological 
saline. 
2)  Two-stage digestion 
protocol for cell release: 
Cartilage was pre-incubated 
with pronase E (2 mg/mL) for 
2h followed by overnight 
digestion with collagenase B. 
Cells were isolated by 
filtration (100mm) to remove 
undigested cartilage. 
3) Cell viability was tested 
using trypan blue 
 
Monolayer Expansion: 
 
 Four different types of media were prepared: DMEM with FCS (10%), 
DMEM with ITS+ (1:100), DMEM with ITS+ and recombinant FGF2 at 
two concentrations ( 5ng/mL and 100ng/mL) 
 All growth mediums were supplemented with gentamycin (50 mg/mL) 
and fungizone (1.5 mg/mL) 
 Cells seeded at a density 4x104 
 Chondrocytes trypsinized at subconfluency (trypsin-EDTA) 
 Start of each new passage serum-free conditions were supplemented with 
FCS(10%) for a day to promote adherence  
 Medium was changed every other day  
 Cells expanded for four passages 
 
 
Redifferentiation Culture: 
 
 
 Chondrocytes from the four different conditions were encapsulated 
individually. 
 Cells were suspended in alginate (1.2%) in saline at a density of 4.3x106 
cells/mL 
 The suspension was dropped into a CaCl2 (102mM) solution via needle to 
create the gelled beads 
 After 10m the beads were washed three times with physiological saline 
 DMEM was supplemented with ITS+1, IGF-1(10 ng/mL), TGFβ2 (10 
ng/mL) and hydrocortisone (0.1 mg/ML). L-Ascorbic was added (25 
mg/mL)  
 Described previously to induce dedifferentiation 
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 Control was set up in the form of bead culture with DMEM w/ FCS 
(10%)   
 Beads were cultured for 21 days in a 24 well plate 
 Each well contained 10 beads and 50 mL of medium  
 
 Medium was changed every other day  
 
  
 
 
 
 
 
 
 
 
 
 
Malda, J. et al. 
Expansion of bovine 
chondrocytes on 
microcarriers enhances 
redifferentiation. Tissue 
Eng. 9, 939–48 (2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bovine Chondrocytes from 
the femoral condyle (6 
months old calves) 
 
 
 
 
 
 
 
1. Tissue dissected into 1-mm 
cubes and digested overnight 
with type II collagenase 
(0.15%). 
2. Cells washed three times 
with PBS then suspended in 
HEPES buffered DMEM v/ 
FCS (10%), ascorbic acid 2-
phosphate (0.2mM), non-
essential amino acids 
(0.1mM), proline (0.4mM), 
penicillin (100 units/mL) and 
streptomycin (100 mg/mL) 
 
 
 
Microcarrier selection, seeding, and culture 
 
 Suitability of several commercially available microcarriers decided by 
initial cell attachment (3h) 
 Cytodex 1 microcarriers were chosen.  
 Microcarriers steam sterilised and washed with PBS twice then, with 
culture medium (37oC)  
 Expansion was achieved by transfer of microcarriers to a Sigmacote-
treated 250mL spinner flask with a working volume of 100mL, end 
concentration of 3mg of Cytodex per ml) 
 Microcarriers seeded (3500 cells/cm2) according to an intermittent stirring 
regime ( 30 min at 0 rpm, 1 min at 20 rpm for 3h)  
 After seeding the stir rate was increased to 30 rpm 
 Culture was maintained in a humidified 5% CO2 incubator at 37 oC 
T-flask culture 
 
 Seeded at a density of 3500 cells/cm2 in T 175 Flasks and maintained in a 
humidified 5% CO2 at 37oC 
 After 8-9 cells reached confluence and were harvested 
 Harvest was achieved by separation of cells from microcarriers by an 
initial 1h collagenase treatment followed by filtration through a Falcon 
filter (100-mm pore size) 
 Microcarriers were rinsed with PBS to remove trace collagenase   
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 Cells were washed three times with PBS then centrifuged for 10 min at 
300 x g 
 Cells were resuspended in culture medium ready for a viable cell count 
(trypan blue)  
 
 
 
Pellet Culture  
 
 Resuspended cells (500, 000 per tube) centrifuged with culture medium 
(1.5mL) for 2m at 300 x g. 
 The resulting pellets were cultured statically at standard CO2/Temp. 
Media was changed every 2-3 days. 
 
 
 
 
 
 
Barbero, A. et al. Age-
related changes in 
human articular 
chondrocyte yield, 
proliferation and post-
expansion 
chondrogenic capacity. 
Osteoarthritis 
Cartilage 12, 476–84 
(2004). 
 
 
 
 
 
 
 
 
 
Cadaveric human 
chondrocytes taken 24h 
post-mortem from 69 
patients with no history of 
joint disorders (age range 
20-91). 
 
 
 
 
 
 
 
1) Cells isolated with type II 
collagenase (0.15%, 10mL /g 
tissue) for 22h. 
2) Cells were suspended in 
DMEM v/ FCS (10%) and 
penicillin (100 U/mL) / 
streptomycin (100 µg/mL)  
 
Monolayer Culture  
 
 Cells seeded in flasks at a density of 1x104 cell /cm2 
 Cells cultured either with control medium (left) or with the addition of 
TGF-β1 (1ng/mL), FGF-2 (5 ng/mL), PDGF-BB (10 ng/mL) in a 
humidified 37oC / 5 % CO2 atmosphere. The growth factor combination 
was based on previous reports that their presence promotes proliferation 
and redifferentiation. 
 After approximately ten days cells were 80% confluent 
 Cells were passaged and rinsed with PBS and detached using trypsin-
EDTA (0.05%-0.53mM) 
 Cells reseeded at 5x103 cells/cm2    
 At 80% confluence (Approx. 1 week) the second passage cells (equivalent 
to a total of 4.6 ± 0.9 and 8.1 ± 1, for control and GF enhanced 
respectively) were introduced into pellet culture. 
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Pellet Culture   
 
 Pellet culture used a serum free medium consisting of DMEM 
supplemented with ITS+1, ascorbic acid 2-phosphate (0.1 mM), human 
serum albumin (1.25 mg/mL), dexamethasone (10-7 M)and TGF-β1 
(10 ng/mL) 
 Aliquots of 5x105 cells / 0.5 ml were centrifuged at 250xg for 5 m in 
propylene conical tubes 
 The pellets were placed onto a 3D orbital shaker at 30rpm 
 Pellets were cultured for two weeks with media changes twice weekly 
before analysis.  
 
 
 
 
 
 
 
Diaz-Romero, J. et al. 
Immunophenotypic 
analysis of human 
articular chondrocytes: 
changes in surface 
markers associated with 
cell expansion in 
monolayer culture. J. 
Cell. Physiol. 202, 
731–42 (2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cadaveric human articular 
cartilage (18 subjects 
between 32 and 89, 
harvested within 24h post 
mortem) 
 
1. Cartilage specimens kept in 
transport medium (DMEM / 
Nutrient mixture F12, 
amphotericin B (2.5 mg/ml), 
penicillin (500U/mL) and 
streptomycin (500mg/mL)) 
until processing (within 24h 
of biopsy)  
2. Specimens were diced in 
PBS 
3. Diced tissue was incubated 
with pronase E (10 ml/g of 
wet tissue) in a shaker water 
bath for 60m at 37.8oC 
4. Pronase was removed and the 
cartilage specimens were 
washed with PBS  
5. Collagenase P in digestion 
medium (10ml/g wet tissue) 
(Digestion medium; 
 
Monolayer expansion:  
 
 Cells were seeded at a density of 50 000 cells/cm2 in T75 flasks in culture 
medium  
 Culture medium: DMEM/F-12, FCS (10%), amphotericin B (2.5 mg/ml), 
penicillin (100U/mL),streptomycin (100mg/mL), bovine insulin 
(1mg/mL) and ascorbic acid (50 mg/mL) 
 Cells cultured at 37oC in humidified 5% CO2 atmosphere for 24h 
 Cells were checked for adherence and non-adherent cells were removed 
 Adherent cells were harvested by incubation with trypsin-EDTA for 10m 
followed by addition of a trypsin inhibitor and cells washed and counted. 
 Cells were re-plated at a density of 10,000 cells/cm2 and the medium 
changed the following day then every two to three days. 
 Cells were passaged after seven days at sub-confluence at a split ratio of 
1:2 and after seven more days cells were harvested in the already described 
manner and cryopreserved. 
 Monolayer culture in some instances were maintained for four weeks for 
collagen II expression analysis  
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DMEM/F-12, bovine insulin 
(1mg/mL) and ascorbic acid 
(50 mg/mL) was added and 
left overnight at 37.8oC in a 
shaking water bath 
6. The suspension was filtered 
through a nylon strainer 
(100mM) 
7. Cells were centrifuged then 
washed twice with PBS 
before counting then either 
cryopreservation  
 
** Note, the authors felt this 
method was superior to 
isolation procedures using 
just collagenase in terms of 
both yield and capacity for 
attachment. ** 
 
 
 
 
 
 
 
 
 
Giannoni, P. et al. 
Autologous 
chondrocyte 
implantation (ACI) for 
aged patients: 
development of the 
proper cell expansion 
conditions for possible 
therapeutic 
applications. 
Osteoarthritis 
Cartilage 13, 589–600 
(2005). 
 
 
 
 
 
Human articular 
chondrocytes from five 
patients (69-75 years) 
undergoing knee 
arthroplasty 
 
Controls were taken from 
three young patients (27-35)  
undergoing reparative 
surgery 
 
1) Cartilage was cleared of 
connective tissue / 
subchondral bone  
2) Specimens were minced into 
small fragments and rinsed 
with PBS (pH 7.2) 
3) Enzymatic digestion 
achieved with hyaluronidase 
(1mg/mL), collagenase I 
(400 U/mL), collagenase II  
(1000 U/mL) and 0.25% 
trypsin in PBS at 37oC 
4) Cells were pooled and 
counted    
 
 The culture dishes used for expansion were pre-coated with 10% FCS 
in Coon’s modified Ham’s – F12. This was to allow attachment of the 
serum fibronectin to the plastic. 
 After 24h the dishes were washed three times with PBS to remove all 
FCS 
 The primary chondrocytes were kept in FCS containing medium for 
48 and then detached and washed with PBS ready for culture 
 HACs from each donor were divided into equivalent aliquots so that 
one could be grown in the serum-free medium and the other in serum-
containing medium. 
 The SF medium was Coon’s modified Ham’s F-12 supplemented with 
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Component  Concentration 
Ascorbic Acid 250mM 
Linoleic Acid 4.5mM 
Cholesterol 13mM 
Dexamethasone 10nM 
N-acetylcysteine 50mM 
Apo-Transferrin 25 mg/mL 
Holo-Transferrin  25 mg/mL 
Sodium Selenite 30 nM 
Sodium Pantothenate 17mM 
Biotin 33mM 
Insulin 10 mg/mL 
EGF 5 ng/mL 
FGF-2 5 ng/mL 
PDGF 5 ng/mL 
Human Albumin  1% 
 
 
 Medium was changed three times a week 
 Cell passaging and counting was performed at sub confluence 
 After five population doublings, cells were trypsinized then used 
either for analysis or to test chondrogenic potential  
 Alternative procedure was to culture cells with FCS for five 
population doublings 
 The effects of TGF-β1 and trans-Retinoic acid were tested by addition 
to some batches as well 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General 
 
 Cells were seeded at a density of 4x104 cells/cm2 in plastic vessels  
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Duval, E. et al. 
Hypoxia-inducible 
factor 1alpha inhibits 
the fibroblast-like 
markers type I and type 
III collagen during 
hypoxia-induced 
chondrocyte 
redifferentiation: 
hypoxia not only 
induces type II collagen 
and aggrecan, but it 
also inhibits type I and 
type III collagen. 
Arthritis Rheum. 60, 
3038–48 (2009) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human articular 
chondrocyte from femoral 
heads of patients 
undergoing joint 
arthroplasty (age range 37-
81). Samples healthy in 
appearance by macroscopic 
analysis were used. 
 
 
 
 
 
 
 
 
 
1) Samples were cut into small 
pieces and ready for a 
sequential digestion 
2) Samples were initially 
incubated at 37oC for 45m 
with protease XIV (2mg/ml) 
followed by an overnight 
digestion with collagenase I 
(1mg/mL) 
3) The cell suspension was 
filtered through a nylon mesh 
membrane (70µm) before 
centrifugation  
 Culture medium consisted of DMEM w/ FCS (10%), penicillin (100 
IU/mL). streptomycin (100g/mL) and fungizone (0.25 g/mL) in an 
atmosphere of 5% CO2 
 Medium was changed every two weeks 
 At confluence, cells were enzymatically harvested with trypsin-
EDTA (0.25% / 1mM) counted and seeded again at the same density. 
 
Hypoxia Studies 
 
 Hypoxic conditions were achieved using a sealed chamber equipped 
with gloves 
 A culture incubator was placed inside and vessels were introduced by 
a special airlock  
 Prior to use the chamber was equilibrated to 5% O2 by flushing with 
a CO2-N2 mix without oxygen 
 Oxygen tension was monitored with a specific probe 
 The oxygen tension of the culture medium was reduced to 5% O2 by 
bubbling a gas mixture without oxygen (reportedly ~1.5h for a 500mL 
flask) 
 Oxygen tension of media was measured by inserting a probe. 
 The media used was absent phenol red due to its anti-oxidant 
properties 
Alginate Bead Redifferentiation Studies: 
 
 Cells were aliquoted, centrifuged and suspended in sodium alginate at 
a density of 107 cells/mL. 
 The beads were formed by slowly dispensing droplets of the solution-
suspension through a needle (.22 gauge) into a solution of CaCl2 
(100mM) 
 The CaCl2 was removed and the beads washed with NaCl (0.15M) 
then washed with DMEM w/ FCS (10%) before culturing with the 
same medium.  
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Adkisson, H. D. et al. 
The potential of human 
allogeneic juvenile 
chondrocytes for 
restoration of articular 
cartilage. Am. J. Sports 
Med. 38, 1324–33 
(2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cadaveric human articular 
chondrocytes from 65 
different donors (19 from 
ranges 4-79 and 46 from 
ages spanning birth to 13, 
classed as juvenile) 
 
 
 
 
 
 
 
1) knees en bloc” were received 
on ice and processed in 
accordance with current good 
tissue practices 
2) Cartilage was taken from the 
proximal femur and the distal 
tibia  
3) The cartilage was minced and 
cells released by initial 
treatment with pronase 
(0.2%) followed by overnight 
digestion with a mixture of 
collagenase(0.07%) and 
hyaluronidase (0.04%) in the 
presence of a proprietary 
chemically defined serum-
free medium HL-1 (Lonza) 
Neocartilage  
 
 Non expanded chondrocytes were seeded in a un specified vessel at a 
density between 0.5 – 1x106 cells/cm2  
 HL-1 medium was again used but sometimes substituted for an 
alternative defined medium that was thought to display similar growth 
characteristics to the HL-1  
 Cells were cultured in an incubator at 37OC in a humidified 
environment (5% CO2) and supplemented with ascorbate (50 mg/ml) 
after day 3 
 Medium exchange was carried out every 3-4 days  
 The Neocartilage was harvested between days 44 and 63 of culture for 
characterisation  
 
Population growth and differentiation culture 
 
 Note the chondrocyte isolation method was slightly different than 
described earlier: The sequential digestion was absent hyaluronidase 
and the medium used was DMEM v/ 10 % FCS. 
 Cells were plated in monolayer culture and grown for 5 to 10 days 
before passaging  (~80% confluence) with trypsin  
 Replicates at 1:3 split  
 Cells cultured for up to 104 days 
 Population doublings were tracked through time based on cell counts 
at each passage. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
1) Cartilage samples were cut 
into small pieces and 
transferred to a Petri dish  
  
 
 
Monolayer Culture: 
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Heidari, M., 
Tahmasebi, M. & 
Etemad, S. In vitro 
Human Chondrocyte 
Culture ; A Modified 
Protocol. 9, 102–109 
(2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human articular 
chondrocytes from 
arthroscopic biopsy 
2) Sliced cartilage were 
maintained overnight in 
Ham’s-F12: DMEM w/FBS, 
ascorbic (100mg/mL), 
penicillin (100 U/ml) and 
streptomycin (100mg/ml) at 
37oC in 5% CO2 atmosphere. 
The overnight cool off was to 
ensure sterility of specimens 
before digestion  
3) The exact duration of the 
enzymatic sequence was 
dependant on the size of the 
cartilage sample 
4) The cartilage was first 
washed in buffered PBS 
containing antibiotics then 
incubated with trypsin 
(0.25% w/v) at 37oC, 5% CO2 
for 30 minutes in the 
presence of the already 
described growth medium. 
5) The supernatant was 
discarded and further 
digestion affected by 
collagenase II (0.8 mg/mL) 
for 4h at 37oC, 5% CO2 again 
with the same growth 
medium 
6) The digested tissue was 
allowed to settle and the 
supernatant containing the 
cells was  collected and 
centrifuged (1500g) for 10m 
at 4oC 
 Cells were seeded in 4 well culture plates at a density of 4000 cell/cm2 
 Culture medium consisted of an equal mix of Ham’s F12: DMEM 
supplemented with a range of growth factors  
 
 
 
 
Group  Supplements 
1 F12:DMEM, 2% FBS 
2 F12:DMEM, 10% FBS 
3 F12:DMEM, FGF2 (1ng/mL), TGF-β(1ng/mL) , 2% FBS 
4 F12:DMEM, FGF2 (1ng/mL), TGF-β(1ng/mL), ITS(10µg/mL) 
5 F12:DMEM, FGF2(1ng/mL), TGF-β(1ng/mL), ITS(10µg/mL) 
+2% FBS 
6 F12:DMEM, FGF2(1ng/mL), TGF-β(1ng/mL), ITS(10µg/mL) 
+10% FBS 
7 F12:DMEM, ITS, 2% FBS 
8 F12:DMEM, ITS, 10% FBS 
 
 Each medium was also supplemented with ascorbic acid(50µl/ml), 
penicillin (100 µl/ml), streptomycin (100µl/ml) and L-glutamine 
(200mM)  
 Cells were incubated at 37oC in a humidified 5% CO2 atmosphere for 
periods of up to 40 days. The medium was changed 2-3 time per week 
 Cells were examined for morphological changes daily by phase 
microscopy 
 When cells reached 70%-90% confluency, they were enzymatically 
detached with trypsin for ~2 min (0.25% w/v) in Ca2+ and Mg2+ free 
PBS 
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7) The pellet was washed three 
times with PBS or serum-free 
medium and resuspended. 
Cell suspensions were passed 
through a nitex nylon filter 
(70mm) into serum-
containing medium. 
8) Cell viability determined by 
trypan blue staining and a 
haemocytometer. 
 Harvested chondrocytes were washed and re-suspended in PBS before 
total cell count and viability assessment. 
 Chondrocytes from each medium were passaged 3 times and re seeded 
at the same starting density and culture media 
 
 
 
 
 
 
 
Markway, B. D., Cho, 
H. & Johnstone, B. 
Hypoxia promotes 
redifferentiation and 
suppresses markers of 
hypertrophy and 
degeneration in both 
healthy and 
osteoarthritic 
chondrocytes. Arthritis 
Res. Ther. 15, R92 
(2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Healthy chondrocytes from 
cadaver femoral condyles 
 
OA chondrocytes taken 
from patients undergoing 
total joint replacement 
surgery  
 
 
1) Samples were taken from the 
condyles and finely minced 
2) Digestion was carried out 
with protease (1% w/v) from 
Streptomyces Griseus in the 
presence of low glucose 
DMEM and penicillin-
streptomycin(1%) for 1h at 
37oC 
3) After 1h protease was 
substituted for collagenase II 
(1,300 U/mL) in DMEM 
antibiotics for 3h/ 37oC 
4) The suspension was passed 
through a strainer (40-µm) 
and centrifuged at 500 x g for 
5m 
5) Cells were then resuspended 
in low glucose DMEM w/ 
FBS (10%) and antibiotics 
ready for plating 
 
 
 
 
Monolayer expansion 
 
 Chondrocytes were seeded at a density of 7,000 cells per cm2 and 
expanded in monolayer culture in a standard tissue culture incubator 
under normoxia / 5% CO2 
 
Pellet Culture 
 
 Chondrocytes were redifferentiated between 1st and 3rd passage in a 
serum-free “chondrogenic induction medium.” 
 Medium consisted of high glucose DMEM, TGF-β1 (10 ng/ml), 
dexamethasone (10-7), ascorbic acid 2-phosphate (37.5µg/ml), sodium 
pyruvate (1mM), L-proline (40 µg/mL), 1 x ITS and antibiotics (as 
before) 
 Pellets were formed by centrifuging 1x105 cells at 500g in medium 
(250µl) and maintained in a hypoxic chamber set a 2% oxygen  
 Medium was changed every 2-3 days. 
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7.3 Conclusion from Survey 
 
             The search indicated that the media composition remains relatively unexplored 
although not without exception. The use of a high nutrient medium such as DMEM or Coon’s 
Modified Ham’s F12 in conjunction with fetal calf serum (or autologous serum in ACI 
protocol) and ascorbic acid derivatives is broadly encompassing of the typical approach. The 
use of serum appears to be the standard and represents one possible factor in phenotype 
modification, especially in ACI cases where serum composition may be affected by lifestyle 
choices or underlying disease. To address this investigators from the University of Genova (P 
Giannoni et al., 2005) suggested a defined medium protocol. Removal of serum from the 
expansion regime and replacement with a total defined medium that uses carefully controlled 
amounts of appropriate growth factors and cytokines to maintain chondrogenic capacity 
offers an advantage, especially from a manufacturing perspective that maybe look to employ 
allogenic cell lines. The use of serum in current regimes is preferential because it is cost-
effective, whereas the addition of exogenous growth factors and cytokines are comparatively 
expensive. For the work to be of any practical value identification of cost management 
opportunities will be paramount. 
  Extensive work by Paolo Giannoni et al. (2005) proposed a defined medium and the 
study brought about several other points of note. Firstly, serum-free conditions promoted 
rapid dedifferentiation of the chondrogenic phenotype in human chondrocytes compared to 
serum conditions yet reportedly provided superior results (defined by COL2 and aggrecan 
expression) when redifferentiated in 3D culture. The defined medium also boosted the 
proliferative capacity of the chondrocytes, reaching a 16 fold increase in population in 35 
days. The authors stated that, in contrast, the same increase in cell number takes three to four 
months in serum. The study also raised questions about the role of TGF-β1in sustaining 
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chondrogenic potential during expansion which with the same concern reiterated in a further 
study (R Narcisi et al., 2012). The work by Giannoni presents itself as an appropriate 
foundation on which to base the initial screening experiment around with other literature 
sources providing supplementary angles. Interestingly the media optimisation study by 
Enochson et al. (2012) found addition of an appropriate amount of TGF-β1was beneficial. 
The TGF β series appears to have a duality in chondrocyte culture that is not yet fully 
understood. 
The reoccurring theme across the literature is that the expansion of the cells to sufficient 
numbers is not the limiting factor but rather retaining the original phenotype of the cells 
during the expansion. To elaborate, Biterberg et al. (1994) would seed defects with an 
average size of 3.1 cm2 with 2.6 – 5 million cells. Following on from this Genzyme 
recommend seeding their expanded chondrocytes at approximately 2 million cells per cm2 
which is fairly representative of recommendations from other commercial outfits (C B 
Foldager et al., 2012). This level of expansion is easily achievable using standard T-flask 
culture. So the challenge can be defined as finding a way to preserve the quality of the cells 
while finding ways to reduce the cost of the manufacturing. 
 
8.0 Study Objectives 
 
The first objective is to isolate and cryopreserve a suitable cell strain for all 
subsequent experiments. Animal or human articular chondrocytes taken from disease-free 
joints are all acceptable sources and although the preference is for human chondrocytes 
circumstance will dictate which is used. Cell strain isolation will be based on existing 
literature accounts. The effect of expanding the chondrocytes using a conventional serum-
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containing medium and an in-house defined medium adapted from the literature will be 
assessed along with the effect of feeding frequency. Culture periods will be kept short as to 
avoid introducing extra variables that may be incurred during passaging. The specific 
metabolic fluxes of glucose, glutamine, lactate and ammonia will be measured in order to 
understand a) the nature of rate limiting event and b) to investigate if any interesting 
behaviours can be observed that may warrant further investigation as a potential marker of 
quality. Alongside this, some conventional methods of assessing quality in chondrocytes will 
be carried out. Specifically, SOX-9, 6 and 5 transcripts will be determined using RT-qPCR. 
Once rate-limiting events have been identified a screening experiment will be carried out to 
identify how the selected culture parameters directly affect the growth rate and SOX 
transcript expression and how they interact with other parameters. The nature of the work 
after this point will depend on the results but the ultimate aim is to time resolve, where 
applicable, the addition of the culture components to the medium as to create a finely 
controlled expansion environment that balances the need to achieve maximum cell volumes 
with cell quality in a cost-efficient manner.  
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CHAPTER B:  METHODOLOGY 
This chapter gives an account of the materials and methods used in the experiments 
described in this thesis. 
 
1.0 Cell Culture Medium, Wash Solutions, and Fibronectin Compositions. 
A variety of culture mediums and wash mixtures were used in the various 
experiments described. The tables below outline the components of the mediums and their 
composition. 
 
 
1.1 PBS with 3% Antibiotic & Antimycotic (AA)* (100mL) 
      
Component Source Catalogue 
Number 
Component 
Storage 
Concentration 
in mixture 
Weight / Volume 
added 
  
    
PBS - Ca2+ / - Mg2+ Lonza 17-516F RT N/A 97mL 
      
Antibiotic-
Antimycotic (100x) 
** 
Thermo Fischer 
Scientific 
 
15240062 
 
-20oC 
 
3% v/v 
 
3mL 
      
 
*  Shelf life of solution is seven days at 2-8oC 
**  Penicillin (10,000 units/mL), Streptomycin (10, 000 µg/mL and Amphotericin B (25 µg/mL) 
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1.2 PBS with 1% Antibiotic & Antimycotic (AA)* (100mL) 
      
Component Source Catalogue 
Number 
Component 
Storage 
Concentration Weight / Volume 
added 
  
    
PBS - Ca2+ / - Mg2+ Lonza 17-516F RT N/A 99mL 
      
Antibiotic-
Antimycotic (100x) 
** 
Thermo Fischer 
Scientific 
 
15240062 
 
-20oC 
 
1% v/v 
 
1mL 
      
 
*  Shelf life of solution is seven days at 2-8oC 
**  Penicillin (10,000 units/mL), Streptomycin (10, 000 µg/mL and Amphotericin B (25 µg/mL) 
 
1.3 Pronase E Digestion Medium*† (50mL) 
      
Component Source Catalogue 
Number 
Component 
Storage 
Concentration 
in mixture 
Weight / Volume 
added 
  
    
DMEM:F12 Thermo Fischer 
Scientific 
17-516F RT N/A 84mL 
      
Antibiotic-
Antimycotic (100x) 
** 
Thermo Fischer 
Scientific 
15240062 -20oC 1% v/v 1mL 
      
Fetal Bovine 
Serum 
Thermo Fischer 
Scientific 
10270098 -20oC 10% v/v 10mL 
      
GlutaMAX™ 
(200mM) 
Thermo Fischer 
Scientific 
35050061 RT 5mM 2.5mL 
      
HEPES (1M) Thermo Fischer 
Scientific 
15630056 2-8 oC 25mM 2.5mL 
      
Pronase E (3.5 U 
mg-1) 
Sigma Aldrich P5147-1G -20oC 70 U ml-1 1g 
      
 
*  Digestion medium divided into 5mL aliquots and frozen (-20oC) 
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† Medium passed through sterile filter before use (Nalgene™ Rapid-Flow™ Sterile, Thermo Fischer 
Scientific, catalogue number: 169-0045) 
** Penicillin (10,000 units/mL), Streptomycin (10, 000 µg/mL and Amphotericin B (25 µg/mL) 
 
1.4 Collagenase II Digestion*† Medium (200mL) 
      
Component Source Catalogue 
Number 
Component 
Storage 
Concentration 
in mixture 
Weight / Volume 
added 
  
    
DMEM:F12 Thermo Fischer 
Scientific 
17-516F RT N/A 68mL 
      
Antibiotic-
Antimycotic (100x) 
** 
Thermo Fischer 
Scientific 
15240062 -20oC 1% v/v 2mL 
      
Fetal Bovine 
Serum 
Thermo Fischer 
Scientific 
10270098 -20oC 10% v/v 20mL 
      
GlutaMAX™ 
(200mM) 
Thermo Fischer 
Scientific 
35050061 RT 5mM 5mL 
      
HEPES (1M) Thermo Fischer 
Scientific 
15630056 2-8 oC 25mM 5mL 
      
Collagenase II Thermo Fischer 
Scientific 
17101015 2-8 oC 300U ml-1 218.18mg 
      
 
*  Digestion medium divided into 40mL aliquots and frozen (-20oC) 
† Medium passed through sterile filter before use (Nalgene™ Rapid-Flow™ Sterile, Thermo Fischer 
Scientific, catalogue number: 169-0045) 
** Penicillin (10,000 units/mL), Streptomycin (10, 000 µg/mL and Amphotericin B (25 µg/mL) 
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1.5 FBS Expansion Medium with Antibiotics & Antimycotic*† (500mL) 
 
      
Component Source Catalogue 
Number 
Component 
Storage 
Concentration 
in mixture 
Weight / Volume 
added 
  
    
DMEM:F12 Thermo Fischer 
Scientific 
17-516F RT N/A 373mL 
      
Antibiotic-
Antimycotic (100x) 
** 
Thermo Fischer 
Scientific 
15240062 -20oC 1% v/v 2mL 
      
Fetal Bovine 
Serum 
Thermo Fischer 
Scientific 
10270098 -20oC 10% v/v 50mL 
      
GlutaMAX™ 
(200mM) 
Thermo Fischer 
Scientific 
35050061 RT 5mM 12.5mL 
      
HEPES (1M) Thermo Fischer 
Scientific 
15630056 2-8 oC 25mM 12.5mL 
      
2-Phospho-L-
ascorbic acid 
trisodium salt 
Sigma Aldrich 49752-10G RT  0.1mM 16mg in 50mL 
PBS 
      
 
* Medium Stored at 2-8 Deg and discarded after seven days. pH approximately 7.25 at 21oC (Degassed). 
Osmolarity not determined. 
 
† Medium passed through sterile filter before use (Nalgene™ Rapid-Flow™ Sterile, Thermo Fischer 
Scientific, catalogue number: 169-0045) 
 
** Penicillin (10,000 units/mL), Streptomycin (10, 000 µg/mL and Amphotericin B (25 µg/mL) 
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1.6 FBS Expansion Medium*† (500mL) 
      
Component Source Catalogue 
Number 
Component 
Storage 
Concentration 
in mixture 
Weight / Volume 
added 
  
    
DMEM:F12 Thermo Fischer 
Scientific 
17-516F RT N/A 375mL 
      
Fetal Bovine 
Serum 
Thermo Fischer 
Scientific 
10270098 -20oC 10% v/v 50mL 
      
GlutaMAX™ 
(200mM) 
Thermo Fischer 
Scientific 
35050061 RT 5mM 12.5mL 
      
HEPES (1M) Thermo Fischer 
Scientific 
15630056 2-8 oC 25mM 12.5mL 
      
2-Phospho-L-
ascorbic acid 
trisodium salt 
Sigma Aldrich 49752-10G RT  0.1mM 16mg in 50mL 
PBS 
      
 
* Medium Stored at 2-8 Deg and discarded after seven days. pH approximately 7.45 at 21oC (Degassed). 
Osmolarity not determined. 
 
† Medium passed through sterile filter before use (Nalgene™ Rapid-Flow™ Sterile, Thermo Fischer 
Scientific, catalogue number: 169-0045) 
 
 
 
 
 
1.7 Fibronectin Solution for Colony Isolation*† (10µg/mL) 
      
Component Source Catalogue 
Number 
Component 
Storage 
Concentration 
in mixture 
Weight / Volume 
added 
  
    
PBS - Ca2+ / - Mg2+ Lonza 17-516F RT N/A 100mL 
      
Calcium Chloride Sigma Aldrich C5670-100G RT 1mM 11mg 
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Magnesium 
Chloride 
Sigma Aldrich M4880-
100G 
RT 1mM 20mg 
      
Plasma Derived 
Bovine Fibronectin 
(1mg) 
Thermo Fischer 
Scientific 
33010018 2-8 oC 10µg/mL N/A 
      
 
* Solution divided into 7mL aliquots and stored at -20oC. 
 
† PBS supplemented with calcium and magnesium chloride passed through a sterile filter (Nalgene™ 
Rapid-Flow™ Sterile, Thermo Fischer Scientific, catalogue number: 169-0045) before using 1mL of 
the sterile mixture to reconstitute the lyophilized Fibronectin. The reconstituted Fibronectin was stored 
at 1µg/mL (-20oC) until needed. Dilutions were made by adding the required amount of stock solution 
to the appropriate volume of calcium and magnesium chloride supplemented PBS.  
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1.8 Defined Expansion Medium*† (100mL) 
 
      
Component Source Catalogue 
Number 
Component 
Storage 
Concentration 
in mixture 
Weight / Volume 
added 
      
DMEM  Thermo Fischer 
Scientific 
A1443001 RT N/A 94.95mL 
      
D-Glucose Sigma Aldrich G7021-1KG RT 1g/L 100mg 
      
Bovine Serum 
Albumin (Fraction 
V)  
Sigma Aldrich A9418-10G 2-8 oC 1% w/v 1g 
      
Chemically 
Defined Lipid 
Mixture 1 
Sigma Aldrich L0288-
100ML 
2-8 oC 0.5% v/v 0.5mL 
      
Kao and Michayluk 
Vitamin Solution 
(100x) 
Sigma Aldrich K3129-
100ML 
-20oC 1% v/v 1mL 
      
L-Glutamine 
(200mM) 
Thermo Fischer 
Scientific 
25030081 2-8 oC 5mM 2.5mL 
      
ITS (100x) Sigma Aldrich I2521-5ML 2-8 oC 1% v/v 1mL 
      
Dexamethasone‡ Sigma Aldrich D4902-
100MG 
-20oC 10-8 M mol/L 40µL 
      
Human 
Recombinant 
PDGF-BB‡ 
R&D Systems 220-BB-010 -80oC 10ng/mL 50 µL 
      
Human 
Recombinant 
FGF2‡ 
R&D Systems 233-FB-
025/CF 
-80oC 10ng/mL 8 µL 
      
Human 
Recombinant EGF‡ 
R&D Systems 236-EG-200 -80oC 10ng/mL 50 µL 
      
HCl (1N) Sigma Aldrich H9892-
100ML 
RT Variable Variable 
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* Medium Stored at 2-8 Deg and discarded after seven days. pH varies depending on the extent of 
degassing induced by vacuum filtration. Target pH approximately 7.30. Higher pHs can be reduced by 
adding HCI - 100µladdition to 100mL total volume achieves an approximate drop of 0.2. Osmolarity = 
 
† Medium passed through sterile filter before use (Nalgene™ Rapid-Flow™ Sterile, Thermo Fischer 
Scientific, catalogue number: 169-0045) 
 
‡ See 1.1.2.2 for reconstitution explanation  
 
 
1.9 Defined Resuspension Medium*† (100mL) 
      
Component Source Catalogue 
Number 
Component 
Storage 
Concentration 
in mixture 
Weight / Volume 
added 
  
    
DMEM  Thermo Fischer 
Scientific 
A1443001 RT N/A 100mL 
      
D-Glucose Sigma Aldrich G7021-1KG RT 1g/L 100mg 
      
Bovine Serum 
Albumin (Fraction 
V)  
Sigma Aldrich A9418-10G 2-8 oC 1% w/v 1g 
      
HCl (1N) Sigma Aldrich H9892-
100ML 
RT Variable Variable 
      
 
* Medium Stored at 2-8 Deg and discarded after seven days. pH varies depending on the extent of 
degassing induced by vacuum filtration. Target pH approximately 7.50. Higher pHs can be reduced by 
adding HCI - 100µladdition to 100mL total volume achieves an approximate drop of 0.2. Osmolarity = 
 
† Medium passed through sterile filter before use (Nalgene™ Rapid-Flow™ Sterile, Thermo Fischer 
Scientific, catalogue number: 169-0045) 
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1.10 Growth Factor and Dexamethasone Reconstitution Description  
      
Component Carrier 
Volume 
Albumin HCl (1N) Aliquot 
Volume 
Aliquot 
Concentration 
  
    
Recombinant 
Human TGF-β1 
(2µg) 
PBS - 100 µL 10mg 
(0.1%w/v) 
4mM 50µL 20 µg/mL (1 µg) 
      
Recombinant 
Human TGF-β3 
(2µg) 
  PBS -100 µL 10mg 
(0.1%w/v) 
4mM 50µL 20 µg/mL (1 µg) 
      
Human 
Recombinant 
PDGF-BB (10µg) 
PBS - 100 µL 10mg 
(0.1%w/v) 
4mM 50µL 100 µg/mL (1 µg) 
      
Human 
Recombinant FGF2 
(25µg) 
PBS - 500 µL 50mg 
(0.1%w/v) 
NA 8 µL 125µg/mL(1 µg) 
      
Human 
Recombinant EGF 
(200µg) 
PBS - 1000 µL 50mg 
(0.1%w/v) 
NA 5 µL 200ug/mL (1 µg) 
      
Dexamethasone Absolute 
Ethanol -  
N/A 4mM 40 µL  
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2.0 Method for Isolating α5-Integrin Receptor-Expressing Cell Sub-Population from 
Bovine Metacarpophalangeal Joints 
 
2.1 Tissue Explant 
Fresh metacarpophalangeal joints were obtained from twenty to twenty-four-month-
old cows at the FOYLE Melton Mowbray animal processing site under an AB117 home 
office permission license. Four joints were used in developing the explant and banking 
method. The clonal chondrocytes used in the described experimental chapters were derived 
from a single joint unless stated otherwise. The animal tag and kill number was recorded in 
the event the provenance of the material need to be evaluated later. Harvested tissue was 
packed on ice and transported back to the University for processing. The explant procedure 
commenced within two hours of the animal sacrifice. The tissue joint was gently washed with 
detergent to remove soil and grease before drying followed by removal of the hair with 
clippers.  The tissue was placed in a dissection tray and, using a scalpel and the appropriate 
PPE; incisions are made to reveal the ligaments that support the joint capsule. Severing the 
ligaments exposed the joint capsule. The joint was transferred to a sterile dissection tray in a 
laminar flow hood. PBS 3% antibiotic-antimycotic (1.1), pre-warmed in a water bath, (37oC, 
minimum 20 minutes) was pipetted over the cartilage surface to maintain a moisture layer. 
The cartilage was scraped off the surface using a sterile scalpel and the shavings placed into a 
Petri dish containing PBS containing 3% AA (1.1).  
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2.2 Primary Cell Isolation. 
The following procedure was conducted under sterile conditions. After the harvest 
was completed, an amount of wet tissue was weighed out and placed into a centrifuge tube 
(50mL) while maintaining sterility. The Pronase E digestion medium (1.3) (pre-warmed to 
37oC) was added to the tissue at a ratio of 1mL per 100mg of tissue. The mixture was placed 
in a water bath (37oC) and gently agitated every ten minutes.  The digestion was halted after 
one hour by removing the digestion medium with centrifugation (300g/5min, room 
temperature) and removal of the supernatant with an aspirator. The mixture was washed with 
PBS containing 3% AA (1.1). The tissue was centrifuged again (300g/5min) and the PBS 
wash removed and replaced with the Collagenase II Digestive Medium (1.4, pre-warmed 
37oC)   at a ratio of 1mL per 100mg of tissue. The mixture was placed in a water bath (37oC) 
and gently agitated every twenty minutes. After three hours the tube was removed from the 
water bath and centrifuged (300g/5min) before washing with 10mL PBS containing 1% AA 
(1.2, pre-warmed to 37oC). The PBS was aspirated off and the wash step repeated. After 
resuspending, the digestion mix was collected with a stripette (10mL) and passed through a 
filter (100µm) to remove undigested matrix and debris. The filtrate was collected and 
centrifuged (300g/5min) before removing the supernatant. The cell pellet was re-suspended in 
5-10mL of growth medium before cell counting. Cell counts were performed using a 
hemocytometer following the description in 7.1 
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2.3 α5-Integrin Receptor-Expressing Cell Strain Separation  
The cell subpopulation was isolated using the differential adhesion to Fibronectin 
assay described by Dowthwait et al. (2004). After performing the cell counts described in 7.1, 
six-well (Thermo Fischer Nunc™ Treated, Cat. No. 140675) plates that were pre-coated 
overnight with Bovine Fibronectin (1.7, diluted with PBS to give a final concentration of 
1µg/cm2).  The next morning the Fibronectin solution was aspirated from the wells prior to 
cell seeding. Densities of 104 cells/cm2, 52 cells/cm2 and 26 cells/cm2 were seeded and the 
volume of medium made up to a  total 1.5mL (1.1.1.5). One well was not subjected to 
Fibronectin pre-coating to confirm fibronectin-dependent attachment. Cells were allowed to 
adhere to the surface for twenty minutes in a humidified incubator (5% CO2/ 37
oC) before 
aspirating off the medium and unattached cells. Each well was replenished with 2mL of 
growth medium (1.5). Colonies, defined as clusters of cells sixty-four or more, were grown 
over a period of seven days. Medium was replenished after approximately 80 hours. 
 
2.4 Colony Isolation  
Colonies were typically judged to be ready for isolation once reaching a size of ~ two 
hundred cells or approximately eight population doublings. Colonies to be harvested were 
located using an inverted microscope and a mark placed on the outer surface of the well plate 
to denote the target area for cloning disks. Under sterile conditions, cloning disks (Sigma-
Aldrich, Cat. No., Z374431-100EA) were soaked in TrypLE Express (Thermo Fischer, Cat. 
No., 12604021) and manoeuvred onto the premarked colony using suitable forceps. Care is 
required not to streak the disk across the plate or over saturate the disk with the enzyme as to 
avoid the possibility of bleeding colonies together. The disk was left in place for five minutes 
before transferring to a fresh well plate containing 2mL of growth medium (1.6, pre-warmed 
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to 37oC). The disk was gently agitated once in the medium to encourage migration of cells to 
the tissue culture plastic. 
 
2.5 Mycoplasma Testing and Monitoring for Adventitious Agents   
After the Colony Isolation step, cells were expanded over five days before detachment 
and reseeding into T25 flasks (Thermo Fischer Nunc™ Treated, Cat. No. 136196) at a 
density of 3000 cells/cm2. Cells surplus to requirement were subjected to mycoplasma testing 
using a MycoAlert™ test kit (Lonza, Cat. No., LT07-118) according to manufacturer 
instructions. Samples that returned a negative group were advanced the cryopreservation 
stage. 
 
2.6 Cryopreservation and Formation of Working-Cell Bank 
The initial cell expansion yields between two to four million cells per colony isolation 
(approximately twenty-one to twenty-two population doublings). After this expansion period, 
cryopreservation was implemented. A master cryomix was made by adding one part DMSO 
(Sigma-Aldrich, Cat. No., D4540-100ML) to nine parts Fetal Bovine Serum (Thermo 
Fischer, Cat. No., 10270098). The cryomix was filtered through a compatible 0.2µm filter to 
achieve sterility. Detached cells were equilibrated with ambient temperature and placed at a 
concentration of 1x106 into pre-labeled cryovials containing 1mL of the cryomix. No more 
than ten minutes were allowed to elapse before placing completed vials in a Cool Cell™ at -
80oC. Processed cryovials were kept at -80oC for twenty-four hours before long-term storage 
in the vapor phase of liquid nitrogen. The expansion of all individual colonies yielded 
approximately one hundred and twenty vials there formed the basis of the working bank.  
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3.0 Thawing and Seeding of Cryopreserved Cells for Serum Based Expansions. 
A T175 was prepared by adding 28mL of medium (1.6) and allowing to thermally 
equilibrate in an incubator (37oC). Additional medium was also warmed (37oC). The vial was 
removed from cryostorage and immediately warmed in a water bath (37oC) until the vial 
thawed (approximately 90 seconds). Under sterile conditions, 1.5mL of the pre-warmed 
medium was added to the cryovial and mixed with a gentle pipetting action. The contents of 
the vial were transferred to a centrifuge tube containing 3.5mL of expansion medium (1.6). 
DMSO was removed by centrifuging at 250g for 5 minutes and aspirating off the supernatant. 
The cell pellet was re-suspended in 2mL of expansion medium. A cell count can be 
performed (7.2) to verify cell number and viability (membrane integrity).  The cell 
suspension was carefully added to the flask containing the pre-warmed medium avoiding 
bubble formation.   
 
4.0 Thawing and Seeding of Cryopreserved Cells for Defined Based Expansions. 
The procedure was as described in 3.0 with the following exceptions. The T175 vessel 
was pre-coated with 1µg/cm2 Fibronectin solution (14mL, 1.7). Once added the T-flask was 
placed in an incubator (37oC) and a two hour incubation period follows. After 2 hours the 
excess coating solution was removed and defined medium (1.8) added to the flask and 
allowed to equilibrate in the incubator for an hour prior to seeding  
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5.0 Cell Detachment Procedure for Serum Medium Expanded Cells. 
Under sterile conditions, the medium from the vessel was aspirated off and the cells 
washed with the appropriate volume (see vessel-volume ratio in the table) of PBS (37oC) as 
to remove traces of serum. TrypLE (37oC) was added to the vessel (see Table 1 for volume), 
the vessel placed back into an incubator (37oC) and the timer started. When processing 
multiple vessels, attention was required to limit the variation in exposure time. This was 
achieved, when working with T-Flasks, by adding the volume of dissociation reagent to the 
flask in an upright orientation and not allowing the enzyme to contact the cell surface till all 
flasks were prepared. In well plates were this was not possible the number of wells processed 
at any one time was limited to twelve so that difference in exposure time to the TrypLE 
between the wells was negligible. After the appropriate time had elapsed serum containing 
expansion medium (1.6) was added at a minimum ratio of 1:1.  
 
     
Expansion Vessel PBS Wash 
Volume 
TrypLE 
Volume 
Cleavage 
Time 
Quench 
Volume 
     
6 Well Plates 1mL 1mL 7 min 1mL 
     
T25 5mL 5mL 7 min 5mL 
     
T75  7mL 7mL 7 min 7mL 
     
T175 14mL 14mL 7 min 14mL 
     
 
 
Table.1 Reagent volumes for various expansion vessles. 
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6.0 Cell Detachment Procedure for Defined Medium Expanded Cells. 
The procedure was the same as in 5.0 with the exception of the quenching agent. Instead 
of using serum-containing medium a defined trypsin inhibitor (Thermo Fischer Scientific, 
Catalogue Number R007100) was added at a 1:1 ratio. 
 
7.0 Cell Counting Methods  
Cell counts were obtained using multiple methods depending on equipment 
availability. The  NucleoCounter® NC-3000™ (Chemotec) is the preferred count platform 
and accepts three formats, designated: Via-1 Cassette, A2 slides & A8 slides.  
 
 
7.1 Haemocytometer 
            The cell suspension was gently vortexed for 10 seconds to ensure mixing. A 50µL 
sample was taken and mixed with 50µL Trypan Blue solution (Sigma-Aldrich, Cat. No. 
T8154-100ML) to ascertain cell viability (membrane integrity). The mixture was gently 
vortexed for 10 seconds before spotting a hemocytometer with a ~20 µL sample. Four 
squares of the hemocytometer squares are counted obeying count rules using an inverted light 
microscope. Live cell number and cell viability is calculated using the formula: 
 
 
 
 
 
𝐓𝐨𝐭𝐚𝐥 𝐋𝐢𝐯𝐞 𝐂𝐞𝐥𝐥𝐬 (𝐦𝐋) =  𝐋𝐢𝐯𝐞 𝐂𝐞𝐥𝐥𝐬 𝐂𝐨𝐮𝐧𝐭𝐞𝐝 𝐗 
𝐃𝐢𝐥𝐮𝐭𝐢𝐨𝐧 𝐅𝐚𝐜𝐭𝐨𝐫
𝐍𝐨. 𝐨𝐟 𝐒𝐪𝐮𝐚𝐫𝐞𝐬
 𝐗 𝟏𝟎^𝟒 
 
 
𝐂𝐞𝐥𝐥 𝐕𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐲(%) = (
 𝐋𝐢𝐯𝐞 𝐂𝐞𝐥𝐥𝐬
𝐓𝐨𝐭𝐚𝐥 𝐂𝐞𝐥𝐥𝐬
) 𝐗 𝟏𝟎𝟎 
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7.2 Via 1-Cassette  
The cell suspension was gently vortexed for 10 seconds to ensure mixing. A 100µL 
sample is transferred to an Eppendorf ™ tube (1.5mL). The cassette tip was offered to the 
sample and the cell suspension drawn up into the cassette by applying pressure to the button. 
Cell counts are automatically calculated based on Acridine Orange total staining and DAPI 
for nonviable staining which are pre-loaded onto the cassettes. 
 
 
7.3 A2 and A8 Slides 
The cell suspension was gently vortexed for 10 seconds to ensure mixing. A 95µL 
sample was removed and mixed with five µL of solution 13 (pre-mix of DAPI and acridine 
orange, Chemotec, Catalogue Number 910-3013). The suspension was mixed by pipetting 
action before loading into the slide chambers (~10 µLper chamber). A2 and A8 slide formats 
use the same procedure with the difference being the number of individual chambers 
available.  
 
 
7.4 Growth Calculations 
Population doublings (equation 1) and specific growth rates (equation 2) were 
calculated using the expressions below  
𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔𝑠 =
1
log (2)
∙ log (
𝑐𝑥(𝑡)
𝑐𝑥(0)
) 
 
Equation 1. Population doubling expression where Cx(t) is the cell number at the end of the growth 
phase and Cx(0) is the cell number at time 0. 
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𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝐺𝑟𝑜𝑤𝑡ℎ 𝑅𝑎𝑡𝑒 =  
ln (𝑐𝑥(𝑡) 𝑐𝑥(0))⁄
∆𝑡
 
 
 
8.0 Light Microscopy 
Routine inspection of cells, cell imaging and cell counts using a hemocytometer were 
performed using brightfield microscopy on a Nikon Eclipse Ti inverted microscope (10x and 
40x magnification).  
 
9.0 pH Measurements 
pH readings were obtained using an Accumet™ AB150 pH meter (Fischer Scientific). 
Before taking readings, a one-point calibration was performed using a pH seven standard 
(Fischer Scientific, Cat. No. 10457440). 
 
10.0 Osmolarity Measurements 
Osmolarity was determined using an Osmomat 010 (Gonotec) osmolarity meter. The 
meter was calibrated before use by normalising with de-ionised water to 0 then calibrated 
using NaCl calibration standards. The osmeter probe was cleaned with distilled water 
between uses.   
 
Equation 2. Population doubling expression where Cx(t) is the cell number at the end of the growth 
phase, Cx(0) is the cell number at time 0 and Δt is the difference in time units between Cx(t) and 
Cx(0). 
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11.0 Metabolite Analysis  
Medium to be analysed was removed from the expansion vessel. After mixing by 
pipetting action, a 1mL sample was taken and placed in an Eppendorf ™ tube (1.5mL). The 
sample was stored at -20oC until processing. The storage conditions were assessed in 
previous experiments (data not shown) which concluded there was no significant difference 
in the observed metabolite concentrations from unfrozen samples tested immediately and the 
same sample tested after one month of storage at -20oC. Frozen vials were thawed at room 
temperature then vortexed before loading onto a Cedex Bio HD analyser (Roche). The 
analyser determines analyte concentration using enzymatic–spectrophotometric methods. 
Table 2 indicates the tests employed by the analyser. Before running, onboard calibration for 
each test is run and an independent sample containing known amounts of glucose, glutamine 
and lactate are run to assess the level of agreement between onboard calibration and sample 
concentration.  
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Component Supplier Catalogue 
Number  
Determination Method 
    
Glucose Bio HT Roche 06608418001 Hexokinase 
    
Glutamine Bio HT Roche 06605800001 Glutamine Hydrolysis to 
Glutamate  
    
Calcium Bio HT Roche 06990100001 NM-BAPTA 
    
Acetate Bio HT Roche 06608493001 Lactate to Pyruvate Conversion 
(IFCC method) 
    
Lactate Bio HT Roche 06608485001 Enzymatic oxidation by lactate 
oxidase 
    
NH3 Bio HT Roche 06608515001 Enzymatic amination by 
glutamate dehydrogenase 
    
Pyruvate Bio HT Roche 07299818001 Enzymatic reduction by lactate 
dehydrogenase with NADH 
    
Acetate Bio HT Roche 07044399001 Enzymatic reaction with acetyl 
CoA synthetase and citrate 
synthase 
    
 
 
Table 2. Consumables for the Cedex Biostation HD and the principle method for 
metabolite determination. 
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11.1 Calculation of Specific Metabolic Fluxes. 
 
           Cell normalised consumption or production rates were calculated using equation 3. 
 
 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑓𝑙𝑢𝑥 = (
𝜇
𝑐𝑥 (0)
) . (
𝑐𝑚𝑒𝑡(𝑡) − 𝑐𝑚𝑒𝑡(0)
𝑒𝜇𝑡 − 1
) 
 
 
12.0 RT-q PCR 
The account here describes how SOX 9, 6 and 5 mRNA transcripts were quantified 
using Reverse Transcriptase-Quantitative Polymerase Chain Reaction (RT-qPCR). The stages 
are broken down into Cell Archiving, RNA extraction, RNA quantification and quality 
control, Reverse Transcription, qPCR and Normalisation and copy number determination. 
The methods described were developed by qStandards PCR and assays were run at their site 
in Middlesex. 
 
12.1 Cell Archiving 
The cell suspension obtained after detachment was mixed with RNAlater™ RNA 
Stabilization Solution (Qiagen, Catalogue Number, 76104) at a ratio of 1:5 in an Eppendorf 
™  tube. The sample was stored at -20oC ready for RNA extraction at a later date. 
Alternatively, this step was excluded, and RNA extraction performed immediately after cell 
detachment.   
Equation 3. Expression for calculating specific flux rates where µ is specific growth rate (day-1), 
Cx(0) is the final cell number, Cmet(t) and Cmet(0) are the final and initial metabolite concentrations 
(mmol), respectively and t is time (day) 
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12.2 RNA Extraction and Purification  
RNA extraction and purification was achieved using RNeasy Mini Kit (Qiagen, 
Catalogue Number, 74104). The cell suspension (1x107 max) was lysed by aggressive 
vortexing for 5 minutes. The ethanol supplemented lysis buffer was added to the lysate then 
loaded onto the affinity column. The column was washed three times with distilled water and 
a centrifuge (30 seconds, 200g) to move the eluent out the column at each wash stage. After 
the initial wash steps, a DNase wash was added to remove genomic DNA contamination 
followed by a centrifugation step (30 seconds, 200g).  RNA was eluted from the column 
using the DNase/RNase free water by the addition of 5µl directly to the surface of the 
column. The product was eluted with a centrifugation step (30 seconds, 200g) into a sterile 
RNase-free collection tube. Samples were frozen before total RNA quantification and quality 
check at a later date. 
 
12.3 RNA Quantification  
RNA quantification was performed using a NanoDrop 2000 UV-Vis 
spectrophotometer. The machine was blanked using DNase/RNase water before loading of 
thawed samples. The 260/280, 260/230 absorbance’s were recorded along with the estimated 
quantity. Total RNA integrity was determined using an Agilent 6000 Bioanalyzer and Nano 
Chips (Agilent, 5067-1511). The ladder and samples were loaded as per instructions. The 
electropherogram was interrogated for 18 and 28s ribosomal peaks. Samples with a RIN 
higher than 9 were accepted and submitted for reverse transcription. 
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12.4 Reverse Transcription 
 The total RNA was reverse transcribed using the Qiagen Quantitect reverse 
transcription kit (Qiagen, Cat. No., 205313). Where possible 500ng of the total RNA was 
used in a 10µl reaction as per manufacturer instructions. Typically a reverse transcription 
duplicate was performed every five samples. Completed reactions were diluted tenfold and 
supplemented with 0.5µg/mL tRNA in water. cDNA was stored at -20oC until ready to 
perform the qPCR reaction. 
 
12.5 Primer Design  
Custom primers for SOX-9, 6 and 5 were designed using the NCBI Primer-Blast tool 
( https://www.ncbi.nlm.nih.gov/tools/primer-blast/ ) and were designed to be intro spanning 
as to avoid the amplification of genomic DNA and produced by Sigma-Aldrich using the pure 
and simple primer service. Primers for the endogenous controls for Beta-Actin (ACTB), 
Beta-2-Microglobulin (B2M) and Ribosomal Protein L13 (RPL13) were obtained as pre-
designed primers (Sigma-Aldrich, Cat. No., KSPQ12012). The primer sequences are outlined 
in table 3. 
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Primer Name Primer Direction Primer Sequence 
SOX-9 
FWD AACAAGCCGCACTCAAGCG 
REV GCCTGGCCGTTCTTCACCGA 
SOX-6 
FWD TCTCCTGCAACAACAGATCCAG 
REV GGGTAGTTATCACCTGGTTTGTATG 
SOX-5 
FWD TTCCCTTGCATGAAGTTGATGGCA 
REV CCTTTGCFCCTTTCAGGAGTTC 
ACTB 
FWD CAAGGCAACCGTGAGAA 
REV GTACATGGCAGGGGTGTTG 
B2M 
FWD CCACCCCAGATTGAAATTGA 
REV CAGGTCTGACTGCTCCGATT 
RPL13 
FWD TCCCACCACCCTATGACAAG 
REV GAGTAGGCTTCAGACGACA 
 
 
12.6 Preparation of Standards 
Separate standards for each of the three SOX genes were prepared from a PCR 
product. The target cDNA PCR product was run and separated using pre-cast agarose E-gels 
(Thermo Fischer, Cat. No., G661818). The electrophoresis and visualisation  was carried out 
on the E-gel Power Snap Electrophoresis device (Thermo Fischer, Cat. No., G8100). The 
intended product was identified using an E-Gel 1Kb plus DNA ladder (Thermo Fischer, Cat. 
No., 10488090). Once the cDNA product was identified, a slice of the gel containing the 
Table 3. Forward and reverse primers for genes of interest and endogenous control genes used in 
the qPCR reactions 
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band was excised and the gel dissolved and purified using the PureLink Quick Gel Extraction 
Kit (Thermo Fischer K2100-12). Purified products were stored in the elution buffer at -20oC 
until ready for use in PCR reactions. 
 
12.7 Quantitative Polymerase Chain Reaction  
 Two microliters of the previously reverse transcribed cDNA were amplified in a 10µl 
reaction using the Qiagen Quantifast SYBR Green master mix (Qiagen, Cat. No., 204154) 
with final primer concentrations of 500 nmol/L. A no template control was set up with 
0.5µg/mL of tRNA). A seven-point dilution of the previously prepared standards ranging 
from 10000000 to 10 copies were included in duplicate for each gene with every run. This 
gave the standard curve for copy number determination. The reactions were pipetted using a 
robot to reduce pipetting error (Qiagility) and loaded into the Rotor-Gene qPCR platform. 
Amplification parameters for the SOX genes were 95oC for 5 mins, followed by 40 cycles of 
95 oC for 10 seconds and 60 oC for 20 seconds. Due to primer-dimer formation in the SOX-6 
assay cycling conditions were altered to measure the fluorescence at 81 oC due to the primer 
dimers melting at 76 oC. The cycles were identical for the endogenous reference genes with 
the exception the annealing and extension temperature was reduced to 57 oC. Melt curves 
were run to check for product specificity. All melt curves produced a single peak with the 
exception of SOX-6. 
 
 
 12.8 Copy Number Determination and Data Normilisation.  
Copy number were determined from the standard curve and calculated directly by 
Rotor-Gene software. To account for differences in RNA quantity, reverse transcriptase 
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efficiency and other uncontrolled variables the gene of interest copy number was normalised 
to endogenous reference genes. The copy number of the three reference genes, ACTB, B2M, 
and RPL13, were calculated from their corresponding standard curves and used to calculate 
the geometric means (average copy number of all three genes). The geometric mean for each 
sample was divided by 10 000 before calculating the grand geometric mean (the average 
geometric mean from all samples). The geometric mean divided by 10000 was then further 
divided by the grand geometric mean to arrive at the normalisation factor. The determined 
copy number for each sample is then divided by the calculated normalisation factor to give 
the normalised copy number. 
 
13.0 Design of Expert and Design of Experiment setup   
Nine factors (Table 4) were screened for their impact on growth rate, metabolic 
function, and SOX gene expression. As discussed earlier, the factors were evaluated in table 
1 against a wider panel of candidates. The nine selected candidates were fed into a ½ fraction 
fractional factorial experiment with three centre points. Due to the erratic nature occasionally 
encountered and the generally sensitive nature of cell culture it was decided that replication 
of edge points was a sensible measure. Replication of edge points decreases the leverage of 
the individual run has over the experiment and also increases the power of the experiment. 
Factorial type experiments offer the advantage of built-in replication which means the 
replicates required to generate the desired power to observe a given effect size may be less 
than those required by non factorial designs. The 9-4 fractional factorial experiment breaks 
down into 32 individual runs, with the addition of four replications of  each edge point and 
three centre points a total size of 132 runs is reached, which is in the region of the suggested 
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sample size concluded from a priori power analysis generated using free-to-use GPower 
software.  
 
13.1 Design of Experiment Software and Setup   
 
The fractional factorial design matrix was generated using Design-Expert V7.0 by 
Stat-Ease. In order to access the design options first, a “new design” was selected from the 
file drop down tab. Next, the “Factorial” tab was selected and subsequently the “2-level 
factorial” option.  A nine-factor, 32-run which corresponds to a 9-4 resolution IV design was 
selected. At the bottom of the page, the “replicate number” was increased from 1 to 4 and the 
number of centre points increased from 0 to 3. The “continue” button generates the design 
alias list and cycling through the “continue” options allows the generic design matrix on the 
final page to be customised with the appropriate name tags for factors and outputs. The 
matrix generated was used to set the experimental conditions for each run. The returned 
experimental data was inputted into design matrix. Completing all the data fields allowed the 
analysis tab for each factor to be explored and the data output interrogated.   
 
13.2 Nuisance Experimental Factors  
A concern of the experiment was the potential impact of factors that were not directly 
under investigation but could have a profound effect on the dependent variable. The three 
factors of most concern were pH, variation between clones, and variation in consistency of 
feed mediums between feeds. The rapid degassing of culture medium that is outside of a 5% 
CO2 environment was a major problem encountered in the earlier chapter B studies, and with 
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the addition of HEPES deemed detrimental to the cell line a different strategy had to be 
adopted. Formulated mediums were allowed to rest for overnight to completely equilibrate 
with their surroundings. The pH at this time was typically about 8.4. Each total medium was 
titrated with 1N HCl to lower the pH to around 7.4. The medium was then transferred to the 
well plates and placed in an 5% CO2 incubator prior to seeding. Before seeding cells into 
their respective well plates, the pH was rechecked to confirm that the buffering capacity 
offered by the 5% CO2 atmosphere was sufficient and that the pH was holding around 7.4.  
The scale of the experiment has made the inclusion of biological (clonal) replication 
difficult to achieve. Previous results have shown that clones typically behave in a similar 
manner as each other although the magnitude of a given output measurement may vary from 
clone to clone. Quite often the variation arising from technical replication can eclipse 
variation arising from biological replication. With this in mind, it was decided that the 
screening experiment would be run with just one clonal replicate. A single vial of clonal 
chondrocytes was thawed according to protocol.  
Extended durations of culture demand replenishment of the growth medium. 
Variation of growth medium formulations made in-house, and the decomposition of proteins 
in stored medium could have an unknown and unquantifiable impact on output 
measurements. To mitigate the risk from this, the experiment was run in fed-batch 
configuration and the culture period limited to five days as to avoid necessary medium 
exchanges. 
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13.3 Experiment Setup 
The nine factors were assigned practical concentrations (Table 4). A single vial of 
clonal chondrocytes was thawed and pre-expanded over six days in the defined medium in 
order to reach appropriate cell numbers for the experiment.  
  Growth medium was made up to complement each of the 32 experimental runs and 
added to a well plate that had the appropriate concentration of fibronectin for that run. After a 
pH adjustment period and final check  (as described in 13.2) cells were added to the well 
plates to achieve the required seeding density for that run. The seed order for the experiment 
was randomised as was the order of cell sacrifice after the five day culture period in order to 
try and minimise time induced systematic bias. 
 
 
 
 
 
Factor Name Units Low Actual High Actual Low Coded High Coded 
A D - Glucose g/L 0.5 2 -1 1 
B 
L - 
Glutamine mmol 2.5 10 -1 1 
C ITS ml/L 5 20 -1 1 
D Fibronectin ug/cm2 0.5 2 -1 1 
E TGFβ1 % 0 10 -1 1 
F PDGF-BB. ng/mL 0 20 -1 1 
G FGF2. ng/mL 0 20 -1 1 
H EGF ng/mL 0 20 -1 1 
J Seed Density cells/cm2 1500 6000 -1 1 
 
 
Table 4. Candidates for screening paired with their respective coded and actual values 
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13.4 Fractional Factorial Screening Experiment Results 
Data from each output field is displayed as a Pareto chart. The chart includes the t 
value limit for significance. The chart shows effects in one of two colours. Orange colours, or 
“positive effects”, show that the highest response for the observed output was achieved when 
that factor was in the higher of the two experimental levels. Conversely, blue colours, or 
negative effects ”, show that the highest response for the observed output was achieved when 
that factor was in the lowest of the two experimental levels. To account for inflation in 
family-wise error rate when making multiple comparisons a correction factor was included. 
The Bonferroni limit (shown in orange) is the threshold for significance in these experiments. 
Anything above the threshold can be considered as having a statistically significant impact on 
the measured output. Two-factor interactions were predominately but not exclusively aliased 
with three factors interactions; any confounding issues are highlighted in the discussion if a 
two-factor interaction is of interest. Three-factor interactions, due to the level of aliasing, 
were disregarded.  To assess the confidence in the returned data a number of diagnostic tests 
are presented to support the Pareto chart. These charts are; the normal probability plots to 
assess whether residuals follow a normal probability, a line fitted residuals versus run order 
to establish if any time-related bias during processing significantly influenced the result, 
externally studentized residuals versus run order to highlight potential outliers and leverage to 
highlight any runs that are having a disproportionate influence on the fitted model 
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CHAPTER C: EVALUATION OF FEEDING FREQUENCY ON THE GROWTH OF 
MONOLAYER EXPANDED CRYOPRESERVED CLONAL BOVINE ARTICULAR 
CHONDROCYTES  
 
The literature contains varied accounts of nutritional regimes for expanding 
chondrocytes as highlighted in chapter A ( pages 30-43). Understanding and identifying a 
preferred regime could be of high value to industry and healthcare outfits that require large 
volumes of cells. In order to evaluate the effect of feeding frequency a cell bank of clonal 
bovine chondrocytes was first established. 
 
1.0 Isolation of Clonal Articular Chondrocytes, Cryopreservation and creation of the 
Cell Bank 
Bovine chondrocytes were isolated from the Metacarpophalangeal joints of eighteen 
to twenty-four-month-old cows. Clonal strains were isolated using the differential adhesion to 
Fibronectin method described by Dowthwaite et al. (2002). Colonies that had reached 
approximately two hundred cells in size after five days (Fig.1) were isolated using cloning 
disks and transferred to T25s and allowed to become confluent before transferring to T75s. 
Cells were banked at P2 in DMSO-FBS and stored in vapour phase liquid nitrogen ready for 
subsequent experiments. In order to minimise biological variation, all experiments were 
performed with clonal strains obtained from a single donor unless otherwise stated.  
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2.0 Cell Counting Methods 
 Cell counting is staple of the project, and as a number of different methods were 
available, a brief experiment was run in order to choose the most appropriate method. A 
10mL cell suspension was divided into 100µl aliquots and the aliquots randomised. Batches 
of aliquots were assigned to one of four methods: Manuel Haemocytometer count, 
Automated NC-3000 Via-1 Count, Automated NC-3000 A2 Count and Automated NC-3000 
A8 count. Each count method used ten aliquots to generate ten cell counts (Fig. 2). The 
experimenter produced single outliers in both the Via-1 and A2 groups. In the instance of the 
Via-1 group the outlier corresponded to a small air bubble introduced into the cassette during 
sample acquisition. The same explanation does not apply to the A2 group and instead, it was 
postulated that the outlier was simply the result of pipetting error. In either case, the outliers 
highlight the importance of care in the sample preparation stage. It was decided not to remove 
the outliers from the data set. Off the back of the experiment, it was decided that the Via-1 
  
Fig.1 Images of colonies after six days of expansion. Cells were seeded at a density of 
approximately 104 cells/cm2 on tissue culture plastic pre coated with 1µg/cm3 of bovine 
fibronectin. Scale bars: 100µm. 
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Cassette would be the exclusive counting method used for all experiments based on a 
combination of ease of use, time to prepare the count and precision of the test data.  
 
 
 
 
 
 
 
 
3.0 Effect of Feeding Frequency on Growth Kinetics. 
Different feed intervals were imposed during a five-day expansion of the clonal 
chondrocyte strains to understand the impact on the growth kinetics and metabolic activity. 
Batch, seventy-two-hour and a twenty-four-hour feed regime were studied separately in T-
flasks. The aim is to understand if increased nutritional supplementation is an effective 
method of increasing biomass while maintaining cell phenotype.   
For each of the feeding regimes under investigation, three vials of cryopreserved 
clonal chondrocyte strains were thawed and expanded with serum containing medium in 
separate T175s for five days to reach appropriate numbers for a growth curve experiment. 
T25 flasks were seeded at a density of 3000 cells cm2 and supplied with 0.2mL/cm2 of FBS 
 
Fig.2 Box plot showing the distribution of total cell counts as determined by four different 
counting methods. Each measurement was performed ten times from independently pipetted and 
randomized samples. 
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containing expansion medium and placed in a humidified incubator (37oC) with a 5% CO2 
atmosphere. The growth curve was obtained by sacrificial cell counts at twenty-four-hour 
intervals. Medium samples were taken from the sacrificed flasks and stored at -20oC prior to 
metabolite analysis. Flasks from each group were fed according to their group. Flasks 
belonging to the batch group were not replenished over the five-day period. Flasks from the 
seventy-two hour were replenished by means of a total medium exchange after seventy-two 
hours in culture and similarly, flasks in the twenty-four-hour feed group were replenished 
with medium daily. Cumulative population doublings were determined from sacrificial cell 
counts taken at twenty-four-hour intervals and the specific growth rates are reported for the 
batch (Fig.3), seventy-two hour (Fig. 4 and 5) and the twenty-four hour (Fig. 6) experiments. 
The mean differences of the growth rates obtained for the batch, seventy-two hour and 
twenty-four-hour groups were tested for significance (Fig 7). 
 
 
  
 
 
Fig.3 Cumulative population doublings (A) of three clonal strains over a hundred and twenty 
hours under batch operation. Specific growth rate (B) for the same three clonal strains over the 
one hundred and twenty hour period. Error bars show standard deviation of the mean (n=3) 
 
 
 
A B 
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Cumulative population doublings of the clonal strains in the batch experiment reached 
2.53 ± 0.19, 2.32 ± 0.06 and 3.25 ± 0.48, respectively, after five days in culture (Fig 3 A). 
The increase in biomass was equivalent to growth rates of  0.44 day -1 ± 0.03, 0.40 day -1 ± 
0.010 and 0.50 ± day -1  0.08 for each of the strains (Fig. 3 B).  
 
 
 
 
 
 
 
 
 
 
Fig.4 Cumulative population doublings of three clonal strains from the same donor (A) over a 
hundred and twenty hours under three day feed operation. Cumulative population doublings (B) of 
three clonal strains over a hundred and twenty hours under three day feed operation. The clonal 
strains used here were obtained from a different biological donor to provide a rough assessment of 
the impact of donor variation. Error bars show standard deviation of the mean (n=3) 
 
A B 
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Cumulative population doublings achieved for the clonal strains in the seventy-two-
hour feed experiment reached 2.53 ± 0.19, 2.32 ± 0.06 and 3.25 ± 0.48, respectively, after 
five days in culture (Fig. 4 A). Strains 1-3 were obtained from the primary cell bank whilst 
strains 4-6 were obtained from a different biological donor in (Fig. 4 B). Population 
doublings obtained from these clonal strains reached 3.29 ± 0.47, 3.65 ± 0.34 and 3.56 ± 
0.45, respectively. The corresponding growth rates for the six strains were recorded as 0.63 
day -1 ± 0.15, 0.51 day -1 ± 0.03, 0.81 day -1 ± 0.13, 0.63 day -1 ± 0.06, 0.62 day -1 ± 0.08 and 
0.48 day -1 ± 0.031. The differences in growth rates between the strains from obtained from 
different donors was approximately 12%. 
 
 
Fig.5 Specific growth rate for the clonal strains, combining the data from two separate biological 
donors onto the same axis with strains four to six from a separate donor. The growth rates were 
obtained from strains fed under seventy-two hour operation cultured over a five-day period. Error 
bars show standard deviation of the mean (n=3). 
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Cumulative population doublings for the three clonal strains from the twenty-four-
hour feed experiment were 4.20 ± 0.06, 4.067 ± 0.27 & 3.93 ± 0.20, respectively, after five 
days in culture (Fig 6 A). The increase in biomass was equivalent to growth rates 1.33 day -1 
± 0.12, 0.75 day -1 ± 0.21 and 0.91 day -1 ± 0.21, respectively for each of the strains (Fig. 6 
B).  
 
c 
 
Fig.6 Cumulative population doublings (A) of three clonal strains over a hundred and twenty 
hours under twenty-four hour feed operation and corresponding specific growth rates (B). Error 
bars show standard deviation of the mean (n=3) 
 
  
B A 
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The difference between the growths rates from the three feed experiments were tested 
for significance (Fig. 7). The three data sets were judged to approximate normality before 
performing a one-way ANOVA.  The ANOVA suggested there difference between the 
groups was significant with the significance threshold set at 0.05. Group data sets were tested 
for equality of variance before performing post-hoc T testing to ascertain between which 
groups a significant difference could be recorded.  Three comparisons were made and as a 
precaution against type I error a family-wise error correction was applied in the form of the 
Bonferroni correction. Accordingly, the threshold for significance was set at 0.017. There 
was no significant difference between the means of the batch (M=0.47, SD=0.084) and 
seventy-two-hour feed (M=0.63, SD=0.09) conditions; t (7) 3.56, p=0.045. A significant 
difference between batch (M=0.47, SD=0.086) and twenty-four-hour feed (M=0.75, 
SD=0.11) conditions; t (16) 6.06, p=0.010 was recorded. The difference between the means 
 Fig.7 Averaged Specific growth rates for all clonal strains across the three different feed 
operations over the one hundred and twenty hour period. Significance was tested using a single 
factor ANOVA (α=0.05) which yielded a p value of 0.012. Individual significances were 
calculated using Bonferroni corrected post-hoc T tests. Error bars show standard deviation of the 
mean (n= 3-6)  
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of the seventy-two-hour feed experiment and the twenty-four-hour experiment were not 
found to be significant, conditions; t (7) 1.82, p=0.11. 
 
 
3.1 Discussion of Batch, Seventy-Two and Twenty-Four Hour Feed Experiments 
 
Imposing different feeding routines on the clonal strains had a quantifiable effect on 
the growth kinetics of the clonal strains. The differences in specific growth rate between the 
twenty-four-hour feed operation for the combined clonal replicates were found to be 
statistically significant when compared to the batch operation (Fig.7). The difference between 
the seventy-two hour and the twenty-four-hour feed operation and the batch operation was 
not found to be significant when the Bonferroni correction was applied. The shape of the 
growth curves from the three experiments yields illustrates the effects of imposing different 
feed operations.  The average number of population doublings at the seventy-two-hour time 
point was similar for all feed operations: 2.26, 2.42 and 2.22 for the batch, seventy-two hour 
and twenty-four-hour operations, respectively. After seventy-two hours the clonal strains 
grown under the batch feed operation began to slow and resulted in a plateau over the next 
forty-eight hours in two of the three clonal replicates. In contrast to this, a medium exchange 
at seventy-two hours sustained proliferation although appeared to induce a lag in growth in 
some of the clonal strains. A daily feed operation resulted in a more linear-like growth phase 
after seventy-two hours had elapsed.   
The feed experiments suggested that a rate-limiting event is occurring around the 
seventy-two-hour time point that can be circumnavigated partially by re-feeding at seventy –
two hours or entirely by refeeding every twenty-four hours. These findings are entirely 
consistent with the literature (J Melero-Martin, 2004) which reported frequent split feeds 
result in an enhanced growth rate of clonal chondrocytes. The same study showed that the 
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growth rate was serum dependent. To investigate whether the nature of the rate-limiting event 
is due to depletion of medium components, build-up of growth inhibiting metabolites or a 
combination of both.  Analysis of the metabolite concentration in the growth medium was 
undertaken in an attempt to better define the nature of the rate-limiting event. 
 
4.0 Metabolite Analysis of Culture Medium taken from Batch, Seventy-Two Hour and 
Twenty Four-Hour Feed Operation. 
 
Frozen medium samples were thawed at room temperature and screened for glucose, 
glutamine, ammonia, and lactate concentration. Metabolite concentrations were determined 
with a Cedex Biostation HT which automates the glucose hexokinase, glutaminase, glutamate 
dehydrogenase and lactate oxidase assays. Assays were run as single reactions. Gross and 
total consumption/production are reported along with specific consumption/production rates 
for each of the metabolites.  
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Fig.8 Gross consumption / production in mM of glucose (A), lactate (B), glutamine (C) and 
ammonia (D) from the batch experiment over a one hundred and twenty hour culture with offline 
measurements made twenty-four hours apart. Error bars show standard deviation of the mean 
(n=3)  
A                                                                                      B 
C                                                                                      D 
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Fig.9 Total consumption / production in mM of glucose(A), lactate (B), glutamine (C) and 
ammonia(D) from the batch fed experiment over a one hundred and twenty hour culture with 
offline measurements made twenty-four hours apart. Lactate and ammonia concentrations were 
adjusted by subtracting background concentrations in the medium Error bars show standard 
deviation of the mean (n=3)  
A                                                                                      B 
C                                                                                      D 
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Fig.10 Specific consumption / production rates in pmol.cell-1.day.-1 for glucose (A), lactate (B), 
glutamine (C) and ammonia (D) from the batch fed experiment over a one hundred and twenty 
hour culture. Error bars show standard deviation of the mean (n=3)  
A                                                                                      B 
C                                                                                      D 
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4.1 Discussion of Batch Metabolite Data 
The metabolite analysis of the batch experiment revealed some interesting points. 
Over the one hundred and twenty hours of culture, glucose and glutamine levels fail to 
deplete  (Fig.8 A and C) so cannot be the rate-limiting substrates. Over the culture period, the 
clonal strains consumed an average of 0.9mM and 0.98mM for glucose and glutamine, 
respectively (Fig.9 A and C) This translates to an average specific consumption of 313 and 
405 pmol.cell-1.day.-1 for glucose and glutamine, respectively (Fig. 10 A and C). These 
figures are in the range of thirty to forty times higher than those previously reported for 
human mesenchymal stem cells (Heathmen et al., 2015) although these bovine clonal 
chondrocytes display growth rates approximately 2.5 larger over a shorter time period and 
restricted feeding.  
        The accumulation of waste product is another possible origin of the stunted growth rate 
seen when imposing a batch operation. Typically regarded as a waste product in cell culture, 
lactate is produced as a by-product of glycolysis when insufficient oxygen is present to allow 
oxidation of pyruvate to acetyl CoA. Instead of being utilised in the tricarboxylic acid cycle 
the pyruvate is reversibly, converted to lactate by lactate dehydrogenase. Some cell lines can 
convert lactate to glucose via the Cori cycle (C Cori 1931), although, it is not known if 
chondrocytes have this capability. The accumulation of lactate in culture medium is known to 
inhibit cell growth, however, concentrations that are deemed inhibitory to growth appear to 
vary greatly depending on cell type. Srček et al. 2010, reported decline in growth rates of 
channel catfish ovary cells starting at lactate concentrations of 2.5mM, in contrast, Hayter et 
al., 1991 reported lactate concentrations as high as 22mM are tolerated by CHO cells. The 
only study to investigate the effect of lactate concentration on growth rate in chondrocytes 
demonstrated that growth did not plateau until the cumulative concentration reached 
approximately 22mM (J Malero-Martin, 2004). Two of the three clonal strains showed 
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average lactate concentrations in the region of 2.5mM and the third strain, approximately 
1.4mM of lactate (Fig 9 B). With this in mind, it is unlikely that the lactate concentrations 
encountered over this short culture duration were rate-limiting. While the primary aim of this 
study was to identify potentially rate-limiting events and interesting metabolic behavioural 
pattern was uncovered. Specific lactate production versus glucose consumption ratios were as 
high as 4:1 which suggests anaerobic glycolysis dominates (Fig. 10 A and B). This apparent 
behaviour arises even without imposing anaerobic conditions on the culture. This behaviour 
is indicative of the Warburg effect, which describes the phenomenon of enhanced lactate 
production even with nominal oxygen concentrations. This effect is associated with altered 
glycolytic pathways, which in turn, is associated with some cancers (J W Locasale et a., 
2016). The significance of this observed effect in this instance is unknown however, one 
concern is that the clones may have developed chromosomal abnormalities. Chromosomes 17 
and 18 carry the P53 tumour suppressor gene and DCC gene. Alteration or deletion of these 
genes is implicated in some colorectal cancers (J Garcia et al., 2003). Karyotypic analysis of 
human clonal chondrocytes isolated using the same methodology described here have 
previously shown abnormalities in the form of deletion of the long arm of chromosome 20 (R 
Williams et al. 2010).  The existence of karyotypic abnormalities in these strains was not 
investigated further but sets a precedent for future investigation.  
Ammonia is another well-documented rate limiting metabolite that is produced as a 
by-product of amino acid metabolism. Ammonia has been reported, in some cell lines, to be a 
more potent inhibitor of growth when compared to lactate, with concentrations as little as 
1mM having a quantifiable impact on specific growth rate (Srček et al., 2010). The average 
net production of ammonia in the batch experiment was approximately 0.5mM, so it is 
unlikely that ammonia accumulation is having a significant impact on the growth rate in this 
instance. While overall ammonia concentrations in the growth media were modest the 
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specific production were comparatively high, averaging approximately 700 pmol.cell-1.day.-
1(Fig. 10 D). This observation may be linked to the apparent metabolic preference for lactate 
production over the oxidative phosphorylation of pyruvate. In order to help meet cellular 
energy requirements a higher rate of glutamine is utilised as a precursor to α-ketoglutarate, an 
intermediary in the TCA cycle. As a consequence of over-reliance on this pathway, increased 
levels of ammonia are encountered as a by-product of the oxidative deamination of glutamate 
(Grabowska et al., 2015). Whilst re-prioritising of metabolic pathways and substrate 
preferences provides a sensible explanation of the high specific ammonia production rates the 
hypothesis is, ultimately, confounded by the non-enzymatic decomposition of glutamine in 
the culture medium. This decomposition obscures both the glutamine consumption rate and 
the ammonia production rate, with one study reporting that the difference between apparent 
and actual uptake/production to be in the region of 200% (O. Palsson et al., 1990). 
Comparative differences in seventy-two hour and twenty-four-hour feed operations may 
reveal if the high specific ammonia production is a common feature of these cell strains or a 
result of imposing a batch strategy and hence were studied next. 
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Fig.11 Gross consumption / production in mM of glucose (A), lactate (B), glutamine (C) and 
ammonia (D) from the seventy-two hour feed (100% exchange)  experiment over a one hundred 
and twenty hour culture with offline measurements made twenty-four hours apart. Only clonal 
strains 1-3 were tracked at each twenty-four-hour time point. Error bars show standard deviation 
of the mean (n=3). 
A                                                                                      B 
C                                                                                      D 
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Fig.12 Total consumption / production in mM/L of glucose (A), lactate (B), glutamine (C) and 
ammonia (D) from the seventy-two hour feed (100% exchange) experiment over a one hundred 
and twenty hour culture . Offline measurements were made every twenty-four hours for 
replicates 1-3 and at 72h and 120h for strains 4-6. Total consumptions were calculated by the 
addition of  the background correct values recorded at 72 and 120hs. Error bars show standard 
deviation of the mean (n=3)  
A                                                                                      B 
C                                                                                      D 
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Fig.13 Specific consumption / production rates in pmol.cell-1.day.-1  for glucose (A), lactate (B), 
glutamine (C) and ammonia (D) from the seventy two hour feed experiment over a one hundred 
and twenty hour culture. Error bars show standard deviation of the mean (n=3)  
A                                                                                      B 
C                                                                                      D 
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4.2 Discussion of Metabolite Date from Seventy-Two Hour Feed Operation 
 
         Metabolic behaviour in the seventy-two-hour feed experiment shows some similarities 
to that of the batch experiment but also some subtle differences.  The average total level of 
glucose consumption over the culture period for all six strains was 1.13 mM (Fig.12 (A)) 
which was only slightly elevated from the batch experiment but equates to a large difference 
in specific glucose uptake (Fig. 13 (A)). It appears that less glucose uptake, in this instance, 
translates to an increased growth rate and it is tempting to speculate that this could be due a 
shift in metabolic pathway preference that favours more efficient glucose usage.  The specific 
lactate production was also, on average, lower with 286 pmol.cell-1.day.-1 (Fig.13 (B)) versus 
844 pmol.cell-1.day.-1 for the batch experiment (Fig, 10 (B)). Specific glutamine consumption 
was substantially lower in the seventy-two-hour feed (Fig. 13 (C)), which, on average, led to 
a drop in specific consumption of 310 pmol.cell-1.day.-1 over the batch culture (Fig.10 (C)). 
Related to this was a large drop in specific ammonia production (Fig. 13 (D)) compared to 
the batch experiment (Fig. 10 (D)). The specific lactate, glutamine and ammonia fluxes are 
all consistent with the view of a shift in metabolic pathway preference that favours the 
oxidative phosphorylation of pyruvate with less demand on glutamine as an alternate energy 
source.  
Although specific lactate and ammonia fluxes are lower than those observed in the 
batch experiment, absolute levels were higher. Gross lactate and ammonia concentrations 
both averaged in the region of 2.3mM. Interestingly, maximum ammonia and lactate 
concentrations of 1.1mM and 2.5mM, respectively, were experienced at seventy-two hours 
but growth for all of the clonal replicates endured. This suggests that lactate and ammonia 
concentrations in this region are, to some extent, tolerated by this cell type.  
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Fig.14 Gross consumption / production in mM of glucose (A), lactate (B), glutamine (C) and 
ammonia (D) from the seventy-two hour feed (100% exchange)  experiment over a one hundred 
and twenty hour culture with offline measurements made twenty-four hours apart. Only clonal 
strains 1-3 were tracked at each twenty-four-hour time point. Error bars show standard deviation 
of the mean (n=3). 
A                                                                                      B 
C                                                                                      D 
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Fig.15 Total consumption / production in mM of glucose (A), lactate (B), glutamine (C) and 
ammonia (D) from the twenty-four hour feed (100% exchange) experiment over a one hundred 
and twenty hour culture. Total consumptions were calculated by the addition of the background 
correct totals recorded at each twenty-four-hour interval. Error bars show standard deviation of 
the mean (n=3)  
 
A                                                                                      B 
C                                                                                      D 
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Fig.16 Specific consumption / production rates in pmol.cell-1.day.-1  for glucose (A), lactate (B), 
glutamine (C) and ammonia (D) from the twenty four hour feed experiment over a one hundred 
and twenty hour culture. Error bars show standard deviation of the mean (n=3) 
A                                                                                      B 
C                                                                                      D 
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4.3 Discussion of Metabolite Date from Twenty-Four Hour Feed Operation 
 
            Data from the twenty-four-hour feed experiment suggest that the imposition of this 
frequency of feeding promotes more efficient use of glucose with respect to specific 
consumption when compared to batch and seventy-two-hour feed modes. Glucose to lactate 
ratios where similar in the twenty-four-hour experiment neared a 1:1 consumption to 
production ratio (Fig 16 (A) and (B)). Total lactate and ammonia (Fig 15 (B) and (D)) 
accumulation was minimal and thought unlikely to impede growth kinetics. A general 
observation was noted that the metabolic behaviour of the cell strains was rather homogenous 
in the twenty-four-hour feed experiment when compared to the data sets from the batch and 
seventy-two-hour feed experiments. The significance of this observation or its direct 
implication on cell expansion strategy is not currently known.    
 
4.4 Summary of Metabolite Results from Batch, Seventy-Two-Hour and Twenty-Four-
Hour Feed Experiments.  
 
The metabolite data obtained from the three experiments allows a number of observations 
to be drawn. The differences in growth rate of the clonal strains observed because of the three 
feeding regimes: 
- Was not caused by depletion of glucose or glutamine. 
- Maybe partly accounted for by build-up of lactate and/or ammonia. Although the total 
differences in metabolite consumption or production between 24h, 72 and fed-batch 
regimes were not statistically significant (Fig. 17) 
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- Maybe dose dependent behavior to components contained within the Fetal Calf 
Serum. 
 
 
 
 
 
 
 
 
 
Publications to date have demonstrated the growth kinetics can be enhanced in a dose-
dependent manner by supplementing the growth medium with recombinant proteins such as 
fibroblastic growth factor (K H Chua et al., 2007., Gerjo van Osch et al., 2002. ) and Platelet 
Derived Growth Factor-BB (J Wroblewski and C Edwall, 1992) as well  as serum on its own 
(Chua KH, 2004).  
 Mammalian cell culture is hugely dependent on the use of fetal calf serum. The exact 
composition of serum varies from batch to batch but can be summarized as a mixture rich in 
albumin, insulin, cortisone, thyroxine, PTH (Parathyroid Hormone), PGE (Prostaglandin E), 
 
Fig.17 Comparison of differences in metabolite consumption or production from the 24h, 72h and 
fed batch experiments. The differences between the groups were tested for significance using 
ANOVA. No differences were found to be significant. Error bars show standard deviation of the 
mean (n=3)  
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Cholesterol and fatty acids (P J Price & E A Gregory, 1982). Serum use is widespread owing 
to the fact it is readily available, relatively affordable and supports the growth of a diverse 
range of cell lines. Despite these apparent advantages of serum, there are number of 
arguments against the use of serum. Serum by nature is a poorly defined component of cell 
culture and varies from batch to batch. The manufacture of therapeutic cells will likely follow 
a similar regulatory framework to that that overseas the manufacturer of pharmaceuticals. 
This demands that the operating space be under tight control of the user, with all variables 
that can affect quality accounted for (FDA Guidance for Industry, 2009). Further, some of the 
components of serum may induce undesirable phenotypic changes in the cell line during 
culture. Any large-scale cell therapy that may employ the use of human serum will be wary 
of the possibility of adventitious agents that may be present in the natural product. A large 
demand for serum may also place pressure on blood banks sparking supply chain problems 
and spark an ethical debate on the use of donated whole blood (Zielinski MD et al., 2014). 
Finally, there is an ethical argument to be made to reduce the reliance on fetal calf serum in 
mammalian cell culture in a bid to reduce the burden on animals and align research practice 
with the 3Rs.  
A chemically defined medium substitutes serum for known quantities of naturally 
sourced or recombinant proteins. The exact composition is specific to the cell type. A number 
of publications to date have published a “recipe” for a chemically defined medium that 
supports the growth of human chondrocytes (Xin-xin Shao et al., 2013., P. Giannoni et al. 
2005., Malpeli et al., 2004). While the formulas vary from author, they all share some 
common components, namely albumin, ITS, EGF, FGF-2 and PDGF-BB. These formulations 
formed the basis for the defined medium described herein. The objective of using a defined 
medium is to ultimately, understand exactly how the individual components influence growth 
 107 
 
rate, metabolic behaviour, and phenotype. The initial studies aim to replicate the work 
completed using the serum-containing medium with a defined medium. 
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5.0 Evaluation of Feeding Frequency on the growth of monolayer-expanded cryo 
preserved clonal bovine articular chondrocytes using a chemically defined medium  
 
5.1 Formulation of a Chemically Defined Medium  
 
A chemically defined medium was developed and tested to assess its impact on cells 
cryopreserved in serum. The composition of the medium is detailed in table 1. In the absence 
of serum, an appropriate adhesion protein is required. Fibronectin was selected due to the fact 
that the initial cell population was selected based off an affinity for the protein. Initial 
experiments (data not shown) resulted in complete loss of the culture after twenty-four hours. 
Further investigation revealed that the pH of the formulation increased to as high as 8.4 
during manufacture possibly because of degassing. This behaviour was not observed with the 
serum-containing medium (SCM). However, the SCM was double buffered with HEPES 
rendering the pH CO2 independent. The pH fluctuations were addressed first by introducing 
HEPES into the culture. Addition of HEPES to the medium did help attenuate the pH and 
allowed for a small degree of proliferation. Morphological assessment of the cells revealed 
the presence of HEPES was inducing cytoplasmic vacuolation and an overall shrivelled 
appearance (Fig.18). The addition of HEPES also increased the osmolarity to the 350 
mOsmol/kg range which appeared to be poorly tolerated. In light of this, the incorporation of 
HEPES into the medium was deemed an unsatisfactory solution. Titration of the medium 
with 1N HCl, although initially thought of as a poor choice, was the most effective at 
reducing the pH to about 7.3-7.4 range while maintaining sterility. Once the pH was lowered 
and placed into the culture vessel 5% CO2 appeared adequate at maintaining the pH. Sparging 
the stock medium with CO2 may be a preferable alternative to HCl titration, however, 
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equipment limitations made achieving this in an aseptic manner was problematic.  Once the 
pH problem was overcome it was found that medium could support the proliferation of the 
clonal chondrocytes (Chapter B, 1.8). It was found that serum weaning or adaption passages 
were not required to support a base bulk growth of the clonal lines, which are necessary for 
some cell lines ( J van der Valk et al., 2010). Cell subpopulations within the clonal lines were 
not characterised and monitored so the possibility that the defined medium was introducing 
pressure selection cannot be ruled out and remains an unknown. Understanding pressure 
selection presents itself as a priority area for future work in relation to the commerlicaltion of 
cell lines as the uncertainty could undermine the principle of quality. 
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Component Source Catalogue 
Number 
Component 
Storage 
Concentration in 
final formulation 
Weight / Volume 
added 
      
DMEM  Thermo Fischer 
Scientific 
A1443001 RT N/A 94.95mL 
      
D-Glucose Sigma Aldrich G7021-1KG RT 1g/L 100mg 
      
Bovine Serum Albumin 
(Fraction V)  
Sigma Aldrich A9418-10G 2-8 oC 1% w/v 1g 
      
Chemically Defined 
Lipid Mixture 1 
Sigma Aldrich L0288-100ML 2-8 oC 0.5% v/v 0.5mL 
      
Kao and Michayluk 
Vitamin Solution (100x) 
Sigma Aldrich K3129-100ML -20oC 1% v/v 1mL 
      
L-Glutamine (200mM) Thermo Fischer 
Scientific 
25030081 2-8 oC 5mM 2.5mL 
      
ITS (100x) Sigma Aldrich I2521-5ML 2-8 oC 1% v/v 1mL 
      
Dexamethasone‡ Sigma Aldrich D4902-100MG -20oC 10-8 M mol/L 40µL 
      
Human Recombinant 
PDGF-BB‡ 
R&D Systems 220-BB-010 -80oC 10ng/mL 50 µL 
      
Human Recombinant 
FGF2
‡ 
R&D Systems 233-FB-025/CF -80oC 10ng/mL 8 µL 
      
Human Recombinant 
EGF‡ 
R&D Systems 236-EG-200 -80oC 10ng/mL 50 µL 
      
HCl (1N) Sigma Aldrich H9892-100ML RT Variable Variable 
      
 
Table.1 Chemically defined medium. Volumes of 1N HCI added varied but were typically in the 
range of 250-300 µl per 100mL of medium. Quoted volumes of recombinant proteins and 
dexamethasone refer to the stored aliquots.  
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5.2 Effect of Feeding Frequency on Growth Kinetics. 
The impact of batch feeding, seventy-two hour total medium exchanges and twenty-
four-hour total exchanges were studied in three independent experiments using cryopreserved 
clonal chondrocytes and conventional tissue culture plastic in a manner identical to the 
serum-based experiments The clonal strains used in this section were from the same donor as 
in the previous. The aim is to understand if increased nutritional supplementation is effective 
at enhancing proliferation like the serum-containing medium was.   
For each of the feeding regimes under investigation three vials of cryopreserved 
clonal chondrocytes were thawed and expanded with the chemically defined medium in 
separate T175s for five days to reach appropriate numbers for a growth curve experiment. 
The T175 flasks were precoated with 1µg/cm3 of bovine fibronectin and left in an incubator 
at 37oC for two hours prior to inoculation. Six-well plates were used instead of T25s to make 
the experiments more cost-effective. Well plates were again precoated with 1µg/cm3 of 
fibronectin and cells were seeded at a density of 3000 cells cm2, supplied with 0.2mL/cm2 of 
defined medium and placed in a humidified incubator (37oC) with a 5% CO2 atmosphere. The 
 
Fig.18 Image of clonal chondrocytes displaying HEPES induces stress. Scale bar: 20µm 
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growth curve was obtained by sacrificial cell counts at twenty-four-hour intervals. Medium 
samples were taken from the sacrificed flasks and stored at -20oC prior to metabolite analysis. 
Flasks from each group were fed according to their group like the serum-based experiments. 
 
 
 
 
Averaged cumulative population doublings of the clonal strains from the batch 
experiment reached 0.99 ± 0.49, 1.19 ±0.27 and 0.94 ± 0.29, respectively, after five days in 
culture (Fig. 19 (A)). The increase in biomass was equivalent to averaged specific growth 
rates of 0.17 day -1 ± 0.09, 0.14 day -1 ± 0.05 and 0.20 day -1 ± 0.02 for each of the strains, 
respectively (Fig. 19 (B)).  
 
 
Fig.19 (A) Cumulative population doublings of three clonal strains over a hundred and 
twenty hours under batch fed operation. (B) Specific growth rate for the same three clonal 
strains over the one hundred and twenty hour period. Error bars show standard deviation of 
the mean (n=3) 
 
 
A                                                                                      B 
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Averaged cumulative population doublings of the clonal strains from the seventy-two-
hour feed experiment reached 2.65 ± 0.61, 2.67 ± 0.24 & 3.08 ± 0.28, respectively, after five 
days in culture (Fig. 20 (A)). The increase in biomass was equivalent to averaged specific 
growth rates of 0.47 day -1 ± 0.07, 0.46 day -1 ± 0.04 & 0.53 day -1 ± 0.05 for each of the 
strains, respectively (Fig. 20 (B)).  
 
  
Fig.20 (A) Cumulative population doublings of three clonal strains over a hundred and 
twenty hours under seventy-two hour feed operation. (B) Specific growth rate for the same 
three clonal strains over the one hundred and twenty hour period. Error bars show standard 
deviation of the mean (n=3) 
  
 
A                                                                                      B 
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Averaged cumulative population doublings of the clonal strains from the twenty-four-
hour feed experiment reached 3.49 ± 0.54, 3.42 ± 0.37 &3.56 ± 0.49, respectively, after five 
days in culture (Fig. 21 (A)). The increase in biomass was equivalent to averaged specific 
growth rates of 0.60 day -1 ± 0.09, 0.59 day -1 ± 0.06 & 0.62 day -1 ± 0.08 for each of the 
strains, respectively (Fig. 21 (B)).  
 
 
 
 
  
Fig.21 (A) Cumulative population doublings of three clonal strains over a hundred and 
twenty hours under twenty-four hour feed operation. The three strains reached average 
cumulative doublings of 3.49 ± 0.54, 3.42 ± 0.37 &3.56 ± 0.49, respectively. (B) Specific 
growth rate for the same three clonal strains over the one hundred and twenty hour period. 
Under seventy two feed operation, rates of 0.60 day -1  ± 0.09, 0.59 day -1 ± 0.06 & 0.62 
day -1 ± 0.08 were achieved for the three clonal strains, respectively. Error bars show 
standard deviation of the mean (n=3) 
 
 
A                                                                                      B 
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The difference between the growths rates from the three feed experiments were tested 
for significance. The three data sets were judged to approximate normality before performing 
a one-way ANOVA.  The ANOVA suggested the difference between the groups was 
significant with the significance threshold set at 0.05. Group data sets were tested for equality 
of variance before performing post-hoc T testing to ascertain between which groups a 
significant difference could be recorded.  Three comparisons were made and as a precaution 
against type I error a family-wise error correction was applied in the form of the Bonferroni 
correction. Accordingly, the threshold for significance was set at 0.017. There was a 
significant difference between the means of the batch (M=0.17, SD=0.034) and seventy-two 
hour feed (M=0.45, SD=0.08) conditions; t (4) 5.1, p=0.0069, and the batch (M=0.17, 
SD=0.034) and twenty-four-hour feed (M=0.60, SD=0.026) conditions; t (4) 2.76, p=6.75E-5. 
The difference between the means of the seventy-two-hour feed experiment and the twenty-
  
Fig.22 (A) Averaged Specific growth rates for the all clonal strains across the three different feed 
operations over the one hundred and twenty hour period. Significance was tested using a single 
factor ANOVA (α=0.05) which yielded a p value of 0.00026. Individual significances were 
calculated using Bonferroni corrected post-hoc T tests. Error bars show standard deviation (n= 
6). (B) Averaged specific rates for all clonal strains comparing rates obtained from the serum-
containing medium and those obtained using the chemically defined medium. Error bars show 
standard deviation of the mean (n=3). 
A                                                                                      B 
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four-hour experiment were not found to be significant (p=0.05) after the error correction was 
applied. 
 
5.3 Discussion of Batch, Seventy-two hour and Twenty-four-hour feed Operations using 
the Chemically Defined Medium. 
 
             The chemically defined medium enabled proliferation of the clonal chondrocytes in a 
manner comparable to what was achieved using a serum-based medium. Like in the serum-
based experiments, specific growth rates increased by statistically significant margins as the 
frequency of feeding was increased (Fig. 21 (A)). The batch culture resulted in the biomass 
reaching a peak at around seventy-two hours in two of the clonal strains, with the third strain 
reaching a peak at ninety-six hours before declining (Fig. 18 (A)).  The seventy-two-hour 
feed experiments resulted in a near inflection of growth after only forty-eight hours (Fig. 19 
(A)). The feeding intervention at seventy-two hours allowed proliferation to resume in all of 
the clonal strains, albeit to varying extents. The twenty-four-hour feed frequency resulted in 
the highest growth rates and equated to a respective average increase of 74% and 25% 
relative to the batch fed and seventy-two-hour feed (Fig. 20 (A)). Comparing the serum to the 
chemically defined medium reveals the serum-containing medium is superior, at least in 
terms of stimulating proliferation. This result is perhaps not unexpected given the chemically 
defined medium is suboptimal and is susceptible to pH fluctuations. Consideration also has to 
be given to the fact that the colonies were isolated, expanded and cryopreserved with serum-
containing medium. It has been reported in the literature that switching a SCM for a defined 
medium requires a “weaning period” or a stepwise reduction of serum concentration in order 
to support survival and growth (JBF van der Valk, 2010). While it was found an adaption 
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passages were not required for cell survival and growth, the possibility that abruptly 
removing serum from the medium could affect the growth rate cannot be discounted. 
Understanding what is directly responsible for stimulating proliferation is key to developing a 
tailored, programmable approach to nutrition. To be pragmatic in terms of approach, the same 
metabolite screening will be employed in a bid to uncover any rate limiting events and 
understand any general trends in metabolic behaviour.     
 
6.0 Metabolite Analysis of Culture Medium taken from Batch, Seventy-Two Hour and 
Twenty Four-Hour Feed Experiments Cultured using a Chemically Defined Medium. 
 
Frozen medium samples were thawed at room temperature and screened for glucose, 
glutamine, ammonia, and lactate concentration. Metabolite concentrations were determined 
with a Cedex Biostation HT which automates the glucose hexokinase, glutaminase, glutamate 
dehydrogenase and lactate oxidase assays. Assays were run as single reactions. Cell 
normalised consumption or production rates were calculated using the same expression as 
described in  section 2.4 
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Fig.23 Gross consumption / production in mM of glucose (A), lactate (B), glutamine (C) and 
ammonia (D) from the fed batch experiment over a one hundred and twenty hour culture with 
offline measurements made twenty-four hours apart. Error bars show standard deviation of the 
mean (n=3)  
A                                                                                      B 
C                                                                                      D 
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Fig.24 Total consumption / production in mM of glucose(A), lactate (B), glutamine (C) and 
ammonia(D) from the fed batch experiment over a one hundred and twenty hour culture with 
offline measurements made twenty-four hours apart. Lactate and ammonia concentrations were 
adjusted by subtracting background concentrations in the medium Error bars show standard 
deviation of the mean (n=3)  
A                                                                                      B 
C                                                                                      D 
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Fig.25 Specific consumption / production rates in pmol.cell-1.day.-1  for glucose(A), lactate (B), 
glutamine (C) and ammonia(D) from the batch experiment over a one hundred and twenty hour 
culture. Error bars show standard deviation of the mean (n=3)  
  
  
A                                                                                      B 
C                                                                                      D 
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The metabolite data from the batch experiment using the chemically defined medium 
revealed a higher specific glucose consumption rate to that of the serum experiment (Fig. 24 
(A) and (B)). Glucose to lactate ratios were roughly 1:2 which although lower than those 
encountered in the serum experiment still suggests inefficient glucose usage. Absolute levels 
of glucose in the defined medium were approximately a third lower to those in the serum 
(Fig. 24 (A) and did not come close to depleting over the course of the culture, which at the 
very least suggests high-glucose formulations are wasteful. High glucose formulations have 
been demonstrated to be detrimental in some cell types (A Stolzing, 2006., Yu-Cheng Lin et 
al. 2017 ) however the data produced from the serum containing experiments, which 
contained approximately three times as much glucose as the defined medium, showed 
superior growth rates versus the lower glucose defined medium. This observation could arise 
from a number of scenarios such as, additional mitogenic components present in the serum 
compensating for any potential rate-limiting effects that exposure to high glucose may incur, 
the relatively short culture periods masking any effect or the cell strain being insensitive to 
glucose concentration. Glutamine and ammonia levels recorded from the experiment were 
confounding (Fig.23 (C) and (D)). Glutamine levels rose significantly at seventy-two hours 
without any intervention in all three of the clonal lines, as did ammonia levels fall in two of 
the clonal lines at the same time point. Note that no such fluctuation is experienced with the 
recorded glucose and lactate levels (Fig. 23 (A). Although the glutamine and ammonia 
fluctuations could be rationalised in terms of cell biology it is more likely the results arose 
from either a problem with assay calibration or sample contamination. Data from the seventy-
two and twenty-four-hour feed experiments will help reveal if this is a feature of using a 
defined medium or a random error.  
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Fig.26 Gross consumption / production in mM of glucose (A), lactate (B), glutamine (C) and 
ammonia (D) from the seventy-two hour feed experiment over a one hundred and twenty hour 
culture with offline measurements made twenty-four hours apart. Error bars show standard 
deviation of the mean (n=3)  
 
A                                                                                      B 
C                                                                                      D 
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Fig.27 Total consumption / production in mM of glucose (A), lactate (B), glutamine (C) and 
ammonia (D) from the seventy-two hour feed experiment over a one hundred and twenty hour 
culture period with offline measurements made twenty-four hours apart. Lactate and ammonia 
concentrations were adjusted by subtracting background concentrations in the medium. Error 
bars show standard deviation of the mean (n=3)  
A                                                                                      B 
C                                                                                      D 
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Fig.28 Specific consumption / production rates in pmol.cell-1.day.-1  for glucose (A), lactate (B), 
glutamine (C) and ammonia (D) from the seventy-two hour experiment over a one hundred and 
twenty hour culture. Error bars show standard deviation of the mean (n=3)  
A                                                                                      B 
C                                                                                      D 
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Total glucose consumption was similar to that of the serum experiments however; 
total lactate production levels were far higher (Fig. 26 (D)). The determined lactate levels 
were less likely to affect the growth rate than the equivalent serum experiment as peak 
concentrations in the medium were lower due to the chemically defined medium been absent 
of background lactate (Fig. 25 (B)). Specific consumption rates of glucose were again far 
higher than the corresponding serum experiment and glucose to lactate ratios were in the 
region of 1:3 (Fig. 26 (A) and (B)). Specific glutamine consumption was also comparatively 
high suggesting a higher reliance on the amino acid to meet cellular energy requirements 
(Fig. 26 (C)). Ammonia levels were found to be quite variable amongst technical replicates 
but average peak concentrations were in the region of 1mM, which were not thought to have 
a significant impact on the growth kinetics. 
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Fig.29 Gross consumption / production in mM of glucose (A), lactate (B), glutamine (C) and 
ammonia (D) from the twenty-four hour feed experiment over a one hundred and twenty hour 
culture with offline measurements made twenty-four hours apart. Error bars show standard 
deviation of the mean (n=3)  
 
A                                                                                      B 
C                                                                                      D 
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 C                                                                                      D 
 
  
Fig.30 Total consumption / production in mM of glucose (A), lactate (B), glutamine (C) and 
ammonia (D) from the twenty-four hour feed experiment over a one hundred and twenty hour 
culture with offline measurements made twenty-four hours apart. Lactate and ammonia 
concentrations were adjusted by subtracting background concentrations in the medium. Error 
bars show standard deviation of the mean (n=3)  
A                                                                                      B 
C                                                                                      D 
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Fig.31 Specific consumption / production rates in pmol.cell-1.day.-1  for glucose (A), lactate (B), 
glutamine (C) and ammonia (D) from the twenty-four hour feed experiment over a one hundred 
and twenty hour culture. Error bars show standard deviation of the mean (n=3)  
A                                                                                      B 
C                                                                                      D 
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The determined metabolic fluxes for the twenty-four-hour experiment were in line 
with the previous chemically defined medium experiments. Specific glucose to lactate 
conversion ratios were in the region of 1:2 to 1:3 (Fig. 30 (A) and (B)), comparable to those 
contained in the serum-based experiments. The high levels of total lactate and ammonia 
concentrations (Fig. 30 (B) and (D)) were offset by the daily 100% medium exchanges and so 
peak levels were in line to the batch and seventy-two-hour feed experiment (Fig. 29 (B) and 
(D)). Glucose and glutamine levels were not exhausted during the experiment and so growth 
appears to be a function of one or more of the proteins in the formulation much in the same 
way growth appeared to be serum dependent in the initial experiments. Unlike the serum 
based experiments, differences in total consumption between twenty-four hour, seventy-two 
hour and batch fed experiments were statistically significant (Fig.32) 
 
 
 
 
 
 
 
 
 
Fig.32 Comparison of differences in metabolite consumption or production from the 24h, 72h and 
fed batch experiments using the defined medium. The differences between the groups were tested 
for significance using ANOVA. Groups showing significant differences were subjected to post hoc 
t tests. The asterisk donates where significant differences after Bonferroni error correction were 
recorded. Errors bars show standard deviation of the mean (n=3)  
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Glucose consumption was significantly higher in the twenty-four hour experiments (M=1.95 
SD=0.28) than the recorded consumption in the batch experiments (M=0.64 SD=0.07) 
conditions; t(4) 5.37 p=0.005). Glutamine consumptions were significantly higher in both the 
twenty-four and seventy-two hour experiments (M=1.57 SD=0.28 and M=1.29 SD=0.26, 
respectively) when compared to the batch experiments (M=0.25 SD=0.06) conditions; (t)4 
7.88 p=0.001 and (t)4 6.71 p=0.002, respectively. Lactate production was again significantly 
higher in both twenty-four and seventy-two hour experiments (M=4.86 SD=0.33 and M=4.04 
SD=0.40, respectively) when compared to the batch experiment (M= 1.13 SD=0.03)  
conditions; (t)4 14.67  p=1.25x10-4 and (t)4 19.43 p=2.07x10-5, respectively. Ammonia 
production was significantly different in all three experimental scenarios.  Ammonia 
production was higher in the twenty-four experiment (M=4.51 SD=0.09) when compared to 
the seventy two hour (M=2.21 SD=0.45) and the batch experiment (M=0.75 SD =0.04) 
conditions; (t)4 8.75 p=9.41x10-4 and (t)4 68.94 p=2.65x10-7, respectively. The difference 
between the seventy-two hour and batch experiment was also found to be significant 
conditions; (t)4 5.67 p=0.005). Although some of the experimental scenarios resulted in 
marked differences in total consumption/production values it is not known if this translates 
into any practical significance. 
The serum-based medium was slightly superior in terms of stimulating proliferation 
of the clonal strains, however, these experiments have yet to address the phenotypic changes 
that can be induced by culturing in the different mediums. An assessment of these changes 
needs to be undertaken before a decision can be made on which medium formulation can be 
taken forward for further investigation.  
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7.0 Quantitative PCR assessment of the impact of using serum-based medium and 
chemically defined medium on expression of SOX-5, 6 & 9 
 
The SOX family of genes code for transcription factors that are ubiquitous amongst 
eukaryotes (P.Koopman at al. 2000). While the role of SOX proteins is varied, their role in 
cartilage is thought to be central in maintaining the phenotype of articular chondrocytes, in 
particular, SOX-5, SOX-6 and SOX-9 (E. Kolettas et al., 2001, S. Ikegawa et al., 2004). 
Determination of SOX-5, 6 & 9 mRNA levels, while unlikely to categorically represent 
quality in terms of chondrocyte phenotype, are a fair indicator of how dedifferentiated the 
cell population has become. SOX-5, 6 & 9 gene expression levels are the sole measure of 
quality in this study and if and how levels vary as a result of culture in the two different 
mediums is the first task. Selection of the SOX trio as a sole means of assessing quality is a 
weakness of the study that has been sustained due to budgetary constraints. Whilst they are 
strong predictors for the induction of efficient matrix producing chondrocytes it is important 
to acknowledge that the presence of the appropriate transcriptome does not necessarily 
translate into the desired proteome. Ideally, both the transcriptome and corresponding 
proteome would be assessed in tandem.  Furthermore, other makers such as Karyotype 
analysis and cell surface antigen profiles could play an equally important role in product 
characterisation.  
  Six vials of cryopreserved clonal strains were thawed and expanded in individual 
T175’s for five days to reach appropriate cells numbers. Cells were then harvested and 
seeded in six-well plates at a density of 3000 cells cm2. Well plates used to be used in 
conjunction with the chemically defined medium were pre-coated with bovine Fibronectin (1 
µg/cm2) prior to seeding. Each well was supplemented with either the serum-containing 
 132 
 
medium or the chemically defined medium (0.2mL/cm2) and expanded in batch mode for a 
period of five days. After the five days cells were harvested and stored at -20oC in RNA cell 
protect ready for RNA extraction and subsequent RT-qPCR. A full account can be found in 
the materials and methods section.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.33 SOX-9 mRNA transcripts copies from clonal strains expanded over five days in either the 
serum based medium or the chemically defined medium. mRNA transcripts were determined using 
RT-qPCR.. The differences between the serum and defined group were found to be significant 
(p=0.05) a using students T test. Groups were first tested for equality of variance prior to 
significance testing. Error bars show standard deviation of the mean (n=3)  
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Fig.34 SOX-6 mRNA transcripts copies from clonal strains expanded over five days in either the 
serum based medium or the chemically defined medium. mRNA transcripts were determined using 
RT-qPCR.. The differences between the serum and defined group were not found to be significant 
(p=0.05) a using students T test. Groups were first tested for equality of variance prior to 
significance testing. Error bars show standard deviation of the mean (n=3)  
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SOX-9 mRNA transcripts were significantly higher in all three of the strains 
(M=1200 SD=194, M=1069 SD=120, M=996 SD=31, respectively) in the chemically defined 
treatment group when compared to the strains cultured in the serum medium treatment group 
(M=273 SD= 181, M=568 SD=107, M=664 SD=85, respectively) conditions; t(4) 6.04 
p=0.004, t(3) 4.9, p=0.01, t(4) 6.3, p=0.003, respectively (Fig.31). 
 
 
 
 
 
Fig.33 SOX-5 mRNA transcripts copies from clonal strains expanded over five days in either the 
serum based medium or the chemically defined medium. mRNA transcripts were determined using 
RT-qPCR.. The differences between the serum and defined group were not found to be significant 
(p=0.05) a using students T test. Groups were tested for equality of variance prior to significance 
testing. Error bars show standard deviation of the mean (n=3)  
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8.0 Summary of Chapter C Studies 
 Maintaining SOX-9 expression during culture is thought to be a key objective in the 
culture of chondrocytes as loss of SOX-9 transcripts is associated with loss of downstream 
extracellular matrix markers of chondrocyte phenotype collagen II and results in increased 
apoptosis (D. Ikegami et al., 2011, K. Von der Mark et al. 1977). SOX-6 and 5 transcript 
markers did not vary significantly (Fig. 32 and 33), however whether or not the two mediums 
do promote real differences in the expression of these transcripts is hard to say when the 
statistical power is low 
The experiments with the serum and chemically defined medium have revealed that 
the growth rate of the clonal strains is dependent on one or more of the components in the 
medium and that growth rate can be enhanced by increasing the frequency of feeding. 
Additionally, the slowing or arrest of growth is not the sole result of lactate or ammonia 
accumulation or depletion of glucose or glutamine. 
 
 
 
 
 
 
 
Fig.35 A cost comparison of serum versus the chemically defined medium per litre. Costs were 
calculated based on current order values placed to a range of suppliers. The cost of the defined 
medium does not take in account pre coating tissue culture plastic with fibronectin. Costs accurate 
at time of composing (December 2017)   
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While the use of serum may appear expedient, the serum-free medium was found to 
be superior in maintaining SOX-9 expression and maintaining phenotypic stability is a key 
milestone in been able to propagate large numbers of therapeutically viable cells. This finding 
was consistent with other studies that experimented with expanding full thickness 
chondrocytes using a defined medium (D J Huey et al., 2013). A major drawback of using a 
chemically defined medium in this instance is the cost factor. In its current format, the 
chemically defined medium is approximately seven times that of the serum formulation 
without factoring in the adhesion protein. This currently leaves the use of a chemically 
defined medium an expensive proposition. In order to address this and further understand 
what each of the individual components in the chemically defined medium are contributing, 
in terms of rates of proliferation and upregulation of the SOX genes, a careful screening 
experiment is proposed for the next chapter. 
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CHAPTER D: DETERMINATION OF PRIMARY FACTORS DURING EXPANSION 
AFFECTING PROLIFERATION AND GENE EXPRESSION 
 
 
1.0 Introduction 
 
           The defined medium described in chapter B was demonstrated to support the growth 
of the clonal chondrocyte cell line in a manner that was similar to the serum-containing 
medium with the added benefit of upregulating SOX-9 expression. In order for the 
proposition of a defined approach to feeding to be of optimum value, the contribution of each 
component to the quality attributes, growth rate and SOX gene expression in this case, needs 
to be carefully considered. It is envisaged that a well understood operating space will not only 
assist in yielding large numbers of quality cells but will lower the cost burden associated with 
using a defined medium by promoting efficient use of expensive recombinant proteins. 
          Factorial design of experiment offers an easily accessible means of screening multiple 
medium components for their effect on a range of independent variables (L M Collins et al., 
2010). The literature presents a number of examples of this type of design applied to the field 
of cellular biology to identify primary and interaction effects (L Enochson et al., 2012).   It 
was envisaged that primary effects and two-way interactions could be resolved using a 
fractional factorial experiment in a manner that balances the desire to uncover as much 
information about the system as possible with the amount of experimental resource available. 
Ideally, all components of the serum-containing medium and, any more of interest would be 
screened for their impact on the output variable of interest. In reality, only a small number of 
dependent variables can be screened with the resources available and so before executing the 
experiment candidates for screening need to be prioritised. The review of the literature 
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looking at commonly employed culture conditions (Chapter A) gives rise to Table 1, which 
explores the arguments for inclusion of a range of candidates for screening. It was decided 
there was enough resource to screen approximately nine candidates depending on the desired 
level of power. 
 
   
Candidate Argument Include 
 
 
 
Glucose 
Elementary media component that may exhibit main effects in 
conjunction with hypoxic conditions. Hyaline cartilage being 
avascular may benefit from low glucose concentrations or prefer 
different carbon sources. High glucose concentrations have been 
demonstrated to exhibit undesirable effects in some cell types by 
some investigators (A Stolzing et al., 2006., C Perio et al. 2001., H 
Heywood et al., 2014) but not by others ( B Weil et al., 2009).  
 
 
 
Yes 
 
 
L-Glutamine 
 The critical medium component may be able to modulate metabolic 
pathway preference when presented either in excess or as a limiting 
factor. Investigators experimenting with human dental pulp stem 
cells concluded glutamine deprivation combined with low glucose  
was better for cell viability ( N Machado et al., 2014)  
 
 
Yes 
 
Glucosamine 
An evidence base exists that this sugar effects on proliferation and 
gene expression in chondrocytes. The researchers reported a dose-
response up to 2mM ( S Varghese et al., 2007). Glucosamine will 
be excluded from screening because of the existing in-depth study.   
 
No 
Ascorbic Acid-
2-Phosphate 
Study by Enochson et al. (2012) indicated this did not display dose-
response behaviour in three-dimension culture. Rejecting here in 
favour of including previously less explored options. 
No 
Serum The study aims to move away from the use of undefined 
components. 
No 
 
pH / Buffer 
Choice 
Undoubtedly illicit a large effect as touched on in chapter B but 
rejected due to technical limitations. Maintaining the pH at two 
distinct levels for a factorial DoE (three states with the inclusion of 
centre points) is experimentally demanding given the level of fine 
pH control that can be achieved using a standard incubator. 
 
 
No 
 
 
Fibronectin 
Fibronectin is a constituent of fetal calf serum.It enhances cell 
adhesion and critically, cell spreading and cell spreading. Its impact 
on SOX-9 expression has previously been reported (T E 
Hardingham et al., 2008) but less is known about its effect on SOX-
6 and 5. Also, previously reported effects pertained to full thickness 
chondrocytes. 
 
 
Yes 
Table 1. Exploration of possible candidates for screening in a fractional factorial experiment 
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Vitronectin Another adhesion promoter that is present in calf serum ( E G  
Haymen, 1985). Its impact on growth kinetics and SOX transcript 
expression in clonal chondrocytes is unexplored.  
No 
O2 Tension Multiple studies have shown expansion under hypoxia positively 
influences chondrogenic potential (B D Markway et al., 2013., E 
Duval et al., 2009 and G Martin et al., 2004) and work 
demonstrating novel interaction effects with other components has 
yet be published. Culturing and analysis of cells under hypoxia 
requires appropriate workstations that are not currently available. 
No 
 
Temperature 
Again, undoubtedly will exhibit a main effect if test over a large 
enough range and may present itself as parameter for optimisation 
but rejecting in favour of higher priority candidates. 
 
No 
 
Seed Density 
It has been suggested that high-density cultures may promote SOX-
9 gene expression by limiting cell spreading. (T E Hardingham et 
al., 2008). Effect of low-density cultures on growth rate is also of 
interest. 
 
Yes 
 
Transferrin 
Selenium 
Insulin 
Evidence base suggesting influential in up-regulating chondrocyte 
phenotype (K H Chua et al., 2005). Was included in the Enochson 
study, however, they reported no significant effect in 
redifferentiation culture.  Will be included as part of a commercial 
formulation supplement. 
 
 
Yes 
Cholesterol No evidence to suggest a role in chondrocyte phenotype 
modification. 
No 
Biotin No evidence to suggest a role in chondrocyte phenotype 
modification. 
No 
 
Dexamethasone 
Studies agree it has a role in down regulating proinflammatory 
responses (J H Jafari et al., 1993) and inducing chondrogenic 
differentiation (A Derfoul et al., 2006). The Enochson study (2012) 
confirmed it as an active variable and recommended optimal 
supplementation concentration.   
 
     No 
 
Linoleic Acid 
Linoleic acid reportedly has a pro-inflammatory effect on cartilage 
when in the presence of TNFα (Y.M. Bastiaansen-Jenniskens et al., 
2013). 
 
No 
 
Albumin 
Major protein component of serum that has a multifaceted role in 
cell culture (G L Francis, 2010). Not included in favour of inclusion 
of other components.  
No 
 
Pyruvate 
May exhibit effects under hypoxic conditions but not practical to 
assess fluxes due to production from glycolysis altering the 
exogenous concentration by unknown amount. 
No 
Pantothenate No evidence to suggest a role in chondrocyte phenotype 
modification. 
No 
 
 
FGF-2 
An established evidence base for the role of FGF2 in up-regulating 
ear chondrocyte phenotype ( E W Mandl, 2002). The growth factor 
has also been included in some MACT expansion regimes and has 
been noted to display mitogenic properties in chondrocyte culture 
((D Gospodarowicz and A L Mescher, 1977).  Should be included 
Yes  
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to confirm the effect in clonal chondrocytes and to understand 
relationship dynamics better. 
 
PDGF-bb 
Reported to boost proliferation and included as part of literature 
described total medium (Jakob, M. et al., 2001) Included for 
confirmation of literature reports. 
Yes  
 
EGF 
Reported to play a role in up-regulating chondrocyte phenotype 
however the study design confounds the growth factor with others, 
so its exact effect is not immediately apparent (APA Prins et al., 
1982). Also reported to display mitogenic properties in 
chondrocytes (D Gospodarowicz and A L Mescher, 1977). 
Yes  
 
TGF- β1 
Controversial growth factor. Numerous studies shed light on its role 
in boosting proliferation however numerous others points towards 
adverse effects on redifferentiation (P Giannoni. et al., 2005, L 
Enochson et al., 2012,  R Narcisi et al., 2012 ).  The evidence base 
will undoubtedly benefit from further contribution.  
 
Yes  
 
TGF- β3 
Demonstrated to stimulate growth in chondrocyte gel culture(A H 
Huang et al. 2009). Little reports of effect on 2D culture to date. As 
growth factors place high demand on resource, it may be more 
prudent to wait until more basic research establishes a link between 
its presence and effect on proliferation/phenotype.  
No 
IL- 1 Implicated in upregulation of MMPs ( E Kolettas et al., 2001). No 
IL- 6 Implicated as a negative regulator for chondrocyte proliferation and 
matrix production ( A Jikko et al., 1998). 
No 
IL- 4 Thought to downregulate pro-inflammatory responses but left out 
due to cost constraints. 
No 
IL- 8 Thought to upregulate pro-inflammatory responses and MMPs (K 
Steinbach et al., 2002). 
No 
IL- 10 Thought to downregulate pro-inflammatory responses ( G Schulze-
Tanzil et al., 2009., K Steinbach et al., 2002) but left out due to cost 
constraints. 
No 
TNFα Regulator of apoptosis in human articular chondrocytes ( B 
Carames et al., 2008). Not included to focus on factors that regulate 
SOX gene expression.  
No 
IGF-1 Exogenous IGF-1 thought to protect from apoptosis in ex vivo 
expansion ( T F Higgins and D B Johnson, 2010) but left out due to 
cost constraints. 
No  
 
 
 The evaluation of candidates in Table 1 give rise to following nine candidates for 
screening: Glucose, Glutamine, ITS, Seeding Density, Fibronectin, FGF-2, PDGF-BB, EGF, 
and TGF-β1.   
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2.0 Pilot Study  
 A concern from the preliminary work in chapter B is the consequence that low 
statistical powering can have on clearly identifying effects. Judging the size of the expected 
effect can aid in conducting a prospective power analysis that will allow a more measured 
estimate of the required sample size. Effect sizes can be judged by using existing literature 
accounts or by assigning a value that is deemed of interest to the investigator. Unfortunately, 
neither approach were thought suitable in this case, so a pilot experiment was set up to assess 
the size of the effect sizes detectable in a range of outputs. 
A pilot experiment was conducted to gauge the magnitude of effect sizes that could 
arise from a run of the main experiment.  Defined medium and culture conditions that 
correspond to the centre point in the proposed fractional factorial experiment were compared 
to a expansion medium that included FGF-2 and TGFβ-1 in there “ + 1” states, i.e. are 
present in higher concentrations. The experiment was batch fed to avoid the possibility of 
large fluctuations in pH that can occur when re-feeding at seventy-two or twenty-four-hour 
intervals. The batch approach also served as a cost efficiency. The following outputs were 
measured: Specific growth rate, glucose consumption, glutamine consumption, lactate 
production, ammonia production, SOX-9 transcript expression, SOX-6 transcript expression 
and SOX-5 transcript expression.  
 
2.1 Growth Data  
Clonal chondrocytes stored in the vapour phase of liquid nitrogen were reanimated 
and pre-expanded in defined medium in T175s for five days to reach appropriate cell 
numbers for the subsequent experiment. Sub-confluent cells were harvested in serum-free 
conditions and seeded into six-well plates coated in 1µg/cm3 of bovine Fibronectin. Three of 
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the six wells were supplied with the 0.2mL/cm2 of the established defined medium described 
in Chapter B. This medium is labelled as “Test Condition 2 (-)” in the pilot experiment. The 
remaining three wells were supplemented with a modified medium that contained 20 ng/mL 
FGF2 and 10 ng/mL TGF-β1, labelled as “Test Condition 1 (+). The cells were cultured in 
batch mode over five days before harvesting. Harvested cells were counted and then 
sacrificed for RNA extraction as previously described. Medium samples were collected and 
frozen before metabolite analysis.  
 
 
 
 
 
 
 
 
 
 
The three clonal lines achieved under “Test Condition 1”, at the end of the five-day 
culture, population doublings of 1.41±1.44, 0.37±2.24 and 0.29±0.64 (Fig.1). In contrast to 
 
Figure 1. Population doublings achieved by three clonal replicates after five days in culture when 
expanded under Test Condition 1 or Test Condition 2.. Error bars show standard deviation of the 
mean (n=3). 
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this, the same three clones cultured under “Test Condition 2” achieved population doublings 
of 2.28±0.018, 2.06±0.11 and 1.96±0.37 (Fig.1).  The population doubling data from this 
experiment is not directly comparable to the growth data from the batch data in chapter B, as 
no cell number was recorded for the twenty-four hour time point. Growth data in this 
experiment was calculated using the seeding density as the starting cell number. In reality, 
plating efficiency is < 100% as which is why growth data is benefited by early cell number 
measurements where possible. The data returned from “test condition 2” which, is the 
previously described defined medium and the proposed centre point in the fractional factorial 
experiment, shows a narrow distribution. In contrast to the narrowly distributed points from 
test condition 2, the data set from test condition 1 showed a high level of noise across two of 
the clonal replicates. The absence of a similar pattern in the same clonal replicates in test 
condition 2 suggests it is the test condition giving rise to the variation. Variation this large 
arising from technical replication is of concern. The level of noise has a knock on impact on 
statistical power, to an end that the degree of replication required to resolve effects may be 
too great for the resource available. To better understand if the observed variation was a 
prominent feature of the test condition or special cause case, a further growth study was 
undertaken.  
 
2.2 Repeated Growth Study 
To understand if the variation in growth data seen in 1.1.2 was a repeatable feature of 
the experimental conditions a further experiment was undertaken. Furthermore, to try and 
understand any relationship, additional concentration points of TGF-β1 were added to the 
experiment. The experiment was run with only one clonal replicate. The justification for this 
lay in the general observation from data in chapter B and from the previous experiment (Fig. 
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1) that clonal replicates typically behave in the same manner as each other, albeit if the 
magnitude of the observed behaviour can differ.   
Clonal chondrocytes sorted in vapour phase liquid nitrogen were reanimated and 
expanded in defined medium in T175s for five days to reach appropriate cell numbers for the 
experiment. Cells were harvested sub-confluent in serum-free conditions and seeded into 
three 6-well plates coated in 1µg/cm3 of bovine Fibronectin. The three well plates were 
supplemented with defined medium containing either 20 ng/mL FGF2 /10 ng/mL TGF-β1 
(A), 20 ng/mL FGF2 / 5ng/mL TGF-β1 (B)  or 20 ng/mL FGF2 (C) . The cells were allowed 
to culture over five days before sacrifice and analysis. No metabolite profiling or gene 
expression data was recorded from this experiment. 
 
 
 
 
 
 
 
 
 
Figure 2. Population doublings from a single clonal replicate treated with defined medium containing 
three concentrations of TGF-β1: 10 ng/mL, 5 ng/mL, and 0 ng/mL after five days in culture. Error 
bars represent standard deviation of the mean (n=6) 
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The data from the experiment failed to show the degree of variation from the technical 
replication seen in the original experiment. Interestingly, the average value of the population 
doublings (Fig.2)  of all biological replicates from test condition 1 is approximately 
proportional to the results seen here (0.73 and 0.13 day-1, respectively). The data also 
suggests TGF-β1 has a small impact on boosting the rate of proliferation in clonal bovine 
chondrocytes, which, is perhaps not unexpected given the reported contribution of the protein 
to chondrocyte proliferation during skeletal growth ( F Beier et al., 2001)  
 
 
2.3 Metabolite Data  
Medium samples taken at day five from the pilot study were screened for glucose and 
glutamine consumption and lactate and ammonia production. Blank measurements were 
taken from the starting medium in duplicate, and the average used as a reference to point to 
calculate net consumption and specific consumption/production rates for the five day culture 
period. Cedex assays from the samples were run as single reactions. The samples run were 
the original growth experiment (1.1.2) and not the repeated study (1.1.3). 
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Figure 3. Total consumption / production in mM/L of (A) glucose, (B) lactate, (C) glutamine and 
(D) ammonia after one hundred and twenty hours in culture. Lactate and ammonia concentrations 
were adjusted by subtracting background concentrations in the medium. Error bars show standard 
deviation of the mean (n=3) 
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The metabolic behaviour follows the growth pattern in that condition 2 gives a tightly 
distributed band of consumption and production rates. In contrast test condition 1 gives a 
more erratic response especially in the instance of total glucose and lactate concentrations 
(Fig.3 (A) and (B)). Total ammonia production, in contrast, was relatively stable between the 
two test conditions (Fig. D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Figure 4. Specific consumption/production rates reported in pmol.cell-1 day-1 for (A) glucose, (B) 
lactate, (C) glutamine and (D) ammonia from the after the one hundred and twenty hour culture. 
Error bars show standard deviation of the mean (n=3) 
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The cell normalised specific fluxes (Fig.4) highlight clonal replicate two as a potential 
outlier. The cause of this behaviour is unknown and the question of whether this unexplained 
behaviour is visible in the gene expression data is of great interest. It should be noted that 
because daily sampling was not featured in the experiment it’s unclear how the specific flux 
changed from day to day as the cell number changed. 
 
2.4 Gene Expression Data  
 
           To assess if the chondrogenic lineage commitment genes were sensitive to the 
different test conditions mRNA transcript levels were assessed in the same manner as 
previously described. Briefly, individual PCR reactions were run in duplicate with random 
replicates further duplicated to check for reverse transcription efficiency. Copy numbers were 
derived from standard curves and normalised to the GeNorm score calculated from the 
endogenous reference genes, B2M, ACTB and RPL13. 
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Figure 5. Normalised copy number from the three clonal replicates for (A) SOX-9, (B) SOX-6 
and (C) SOX-5). The difference in means from the two test conditions were tested for significance 
using an unpaired students t test. Each show standard deviation of the mean (n=3) with the 
exception of clonal replicate 2 in A, B & C where n=2.  
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Quantitative PCR assays from the pilot experiment answered some key questions. The 
assays are sensitive to the changes made to the formulation of the medium (test condition 1) 
and gave rise to a  statistically significant detectable change in SOX-9 transcript (Fig.5 (A))  
for  clonal replicate 1 and 3 and when compared to the same clones expanded in the control 
medium (test condition 2) (Table 2). SOX-6 returned similar copy numbers between the two 
test conditions and the differences were not significant (Fig.5 (B)). SOX-5 transcripts showed 
a small difference (Fig.5 (C)) between the means of the two test conditions, of which one, 
clonal replicate 3, was found to be significant. The erratic growth kinetics from test condition 
1 did not translate into erratic gene expression data which implies the GeNorm control 
method is providing a robust normalisation of the data. As a fractional factorial screening 
experiment would be expected to return both high and low yielding cell densities it is crucial 
that the PCR assays cannot be influenced significantly by the amount of material available. 
 
2.5 Discussion of Pilot Study Data 
The presence of TGF-β1 in test condition 1 along with the increased FGF2 
concentration led to a marked and increase in SOX-9 expression. As a known chondrogenic 
promoter and a common feature of redifferentiation protocols (Malpeli et al., 2004) the result 
is not surprising. However, it has been reported that the addition of TGF-β1during the 
expansion phase harms down stream redifferentiation potential ( R.Narcisi, 2014). If the 
addition of TGFβ1 is indeed detrimental to redifferentiation capacity then this experiment 
suggests that the cause of this is not from the downregulation of SOX-9.  
The three groups of data from the experiment; Growth kinetics, metabolic flux and 
gene expression demonstrated that the cell growth was the most erattic output variable and 
the gene expression was the most stable. Powering of the experiment can be based off any of 
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the output variables but the decision was taken to estimate an appropriate sample size based 
off the gene expression results. Reasoning for this lay in the investigators view that the 
factors the promote the maintenance of the gene profile of interest takes priority over the 
factors that affect growth rate and the related metabolic flux behaviours.  
 
3.0 Priori Power Analysis 
The principal aim of the pilot experiment was to put a range on observed effect sizes 
to inform a priori power analysis which in turn would suggest an appropriate sample size for 
the desired power. Of the two key outputs, cell number and gene expression, it was decided 
that the powering would be based off gene expression results due to the endogenous controls 
being able to minimise the effect of final cell number on the result. The qPCR data (Fig. 5 
(A, B and C)) was used to estimate the size of the effects observed from the pilot experiment 
in table 2. 
 
 
Gene 
Clonal 
Replicate 
Test Condition 1 Test Condition 2 Cohen's 
d  Mean 
(M) 
St.Dev 
(SD) 
Sample 
Size 
Mean 
(M) 
St.Dev 
(SD) 
Sample 
Size 
SOX-9 
1 735 107 3 216 45 3 6.3 
2 1069 120 2 443 27 3 7.0 
3 853 275 3 340 87 3 2.5 
SOX-6 
1 149 89 3 72 52 3 1.0 
2 256 99 2 274 49 3 0.2 
3 80 43 3 153 74 3 1.2 
SOX-5 
1 219 82 3 310 78 3 1.1 
2 275 91 2 399 9 3 1.9 
3 204 57 3 334 38 3 2.7 
 
 
 
Table 2. Effect size between the two test conditions for each clonal replicate and gene of interest 
quoted as Cohen’s D 
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An effect size above 1 is defined as a very large effect and anything 0.2 or less as 
negligible or nonexistent (S. Sawilowsky,2009). The effect sizes obtained in table 2 were 
used as a guide to estimate the sample size required for the smallest size effect of interest at a 
minimum of 80% power at the 0.05 alpha level using a power simulator.  
 
 
 
 
The power curve (Fig. 6) suggests that a sample size of one hundred and twenty 
should allow an effect size as small as 0.4 to be detected with a power of 0.9. A total sample 
size in this region was deemed to be just deliverable with the resource available and so this 
was the perspective sample size taken forward to the DOE stage. 
 
 
 
Figure 6. A priori power curve generated using G*Power 3.0.10. Plotted is total sample size 
versus power for three different effect sizes.  
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Estimating sample sizes through a pilot study, as done here, has the advantage of 
delivering robust data on which to base powering decisions when obtaining the same 
information from the literature is either not possible or problematic. Pilot studies like this also 
come attached with their own distinct disadvantages. Of chief concern is the fact that the 
factors altered to create the test condition, TGF-β1, and FGF-2, were selected based on 
literature accounts that they would induce a change. The magnitude of the change in 
transcript levels here was, on average, large; however other conditions that are to be included 
in the screening may produce a real change of a much smaller magnitude. These smaller 
changes may go undetected, and so it is noted that basing the powering decisions on this pilot 
study may come at the risk of increasing the incidence of recording a “false negative” or type 
II error.   
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4.0 Design of Experiment (DoE) – Fractional Factorial Screening Experiment 
 
4.1 Growth Rate 
The growth rate was assessed at the end of the five day culture period. Seeding efficiency 
was assumed to be 100%. The data was fed into the Design Expert™ 7.0 design matrix 
without a power transform before been subject to manual regression. Some terms not selected 
in the manual regression process were automatically included to preserve model hierarchy.  
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4.1.1  Specific Growth Rate 
 
 
 
 
 
 
Figure 7. A pareto chart showing significant factors that influence specific growth rate of clonal 
chondrocytes over a five day culture. The Bonferoni limit is the threshold for signifiacne. Lack of 
model fit was deemed not significant (Model F value = 1.39). Curvature ( the difference between 
the centre and factorial points) in the data was deemed significant (F = 15.80). 
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Figure 8. Diagnostics from the specific growth data anaysis. (A) Normal Plot of Residuals, (B) 
Residuals versus Run Order, (C) Externally studentized Residuals and (D) Leverage versus Run. 
 
 
A                                                                                                   B 
C                                                                                                  D 
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The Pareto chart (Fig.7) identifies single factors  J (Seed Density), H (EGF), F 
(PDGF-BB), D (Fibronectin), A (Glucose) and G (FGF-2) as significant contributors to the 
growth rate. Seeding density (J) appearing as the most significant single effect is perhaps 
intuitive and could be rationalised in terms of, more cells seeded at the start equals a larger 
proportion of cells successfully attaching and so more cells dividing and contributing to the 
overall population growth. Higher seeding densities have been previously touted as a method 
of achieving phenotypic stability in chondrocytes (F M Watt, 1988) however high-density 
culture can reduce the maximum achievable expansion capacity in traditional flask cultures. 
By increasing the seed density the maximum number of doublings that can be achieved 
before the confluency is reach and passaging becomes necessary is lowered. This problem 
could be mitigated by using expansion platforms that allow for the addition of more growth 
substrate during the culture period.  The three growth factors EGF (H), PDGF-BB (F) and 
FGF-2 (G) have an important role in stimulating proliferation. To best understand how to 
employ them in a financially feasible manner, first the shape of the relationship needs to be 
understood. The curvature detected Fig.7, F=15.80, p=0.0001) means additional exploration 
of the design space may be required in order to appropriately understand the relationship. 
Additionally, consideration of the contribution of the growth factors to gene expression in 
required. Fibronectin coating concentration was a significant effect and again this result 
might of been predicted on the basis that more binding protein should allow for more cell 
attachment and subsequently more actively dividing cells. The more interesting discovery is 
arguably the contribution of glucose (A) to growth rate. Higher growth rates were achieved 
when glucose (A) was present in its lowest concentration which infers high glucose 
concentrations are detrimental to the growth of clonal chondrocytes. This finding adds a 
further view to the findings of other investigators highlighted in table 1. 
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 The results obtained from the model and displayed in the Pareto chart (Fig7.) were 
subject to a number of diagnostic tests (Fig. 8) to test the credibility of the data and the 
impact of any erroneous data points on the overall output. The normal probability plot of 
residuals (Fig. 8 (A)) shows a slight “S” like character to the distribution with initial and final 
data points landing to the left and right of the fitted line, respectively. This implies the 
distribution has slightly shorter tails then may be expected from a totally normal distribution. 
It was not expected that the model would fit a normal distribution perfectly and it was 
decided the deviation from the straight line was within an acceptable limit. The residuals vs 
run order (Fig. 8 (B)) was interrogated in order to ascertain if there was any time related 
variable influencing the data. This is especially important given the difference in the time 
between sacrificing individual experiments and the potential for this to skew the data. The 
plot displays a random pattern showing that no time-dependent variable was influencing the 
output data. The externally studentized residuals plot (Fig 8. (C)) provides an easy visual 
method of identifying possible outliers in the data set. The plot identified runs 30 and 126 as 
outliers. The values entered for the runs were checked for errors or any evidence of special 
cause, but in the absence of either factor, it was concluded that the two data points just did 
not fit the model that well. Employing a power transform to try and improve model fit did not 
significantly alter the outcome regarding main effects, and so the data set was left as is.  The 
leverage versus run plot (Fig. 8 (D))  looks at the possibility that an individual design point 
can significantly influence the fit of the model. The diagnostic failed to highlight any 
individual data points that were having a disproportionate effect on the model which. The risk 
of this was lowered due to the incorporation of replicates into the design.  
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4.2 Metabolic Flux 
Glucose, glutamine, lactate and ammonia fluxes were assessed by determining total 
consumption/production at the end of the culture and relating to the final cell number in the 
same manner as previously described. The resulting data was added into the design matrix 
and a model fitted as was done for the growth rate.  
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4.2.1 Specific Glucose Consumption 
 
 
 
Figure 9. A pareto chart showing significant factors that influence specific glucouse consumption 
in chondrocytes over a five day culture. The Bonferoni limit is the threshold for significance. A 
log power transform was employed.  Model fit was deemed significant (Model F value = 19.84, 
p=<0.0001). Curvature ( the difference between the centre and factorial points) in the data was 
deemed not significant (F = 0.12). 
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Figure 10. Diagnostics from the specific growth data anaysis. (A) Normal Plot of Residuals, (B) 
Residuals versus Run Order, (C) Externally studentized Residuals and (D) Leverage versus Run. 
A                                                                                                   B 
C                                                                                                  D 
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The Pareto chart (Fig.10) for specific glucose consumption identifies single factors B 
(Glutamine), A (Glucose) and  H (EGF) as significant contributors to specific glucose 
consumption.  Glucose consumption was highest when glutamine (B) was present in its 
higher concentration which suggests restricting glutamine does not promote increased 
glucose usage. Glucose (A) was disregarded as it is both a dependent and independent 
variable in the study. EGF (H) increases specific glucose consumption, and this is sensible 
given the previously reported mitogenic activity (Fig. 7) 
The diagnostic graphs highlight some concerns with the returned data. The normal 
probability plot (A) indicates the residuals deviate from a normal distribution and that caution 
may be needed when interpreting the results. Several power transforms of the data were 
attempted in order to improve the distribution, but none were successful in doing so. The 
internally studendised residuals vs run order (Fig. 9 (B)) did not appear to show anytime 
time-related correlation, however, the externally studendised plot (Fig.9 (C)) highlighted a 
number of outliers, runs 57,58 and 69. The data for those runs was checked for error, but in 
the absence of any obvious cause of the unexpected result, it was decided to retain the values 
in the data set. 
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4.2.2 Specific Lactate Production 
 
 
Figure 11. A pareto chart showing significant factors that influence specific lactate production in 
chondrocytes over a five day culture. The Bonferoni limit is the threshold for significance. Model 
fit was deemed significant (Model F value = 12.09, p=<0.0001). Curvature ( the difference 
between the centre and factorial points) in the data was deemed to be significantt (F = 8.15). 
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Figure 12. Diagnostics from the specific growth data anaysis. (A) Normal Plot of Residuals, (B) 
Residuals versus Run Order, (C) Externally studentised Residuals and (D) Leverage versus Run. 
A                                                                                                   B 
C                                                                                                  D 
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The Pareto chart (Fig.11) for specific lactate production identifies single factors J 
(Seed Density), H (EGF), A (Glucose) as significant effects. Factor F (PDGF-BB) just fell 
short of the significance threshold.  Specific lactate production was at its highest when seed 
density (J) and EGF (H) were in their lowest experimental level. In the instance of EGF (H), 
rationalisation of the result is relatively straightforward. As EGF has mitogenic properties it 
would follow that lower concentrations may stimulate growth to a lesser extent and decrease 
the rate of glycolysis resulting in lower lactate production. Explaining why the seed density 
(J) lower experimental level yielded the higher specific production rate is harder. One 
explanation is that low seed densities could trigger changes in metabolic behaviour, possibly 
through paracrine signalling that results in inefficient glucose usage. This high lactate 
production was encountered in the previous chapter when rates of proliferation stalled. To 
date this claim is not supported by existing literature accounts.   
A power transform of the data was undertaken in order to obtain the data presented in 
figures 11 and 12, this was done due to the large range of maximum and minimum responses. 
The normal probability plot (Fig. 11 (A)) indicates the residuals largely conform to a normal 
distribution although deviation around the tails can be observed. The internally studendised 
residuals vs. run order (Fig. 11 (B)) did not appear to show anytime time-related correlation. 
The externally studendised plot (Fig.11 (C)) highlighted some clear outliers, runs 30 and 126 
and a possible outlier, run 125. As was done previously, the input value for the runs was 
inspected for input error. Removing the data points from the set did not drastically alter the 
conclusion and so they were left in. No individual data points were thought to be casting 
significant leverage on the model (Fig.11 (D)). 
 
 
 166 
 
4.2.3 Specific Glutamine Consumption 
 
 
 
Figure 13. A pareto chart showing significant factors that influence specific glutamine 
consumption in chondrocytes over a five day culture. The Bonferoni limit is the threshold for 
signifiacne. Model fit was deemed significant (Model F value = 71.34, p=<0.0001). Curvature ( 
the difference between the centre and factorial points) in the data was deemed to be significantt (F 
= 43.31). 
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Figure 14. Diagnostics from the specific growth data anaysis. (A) Normal Plot of Residuals, (B) 
Residuals versus Run Order, (C) Externally studentized Residuals and (D) Leverage versus Run. 
A                                                                                                   B 
C                                                                                                  D 
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The Pareto chart for specific glutamine consumption (Fig.13)  identified significant 
single factors effects as B (Glutamine), J (Seed Density), F (PDGF-BB), H (EGF) and D 
(Fibronectin/Adhesion Protein).  Glutamine (B) was expected to feature as a main effect 
given that it is, like glucose, also an independent variable in the experiment. Lower seed 
densities (J) favoured higher glutamine consumption in a manner not dissimilar to specific 
lactate production (Fig. 11). Lower fibronectin concentration (D) gave higher glutamine 
concentrations which is most likely linked to the seed density (J).  The lower experimental 
levels of the mitogenic growth factors  PDGF-BB (F) and EGF (H) gave the highest returned 
glutamine consumption values. A cautionary note, the true specific consumption rate of 
glutamine is probably obscured by the natural decomposition of the component in the culture 
environment (O. Palsson et al., 1990). 
A power transform of the data was undertaken in order to obtain the data presented in 
figures 13 and 14. Again this was done due to the large range of maximum and minimum 
responses. The normal probability plot (Fig. 14 (A)) indicates the normality is a reasonable 
assumption. The internally studendised residuals vs run order (Fig. 13 (B)) did not a show 
time-related correlation. The externally studendised plot (Fig.11 (C)) highlighted single clear 
outliers, run 126 a possible outlier, run 30. As was done previously, the input value for the 
runs was inspected for input error. Removing the data points from the set did not drastically 
alter the conclusion and so they were left in. Interestingly though, this is the third time run 
126 has flagged as an outlier.  No individual data points were thought to be casting 
significant leverage on the model (Fig.11 (D)). 
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4.2.4 Specific Ammonia Production 
 
 
 
Figure 15. A pareto chart showing significant factors that influence specific ammonia production 
in chondrocytes over a five day culture. The Bonferoni limit is the threshold for significance. 
Model fit was deemed significant (Model F value = 57.80, p=<0.0001). Curvature ( the difference 
between the centre and factorial points) in the data was deemed to be significantt (F =6.70). 
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Figure 16. Diagnostics from the specific growth data anaysis. (A) Normal Plot of Residuals, (B) 
Residuals versus Run Order, (C) Externally studentized Residuals and (D) Leverage versus Run. 
A                                                                                                   B 
C                                                                                                  D 
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The Pareto chart for specific ammonia production (Fig.15)  identified almost the same 
significant single factor effects as for specific glutamine consumption, namely B 
(Glutamine), J (Seed Density), F (PDGF-BB), H (EGF).  Glutamine (B) was expected and the 
higher experimental level returned the greatest production rates. This will likely be the result 
of both genuine metabolic production and spontaneous decay of glutamine in the medium (O. 
Palsson et al., 1990). Again, lower seed densities (J) favoured higher ammonia production.  
The lower experimental levels of growth factors  PDGF-BB (F) and EGF (H) gave the 
highest returned ammonia production values. Specific production of ammonia, again, is likely 
obscured by the natural decomposition of glutamine in the culture environment (O. Palsson et 
al., 1990). 
A power transform of the data was undertaken in order to obtain the data presented in 
figures 15 and 16. The normal probability plot (Fig. 16 (A)) indicates the model distribution 
is not considered entirely normal. The internally studendised residuals vs run order (Fig. 16 
(B)) did not a show time-related correlation. The externally studendised plot (Fig.16 (C)) 
highlighted a sole outlier, run 85, which was left in the data set.  No individual data points 
were thought to be casting significant leverage on the model (Fig.16 (D)). 
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4.3 Gene Expression Data 
 
              SOX-9, 6 and 5 were assessed as described previously. Individual PCR reactions 
were run in duplicate with random replicates further duplicated to check for reverse 
transcription efficiency. Copy numbers were derived from standard curves and normalised to 
the GeNorm score calculated from the endogenous reference genes, B2M, ACTB and RPL13.  
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4.3.1 SOX-9 Gene Expression 
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Figure 17. A pareto chart showing significant factors that influence SOX-9 gene expression in 
chondrocytes over a five day culture. The Bonferoni limit is the threshold for signifiacne. Model 
fit was deemed significant (Model F value = 55.8, p=<0.0001). Curvature ( the difference between 
the centre and factorial points) in the data was deemed to be significantt (F =0.04). A square root 
power transform (k=1) was employed to reduce the output range. 
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Figure 18. Diagnostics from the specific growth data anaysis. (A) Normal Plot of Residuals, (B) 
Residuals versus Run Order, (C) Externally studentized Residuals and (D) Leverage versus Run. 
A                                                                                                   B 
C                                                                                                  D 
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The Pareto chart for SOX-9 transcript expression (Fig.17)  identified that eight of the 
nine independent variables investigated showed a significant single factor effect. Only factor 
C (ITS) fell short of the error corrected significance threshold. Factors G (FGF2), E ( TGF-
β1) and A (glucose) elicited the highest level on transcript expression when present at their 
higher levels experimental whereas factors J (seed density), B (glutamine), D (Fibronectin),  
F (PDGF-BB) and H (EGF) allowed for the greatest transcript expression when present in 
their lowest experimental concentrations.  
The normal probability plot (Fig. 18 (A)) indicates the model distribution again 
deviates slightly from the straight line in a manner that suggests the data has a short tail but 
again on balance it was decided that assumption of normality was not totally unreasonable. 
The internally studendised residuals vs run order (Fig. 18 (B)) did not show time-related 
correlation. The externally studendised plot (Fig.18 (C)) highlighted no outliers and no 
individual data points were observed to be casting significant leverage on the model (Fig.18 
(D)). 
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4.3.2 SOX-6 Gene Expression 
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Figure 19. A pareto chart showing significant factors that influence SOX-6 gene expression in 
chondrocytes over a five day culture. The Bonferoni limit is the threshold for signifiacne. Model
fit was deemed significant (Model F value = 15.45, p=<0.0001). Curvature ( the difference 
between the centre and factorial points) in the data was deemed to be significantt (F =3.67).  
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Figure 20. Diagnostics from the specific growth data anaysis. (A) Normal Plot of Residuals, (B) 
Residuals versus Run Order, (C) Externally studentized Residuals and (D) Leverage versus Run. 
A                                                                                                   B 
C                                                                                                  D 
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The Pareto chart for SOX-6 transcript expression (Fig.19)  identified a sole factor, H 
(EGF) as a significant main effect, although factor B (glutamine) was close to the 
significance threshold. EGF (H) promoted the highest level of expression when present in its 
higher experimental dosage.  
The normal probability plot (Fig. 20 (A)) showed a small deviation from the 
regression line. The internally studendised residuals vs. run order (Fig. 20 (B)) did not a show 
time-related correlation. The externally studendised plot (Fig.20 (C)) highlighted no outliers 
and no individual data points were observed to be casting significant leverage on the model 
(Fig.20 (D)). 
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4.3.3 SOX-5 Gene Expression 
 
 
 
 
 
Figure 21. A pareto chart showing significant factors that influence SOX-5gene expression in 
chondrocytes over a five day culture. The Bonferoni limit is the threshold for significance. Model 
fit was deemed significant (Model F value = 55.8, p=<0.0001). Curvature ( the difference between 
the centre and factorial points) in the data was deemed to be significantt (F =0.04).  
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Figure 22. Diagnostics from the specific growth data anaysis. (A) Normal Plot of Residuals, (B) 
Residuals versus Run Order, (C) Externally studentized Residuals and (D) Leverage versus Run. 
A                                                                                                   B 
C                                                                                                  D 
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The Pareto chart for SOX-5 transcript expression (Fig.21)  identified factors, A 
(glucose), C (ITS) and G (FGF2) as significant main effects. All three of the factors promoted 
the highest level of expression when present in their higher experimental dosage.  
The normal probability plot (Fig. 22 (A)) suggests the data have short tails which is a 
feature in common between the dependent variable data. The internally studendised residuals 
vs run order (Fig. 22 (B)) did not a show time-related correlation. The externally studendised 
plot (Fig.22 (C)) highlighted a sole outlier, run 34, which was left in. No individual data 
points were observed to be casting significant leverage on the model (Fig.22 (D)). 
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5.0 One Factor Effects Discussion 
 
The fractional factorial design revealed the key single effect contributors to the 
growth rate of the clonal chondrocytes (table 4). The main positive effects were broadly 
anticipated, especially in the case of the growth factors that have previously been reported as 
mitogenic. Arguably the most interesting discovery was the result that shows high glucose 
(factor A) concentration is detrimental to the growth rate of clonal chondrocytes which adds 
favour to the low glucose argument made by other investigators (table 1). The choice, 
however, may not be straight forward when taking it account that high glucose appears to 
promote SOX-9 transcript expression. The mechanism that underpins this discovery is 
currently unknown. 
The specific metabolic fluxes for glucose, lactate, glutamine and ammonia returned 
significant single factor effects that could have been reasonably estimated using prior 
knowledge of the system. No surprising effect was or unexpected effect was uncovered. 
The data obtained from mRNA expression levels of the three genes of interest suggest 
there are a number of variables that contribute to the upregulation of transcript levels. SOX-9 
transcript levels were positively influenced by FGF-2, TGF-β1 and glucose concentration. 
The contribution from TGF-β1 to SOX-9 gene expression is consistent with earlier findings 
in the pilot study and the literature  (G. Coricor, 2016). FGF-2 contribution to SOX-9 mRNA 
expression has also been previously reported ( S. Murakami, 2000) and so the finding was not 
unexpected although the magnitude of the effect was surprising, greatly surpassing the effect 
of TGFβ1 as a SOX-9 promoter. Unexpected results arrived in the form of negative impacts 
detected. The data shows that high seeding densities and fibronectin concentrations decrease 
SOX-9 mRNA expression. The effect of fibronectin concentration on SOX-9 expression has 
 183 
 
been previously reported in the literature (Hardingham et al., 2008). The study agreed with 
the findings presented herein that lower concentrations improved SOX-9 transcript 
expression. The reason for this was attributed to lower concentrations limiting cell spreading 
which subsequently reduces the formation of actin stress filaments. This type of cytoskeleton 
modification leads to the downregulation of SOX-9. The authors of the study logically 
suggested higher cell densities combined with low fibronectin coating may further limit cell 
spreading and loss of SOX-9 expression. The results here, however, do not support high-
density cultures with respect to SOX-9 expression conservation. Furthermore, as highlighted 
earlier, high cell density limits the maximum achievable expansion factor in conventional 
culture systems (i.e., before maximum confluency is achieved), and so low seeding densities 
may have a double-edged benefit. PDGF-BB also presented as a factor that decreases SOX-9 
expression but which also boosts proliferation. Given that FGF-2 also bolsters that rate of 
proliferation and does not decrease any of the measured gene transcript outputs it may be 
worth excluding the growth factor from medium formulations purely as a cost saving. Only a 
sole factor had an impact on SOX-6 mRNA expression. EGF, already identified as positive 
factor in stimulating growth and also upregulates SOX-6 expression. No single factor was 
identified that had a negative impact on expression levels. SOX-5 transcript levels were 
predominantly affected by glucose and ITS concentrations. The findings resonate with SOX-
9 mRNA which also shows a positive relationship with glucose. Somewhat paradoxically 
though, the growth rate is adversely affected by high levels of glucose. No single factor 
displaying a negative impact was identified.  
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Output “Positive” 1 Factor Contributions “Negative” 1 Factor 
Contributions 
Growth Rate Seed Density (J), EGF (H), PDGF-
BB(F), Fibronectin (D), FGF-2 (G) 
Glucose (A) 
Specific Glucose Consumption Glutamine (B), EGF (H) Glucose (A) 
Specific Lactate Production Glucose (A) Seed Density (J), EGF (H) 
Specific Glutamine Consumption Glutamine (B) Seed Density (J),  
PDGF-BB (F), EGF (H) 
Specific Ammonia Production Glutamine (B) Seed Density (J),  
PDGF-BB (F), EGF (H) 
SOX-9 gene expression FGF-2 (G), TGF-β1 (E), 
Glucose (A) 
Seeding Density (J), Glutamine 
(B), Fibronectin (D), PDGF-BB 
(F), EGF (H) 
SOX-6 gene expression EGF (H)  
SOX-5 gene expression Glucose (A), ITS (C), FGF-2 (G)  
 
 
 
 
Table 4. Summary of all primary effects that surpass the Bonferroni correction threshold. Effects 
are divided into positive and negative contributions and are listed in order of the mangtitude of 
their contribution. “Positive” effects are defined as those that gave the highest the output response 
the when at the highestof the two experimental levels and “Negative “effects those that returned 
the highest reponse when at their lowest experimental level. 
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6.0 Two Factor Interaction Effect Discussion 
 
The most distinguishable feature of the significant interactions effects is the role of 
glucose (Table 5). Glucose interacts with other factors in such a varied manner that it makes 
the data difficult to interpret. It is difficult to say whether higher or lower levels of glucose 
would be of most benefit, so opting to keep levels at their centre point values (1g/L) would 
appear the most logical choice. The interaction effect between glucose and glutamine is 
apparent in the instance of SOX-9, and SOX-6 mRNA expression were overloading the 
culture medium with the two growth substrates contributes to downregulation of expression. 
Finally, the Glucose-PDGF-BB (A-F) interaction while bolstering growth rate had an adverse 
effect on SOX-9 expression. Since more potent promoters of proliferation like EGF have 
been identified further weight is added for the case to remove PDGF-BB from optimised 
formulations. It should be noted that because some runs of the experiment were lost not some 
two-way interactions were confounded and so potential relationships may have been missed.  
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Output Positive 2 Factor Interaction 
Contributions 
Negative 2 Factor Interaction 
Contributions 
Growth Rate Glucose - PDGF-BB (A-F) 
Glucose – EGF (A-H) 
Glucose – Seed Density (A-J) 
Glucose – Fibronectin (A-D) 
Glutamine - Fibronectin (B-D) 
Glutamine – TGFβ1 (B-E) 
Glutamine – FGF2 (B-G) 
Glucose – FGF2 (A-G) 
Glutamine – Fibronectin (B-D) 
Specific Glucose Consumption Glucose-Seed Density (A-J) Glutamine-Seed Density (B-J) 
Specific Lactate Production Glucose-Seed Density (A-J) 
Glutamine - Fibronectin (B-D) 
Glucose – FGF2 (A-G) 
Glucose – Fibronectin (A-D) 
Glucose - PDGF-BB (A-F) 
 
Specific Glutamine Consumption Glucose-Seed Density (A-J) 
Glucose – Fibronectin (A-D) 
Glutamine – TGFβ1 (B-E) 
Glucose – EGF (A-H) 
Glucose - PDGF-BB (A-F) 
ITS-Fibronectin (C-D) 
Specific Ammonia Production Glucose – Seed Density (A-J) 
Glucose – Fibronectin (A-D) 
Glucose – FGF2 (A-G) 
Glucose – Glutamine (A-B) 
Glucose - PDGF-BB (A-F) 
Glutamine - PDGF-BB (B-F) 
Glutamine-Seed Density (B-J) 
Glucose – EGF (A-H) 
Table 5. Summary of all two-factor interactions that surpass the Bonferroni correction threshold. 
Interactions are divided into positive and negative contributions and are listed in order of the 
magnitude of their contribution. “Positive” effects are defined as those that impacted the output 
the most when at the highest experimental level and “Negative “effects those that had the most 
impact when at their lowest experimental level 
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Glucose – ITS (A-C) 
 
ITS– Fibronectin (C-D) 
Fibronectin-TGFβ1 (D-E) 
SOX-9 gene expression  Glucose – PDGF-BB (A-F) 
Glucose – Glutamine (A-B) 
SOX-6 gene expression Glucose – Insulin (A-C) Glucose – Glutamine (A-B) 
Glutamine – PDGF-BB (B-F) 
SOX-5 gene expression Glucose – Insulin (A-C) 
Glucose – TGF-β1 (A-E) 
Glucose – FGF-2 (A-G) 
 
 
7.0 Chapter D Summary 
The screening of the nine candidates for effect on growth rate and SOX9,6 & 5 mRNA 
identified EGF and FGF2 as the most prolific promoters of growth and SOX-9,6 & 5 
transcript expression. The data for the effect of the nine independent variables on metabolic 
behaviour uncovered no significant relationships of interest.  
The current concern with the output data is that the model reported significant 
curvature in the majority of the outputs. Navigation of the design space using a linear model 
is not justified and so further experiments that examine the shape of the relationship are 
warranted. Further to this, the timing of the addition of mitogenic components into the 
medium is of interest. 
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CHAPTER E: TIME-DOSE STUDIES OF THE EFFECT OF FGF-2 & EGF ON 
GROWTH KINETICS. 
1.0 Introduction 
The fractional factorial experiment undertaken in Chapter C highlighted a number of 
medium components that have a direct impact on both growth kinetics and SOX gene 
expression. A drawback of factorial experiments, however, is that the predictive capability of 
the resulting model is bound by the limits of the design space. In this instance of the 
screening experiment, growth factor limits were set as zero for the lower limit and 10ng/mL 
for the upper limit. To understand the impact of increasing the dose concentration or the 
frequency of the dose, further experiments need to be undertaken. Rather than study both the 
dose-response and the time-dose response together it was envisaged that results would be 
easier to interpret by studying the two separately. The aim here was to gain understanding 
that will allow the minimum amount of growth factor to be introduced into the medium at 
time points that will allow for maximal boost in growth rates whilst maintaining SOX 
expression. 
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2.0 EGF and FGF-2 Dose-Response Studies on Growth Kinetics 
 
            The effect of varying the dose on growth rate was assessed by means of a seven-point 
concentration series. The growth factor under study was added to the chemically defined 
medium as a bolus dose. A single vial of cryopreserved clonal chondrocytes was thawed and 
expanded in a T175 over five days prior to seeding in six-well plates. The pre-expansion was 
not necessary to achieve workable cell numbers but was undertaken for continuity with 
previous experiments. Prior to seeding, six-well plates were pre-coated with 0.5µg/cm3 of 
bovine fibronectin and placed in an humidified incubator for two hours. Seven batches of 
chemically defined medium were prepared as previously described with the exception of the 
growth factor under investigation. EGF or FGF-2 was then added to give concentrations of 
100ng/mL, 80ng/mL, 60ng/mL, 40ng/mL, 20ng/mL, 10ng/mL (control) and 1ng/mL.  Clonal 
chondrocytes were seeded at density of 3000 cells/cm2 and supplied with 0.2 mL/cm2 of the 
relevant medium. Cells were cultured over five days in a humidified, 5% CO2 atmosphere 
incubator maintained at 37oC in a fed-batch scenario with respect to the medium components 
not under investigation. Sacrificial cell counts were taken at twenty-four and seventy-two 
hours to provide the growth data.   
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2.1 EGF Dose-Response Study  
 
 
 
 
  
  
Fig.1 Cumulative population doublings in response to varying the medium concentration of EGF. 1 
ng/mL (A), 20 ng/mL (B), 40 ng/mL (C), 60 ng/mL (D), 80 ng/mL (E) and 100 ng/mL (F) were 
compared to the standard dose of 10 ng/mL. Sacrificial cell counts were taken at twenty-four, 
seventy-two and one hundred and twenty hours. Error bars show standard deviation of the mean 
(n=3) 
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EGF was found to be the most mitogenic growth factor in the previous chapter. 
However, the mitogenic capacity of EGF in the clonal chondrocyte strains does not display a 
dose-response behaviour with a 1ng/mL dose found to be no more effective at stimulating 
proliferation as a 100ng/mL dose (Fig. 1). There are, however, confounding factors that cloud 
the result. The mitogenic action of EGF has previously been reported to be dependent on 
modulation of EGF receptors by dexamethasone in human diploid foreskin cells (J B Baker et 
al. 1978) and the possibility of the same relationship existing with these clonal chondrocytes 
cannot be discounted. Dexamethasone is present in the chemically defined medium in low 
concentrations (1x10-7 M) and so by increasing the level, it may be possible to observe a 
dose-response behaviour in the ranges experimented with here. Another consideration is that 
the data displayed could be considered relatively noisy and so the power to detect true change 
  
Fig.2 Specific growth rates for time 24 h – 120 h (A) and 24 h – 72 h (B) obtained for the various 
EGF concentrations. No statistically significant difference between the control of 10ng/mL and any 
concentration of EGF used for either of the growth rates. Errors bars show standard deviation of the 
mean (n=3)  
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is low. The final consideration is the ill-defined half-life of the EGF protein under culture 
conditions. The twenty-four feed experiments in Chapter B demonstrated increased exposure 
to fresh medium promoted proliferation and one explanation to this is that the half-life of 
EGF in culture is less than twenty-four hours. In this case, increasing the concentration would 
have little effect on a five-day fed-batch culture. This could be commercially significant as 
adding frequent low doses of growth factor may be economically advantageous over adding a 
large bolus dose.    
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2.2 FGF-2 Dose-Response Study 
 
 
  
  
  
Fig.3 Cumulative population doublings in response to varying the medium concentration of FGF-2. 
1 ng/mL (A), 20 ng/mL (B), 40 ng/mL (C), 60 ng/mL (D), 80 ng/mL (E) and 100 ng/mL (F) were 
compared to the standard dose of 10 ng/mL. Sacrificial cell counts were taken at twenty-four, 
seventy-two and one hundred and twenty hours. Error bars show standard deviation of the mean 
(n=3) 
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FGF-2 has previously been previously cited as a growth-promoting agent in auricular 
chondrocytes (J D Richmon et al., 2005), a redifferentiation promoting agent when used in 
high doses (E W Mandl et al., 2002) and as a direct intervention agent in the repair of hyaline 
cartilage defects (P Cuevas et al., 1989). The data collected in this experiment failed to 
identify a statistically significant dose-response relationship however, visually it would 
appear there is weak evidence for the existence of a dose-response that may warrant further 
investigation. Compared to the 10 ng/mL control there is a small increase in population 
doublings and growth rate with each subsequent increase in FGF-2 concentration. A one way 
ANOVA was performed which showed a difference between the means existed. Post hoc T-
tests were used to try and establish where the significance existed. P values were less than 
0.05 for 80 ng/mL and 100 ng/mL but did not meet significance criteria after a conservative 
  
Fig.4 Specific growth rates for time 24 h – 120 h (A) and 24 h – 72 h (B) obtained for the various 
FGF-2 concentrations. A one-way ANOVA was performed and indicated there was a significant 
difference between the means but post hoc t tests did not show significance after the Bonferroni 
correction was applied. Errors bars show standard deviation of the mean (n=3)  
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family-wise error correction was applied. One observation of interest is that the 1ng/mL dose 
performed at least as well as the 60 ng/mL dose and a similar result was observed in the EGF 
dose series. The reason for this is not immediately clear. Possible explanation may be an 
experimental error incurred during dose preparation; the 1 ng/mL dose preparation entailed 
pipetting a small volume of 0.2 µl into a large 30 mL volume. It is possible improper mixing 
may have effectively resulted in no growth factor been presented to the cells. Such a scenario 
lays way to a more perplexing conundrum however, why would no FGF-2/EGF yield a better 
proliferative response than the standard l0ng/mL supplemented medium. Further 
experimental investigation will help answer this question by the inclusion of a 0ng/ml 
control. The experiment is further hampered by low statistical power, the result of financial 
constraints, which leaves us in the situation where a mitogenic FGF-2 dose response is 
suspected but cannot be robustly backed up the data. 
Establishing a dose-response relationship represents one important step towards an 
informed feeding regime but equally as important is to try and time resolve the addition of the 
key medium components. As demonstrated in chapter B, the time at which a feed takes place 
has a profound impact on the growth kinetics and being able to replace only components of 
the medium that are required for optimal growth at a given time would be advantageous.    
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3.0 EGF and FGF-2 Time- Dose Impact on Growth Kinetics and SOX Expression Study 
 
To assess how the timing of the addition of EGF and FGF-2 to the culture medium 
impacted growth kinetics and SOX-9,6 & 5 gene expression a time-dose study was 
conducted. A vial of cryopreserved clonal chondrocytes was thawed and pre-expanded under 
defined conditions for five days to achieve sufficient cell numbers. Harvested cells were 
seeded into six-well plates that had been precoated with bovine fibronectin (1µg/cm2). Plates 
were seeded and labelled according to the frequency of feeding. Wells were supplemented 
with specific medium for the growth factor under investigation. Medium for the EGF study 
lacked EGF, which was introduced separately at the required time. The EGF medium still 
contained all other components of the chemically defined medium including FGF-2. The 
FGF-2 medium contained the base level of EGF with the FGF-2 introduced as stipulated by 
the experimental condition. Twenty-four-hour dose feeding commenced with the addition of 
the specified growth factor at time 24h and not time zero, this was the case for the forty-
eight-hour dose feed as well. The rationale behind delaying the growth factor addition was to 
assess the impact of immediately exposing the cell strain to the growth factor, as is the case in 
the fed-batch scenario. A negative experiment was also set up to investigate the observation 
from the dose-response study that suggested little to or no EGF/FGF-2 could be as beneficial 
as higher dosages.  
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3.1 EGF Time- Dose Studies on Growth Kinetics 
 
 
 
 
 
Fig.5 Cumulative population doublings in response to addition of EGF (20 ng/mL) at twenty-four 
hour intervals (A) and forty-eight hour intervals (B). An EGF negative experiment was run (C). 
Graph D displays all data points on the same axis for comparison. Sacrificial cell counts were taken 
at twenty-four, seventy-two and one hundred and twenty hours in order to obtain the growth curve. 
Error bars show standard deviation of the mean (n=3) 
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The results from the EGF dose frequency experiment were unexpected and 
perplexing. On the one hand, the data demonstrated that the addition of EGF at twenty-four-
hour intervals yielded the greatest growth rate of all the test conditions and a statistically 
significant difference over the fed-batch approach. On the other hand, the absence of EGF 
from the culture medium resulted in a similar growth rate to that of the twenty-four group. 
The result was also found to be statistically significant when compared to the fed-batch 
group. Keeping the two facts separate for now makes interpreting the results simpler. Cell 
growth appears to respond positively but weakly to the addition of EGF into the culture 
medium. Interrogation of the fed-batch growth curve gives way to a common feature of 
growth curves obtained from fed-batch experiments, that is, the growth curve tends to plateau 
around the seventy-two-hour mark, which can be averted by addition of EGF at twenty-four 
 
Fig.6 Specific growth rates for the EGF dose frequency experiment over one hundred and twenty 
hours (A) and over seventy-two hours (B).  A one-way ANOVA was performed and indicated there 
was a significant difference between the means. Post hoc t tests showed significance between the 
24h dose and EGF negative compared to Fed batch after the Bonferroni correction was applied. 
Errors bars show standard deviation of the mean (n=3)  
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or forty-eight-hour intervals. This observation occurs without the culture reaching 
confluency. A possible explanation for this, as stated earlier, is the half-life of EGF under 
culture condition is in the region of seventy-two hours. Further, the data suggests there is not 
only any advantage to be had in terms of stimulating proliferation from exposing the clonal 
strains to EGF at the time of seeding but doing so actually harms the initial growth phase. 
The proliferation in the “EGF negative” experiment is driven by the FGF-2 and the PDGF-
BB, both weaker mitogens than EGF as inferred by the DOE. The growth curve again shows 
a plateau in growth in a manner that is almost identical to that of the fed-batch experiment. 
This would again point to the stability of the FGF-2 and PDGF-BB proteins in the culture 
medium beyond seventy-two hours. Explaining why the EGF negative experiment resulted in 
the greatest number of population doubling at seventy-two hours requires a greater degree of 
speculation. The result could be due to a two or more factor interaction, likely between the 
other growth factors that give rise to a “too many cooks” type scenario during the initial 
stages of the culture. This appears to be the first time this behaviour has been reported but to 
understand the mechanism further studies would be required. It should be noted that the two-
factor interactions between EGF and FGF-2 and PDGF-BB were aliased in factorial 
experiment and so if such an interaction did exist, has been missed.  
Growth factors are generally expensive, delaying the addition of EGF until a later 
stage in the culture may be considered efficient or least that is until you consider the result of 
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the EGF negative experiment. The impact of dose frequency on SOX expression needs to be 
first assessed before concluding how EGF is best employed in a defined culture medium.  
 
3.2 EGF Time- Dose Studies on SOX Gene Expression 
Clonal chondrocytes from all four experimental conditions were harvested after one 
hundred and twenty hours. Half of the harvested cells were suspended in RNA Cell Protect™ 
and stored at -20oC until the RNA extraction step was ready to be performed. RT-qPCR was 
performed to determine gene transcript levels of SOX-9, 6 & 5. Gene expression levels from 
the EGF negative, EGF 24h and EGF 48h were compared to the Fed-batch results. 
 
 
 
 
Fig.5 SOX-9 mRNA transcript copies from clonal chondrocytes expanded over five days with 
different EGF interventions imposed. mRNA transcripts were determined using RT-qPCR.. The 
differences between the groups were not found to be significant (p=0.05) using a one-way 
ANOVA. Error bars show standard deviation of the mean (n=3)  
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Fig.6 SOX-6 mRNA transcript copies from clonal chondrocytes expanded over five days with 
different EGF interventions imposed. mRNA transcripts were determined using RT-qPCR.. The 
differences between the groups were not found to be significant (p=0.05) using a one-way 
ANOVA. Error bars show standard deviation of the mean (n=3)  
 
 
Fig.7 SOX-5 mRNA transcript copies from clonal chondrocytes expanded over five days with 
different EGF interventions imposed. mRNA transcripts were determined using RT-qPCR.. The 
differences between the groups were not found to be significant (p=0.05) using a one-way 
ANOVA. Error bars show standard deviation of the mean (n=3)  
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SOX-9 gene expression was not found to be positively affected by the presence of 
EGF to a statistically significant extent like in the screening experiment detailed in chapter B. 
The data in Fig.5 shows the EGF fed-batch group resulting in a higher mean average of SOX-
9 transcripts when compared to the EGF negative group. SOX-9 expression was at the 
highest level in cultures exposed to twenty-four hour EGF dosing. The variability observed 
creates a high degree of noise, which makes statistical comparison difficult at low replicate 
number, a feature shared with the kinetic growth experiments too. Like SOX-9, SOX-6 was 
shown to be upregulated by EGF. The data here again was not found to be statistically 
significant however; Fig. 6 shows a weak correlation in that the addition of EGF at time zero 
and more frequent EGF addition leads to higher SOX-6 transcripts. The screening experiment 
was designed to be more statistically powerful than the experiment here which is likely why 
the difference between means fall just outside of the significance threshold here. EGF was 
not found to make any difference to SOX-5 expression in the screening experiment and here 
the data is absent any form evidence to the contrary.  
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3.3 FGF-2 Time- Dose Studies on Growth Kinetics 
 
 
 
 
 
  
  
Fig. 8 Cumulative population doublings in response to addition of FGF-2 (20 ng/mL) at twenty-
four hour intervals (A) and forty-eight hour intervals (B). An FGF-2 negative experiment was run 
(C). Graph D displays all data points on the same axis for comparison. Sacrificial cell counts were 
taken at twenty-four, seventy-two and one hundred and twenty hours in order to obtain the growth 
curve. Error bars show standard deviation of the mean (n=3) 
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                The impact of varying the frequency of FGF-2 addition into the culture was 
assessed in much the same manner as EGF. The differences between mean growth rates of 
the different experimental groups did not show statistical significance.  A weak visual trend 
provides some points for debate. Firstly, the more frequent addition of FGF-2 the higher the 
growth rate over a one hundred and twenty hour period. The screening experiment showed 
that FGF-2 had the weakest mitogenic effect of the growth factors and so, as the power in this 
experiment is lower, it follows that the relationship that forms here falls short of the 
significance threshold. The experiment here requires more replicates to increase the power in 
order to confirm the effect is genuine. The next point of interest is the apparent stability of 
FGF-2 versus EGF under culture conditions. The FGF-2 negative group contains EGF and it 
follows that the EGF and PDGF-BB are driving the proliferation up until seventy-two hours 
where the population starts to decline. The FGF-2 fed-batch control continues to support 
  
Fig.9 Specific growth rates from the FGF-2 dose frequency experiment over one hundred and 
twenty hours (A) and over seventy-two hours (B).  A one-way ANOVA was performed and 
indicated there was no significant difference between the means at one-hundred and twenty hours 
or seventy-two hours. Error bars show standard deviation of the mean (n=3)  
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proliferation after this time.  A similar trend was observed in the EGF-dose frequency 
experiment, which adds weight to the notion that the EGF protein has a half-life of seventy-
two hours under the culture conditions reported here. The most striking feature of the data 
collected here is the difference in growth observed between the FGF-2 negative group and the 
FGF-2 fed-batch group. Similar to the EGF experiment it appears withholding the addition of 
FGF-2 at the start of the culture results in enhanced proliferation in the first seventy-two 
hours of culture. Like with EGF, the impact of varying the frequency of  FGF-2 dosing on 
SOX-9,6 and 5 gene expression was assessed.  The two proteins, EGF and FGF-2, have a 
negative interaction effect in early stage culture, which is overcome as time increases.  
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3.4 FGF-2 Time- Dose Studies on SOX Gene Expression 
Clonal chondrocytes from all four experimental conditions were harvested after one 
hundred and twenty hours. Half of the harvested cells were suspended in RNA Cell Protect™ 
and stored at -20oC until the RNA extraction step was ready to be performed. RT-qPCR was 
performed to determine gene transcript levels of SOX-9, 6 & 5. Gene expression levels from 
the FGF-2 negative, FGF-2 24h and FGF-2 48h were compared to the fed-batch results. 
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Fig.5 SOX-9 mRNA transcript copies from clonal chondrocytes expanded over five days with 
different frequency FGF-2 interventions imposed. mRNA transcripts were determined using RT-
qPCR.. The differences between the mean of the fed-batch and the three groups were all found to 
be significant using student’s t test (equal variance) with a Bonferroni error correction (p=0.016). 
Error bars show standard deviation of the mean (n=3)  
 
 
Fig.5 SOX-6 mRNA transcript copies from clonal chondrocytes expanded over five days with 
different frequency FGF-2 interventions imposed. mRNA transcripts were determined using RT-
qPCR.. The differences between the mean of the fed-batch and the three groups were all found to 
be significant using student’s t test (equal variance) with a Bonferroni error correction (p=0.016). 
Error bars show standard deviation of the mean (n=3)  
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The gene expression analysis allowed for some interesting observations. SOX-9 
mRNA transcripts were positively impacted by the presence of FGF-2 which is not surprising 
since the screening experiment and existing literature both demonstrate this ( E Mandl et al. 
2002). Interestingly, to achieve a significant increase in SOX-9 transcripts the data suggests 
that FGF-2 has to be present at the time of inoculation, twenty-four hour and forty-eight 
dosing was not found to be any more effective at upregulating expression than the FGF-2 
negative group.  
The data from SOX-6 expression shows a clear trend of transcript decline with 
increased dosing of FGF-2. This negative impact of FGF-2 on SOX-6 mRNA expression was 
 
Fig.5 SOX-5 mRNA transcript copies from clonal chondrocytes expanded over five days with 
different frequency FGF-2 interventions imposed. mRNA transcripts were determined using RT-
qPCR.. The differences between the mean of the fed-batch and the FGF-2 negative and 24h groups 
were found to be significant using student’s t test (equal variance) with a Bonferroni error 
correction (p=0.016). Error bars show standard deviation of the mean (n=3)  
 
 209 
 
observed during screening but the relationship was disregarded because it failed to pass the 
Bonferroni corrected threshold for significance. This highlights a drawback of using this 
method of familywise error correction in that when large comparisons are made the risk of a 
type II error or false negative increases. The absolute impact of harming SOX-6 expression 
with the use of FGF-2 is not known. Whilst upregulation of SOX-9,6 & 5 is thought to be one 
of the keys to allowing the efficient induction of mature cartilage, the exact impact of SOX-
6’s contribution to this paradigm is not fully understood.  
 The returned data from the SOX-5 gene expression returned the most interesting 
feature and perhaps a cautionary lesson regarding the interpretation of data from DoE models 
alone. The data here showed that the presence of FGF-2 in the fed-batch culture significantly 
increased transcript expression over the negative group, which is shown clearly in the 
screening data. What might not be expected from the screening data is that continued addition 
of FGF-2 to the system has the opposite effect and actually reduces SOX-5 transcript levels 
to below that recorded for the FGF-2 negative group. A limitation of the DoE model is that 
the relationships are, at best, only valid within the fixed limits of the design space and that 
extrapolating trends beyond the original parameters is not sensible.    
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4.0 Summary of Chapter E 
The data from the dose and dose frequency experimenting revealed in more detail, the 
role of EGF and FGF-2 in the expansion of the clonal chondrocytes. The question of how 
best to employ the proteins in a manner that best promotes growth, maintenance of SOX 
expression and cost efficiency is not straightforward. The experiments suggest that the 
introduction of both EGF and FGF-2 at the time of cell seeding is detrimental, resulting in an 
increased lag phase that can be mitigated in late-stage culture with increased frequency of 
EGF dosing. FGF-2 did not show the same level of mitogenic activity as EGF here but is a 
clear driver of SOX gene regulation in these clonal strains. Key points are summarised in 
Table 1. 
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 Dose Response on 
Growth Kinetics 
Dose Frequency 
Response on Growth 
Kinetics 
Dose Frequency 
Response on SOX-9, 6 
& 5 
 
EGF 
 
No significant difference 
between 1 ng/mL – 100 
ng/mL range when added 
as a bolus dose at time of 
seeding. 
24h dosing of EGF 
significantly increased growth 
rate over the 120h culture 
compared to batch fed. 
Growth rate over 72h was not 
significant however; the EGF 
negative group was 
significantly different when 
compared to the fed-batch 
group. 
 
 
No significant effect detected 
 
 
FGF-2 
 
ANOVA identified a 
significant difference 
between the means but 
error corrected post hoc 
testing failed to pinpoint 
between which groups the 
difference existed. 
Strongest difference was 
between the 10ng/ml and 
100ng/mL. Weak evidence 
of a dose-response effect. 
 
 
No beneficial effect of 
increasing the frequency of 
FGF-2 dosing on growth rate 
within the 120h observation 
window. A larger dose at time 
of inoculation may harbour an 
advantage. 
 
Varied effects observed: 
SOX-9 – most effective when 
introduced at time of seeding.  
SOX-6 – Negatively affects 
expression. The more 
frequent the dose the greater 
the negative effect.  
SOX-5 – Evidence increased 
dosing negatively affects 
expression. Fed-batch 
superior to the EGF negative 
group.  
 
 
 
Table 1. Summary of keys points from the experiments in this chapter  
 212 
 
 The points summarised allow a speculative partially optimal nutritional regime to be 
proposed. A basal medium containing all the components in their nominal concentrations 
minus EGF and FGF-2 should be formulated. FGF-2 should be introduced as a single bolus 
dose at the time of cell seeding, evidence for the concentration of the dose is inconclusive but 
a 100ng/mL may be superior to 10ng/mL with respect to enhancing growth rate. EGF should 
be withheld from the culture until the seventy-two hour time point where doses of 10ng/mL 
should be added every twenty-four hours.  
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CHAPTER F: GENERAL CONCLUSIONS AND FUTURE WORK  
 
1.0 General Summary 
The growth of clonal chondrocytes is serum dependent, and the rate of proliferation 
enhanced by increasing the frequency at which the serum-containing medium is exchanged. 
Clonal chondrocytes cultured over a five-day period achieved, on average, a specific growth 
rate of 0.75 day-1 when the serum-containing medium was replaced every twenty-four hours. 
In contrast to this clonal chondrocytes cultured under the same conditions achieved averaged 
specific growth rates of 0.63 day-1 and 0.47 day-1 when the frequency of medium exchange 
was reduced to seventy-two hours and one hundred and twenty hours, respectively. 
Metabolite analysis of the medium showed that glucose and glutamine depletion were not a 
rate-limiting factor. Additionally, lactate and ammonia build up were not thought to be 
significant contributors to the different growth rates obtained. Metabolite analysis did reveal 
that specific glucose consumption to specific lactate production was higher in the one 
hundred and twenty hour and seventy-two-hour feed frequency experiments compared to the 
batch. The results suggest that in the event of the depletion of mitogenic signalling factors 
present in the serum the cells turn over glucose in an inefficient manner. Serum containing 
medium was demonstrated to adversely affect expression of SOX-9 transcripts when 
compared to a defined medium. This is largely thought to be a consequence of the 
Fibronectin that is present in unknown concentrations in the serum. Interestingly, despite the 
significant difference in SOX-9 transcripts between the serum and defined cultures, SOX-6 
and 5 transcripts were similar suggesting their expression is not tied to same fate as that of 
SOX-9. 
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The defined medium formulation, adapted from existing literature accounts, yielded averaged 
specific growth rates of  0.17, 0.44 and 0.60 day-1 for the batch fed, seventy-two hour and 
twenty-four-hour feed frequency experiments, respectively. The growth rates obtained from 
the defined medium were inferior to those obtained from using the serum-containing 
medium. Unlike the serum experiments, there was no obvious pattern in metabolic behaviour 
with regard to the glucose to lactate conversion ratio. Absolute flux rates in some instances 
were over an order of magnitude higher than those seen in the equivalent serum experiments. 
It became apparent the defined medium was sub-optimal for the expansion of clonal 
chondrocytes although, as already eluded to, SOX-9 transcript expression was better 
sustained in the defined medium. The defined medium used a tightly controlled amount of 
fibronectin which was thought, based on the literature, to be the major contributor to this 
observation. Finally, a cost comparison of the serum containing medium and the defined 
medium as used in the experiments that the defined culture route cost is approximately nine 
times greater. The cost is largely attributable to the fibronectin, FGF-2, EGF, and PDGF-BB.  
The two-level fractional factorial-designed experiment, employed to understand the 
effect of nine independent variables on growth rate, metabolic flux, and SOX gene 
expression, returned both expected and unexpected results. The growth rate was primarily 
driven by the mitogens EGF, PDGF-BB and FGF-2. Additionally higher seeding densities 
and fibronectin concentrations contributed to improved growth rates. The higher level of 
glucose was found to be detrimental to the growth rate and so lower glucose concentrations 
of approximately 0.5g/L (2.75mM) are recommended if the focus is on optimising growth 
rate. The metabolic fluxes for glucose, lactate, glutamine and ammonia were determined as a 
function of the nine candidates. None of the returned data sets provided any major insight 
into the metabolicbehaviour of the clonal chondrocytes; this may be due to the effect size 
been too small to detect at the power level of the experiment. Further, none of the metabolic 
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fluxes presented themselves as possible surrogate markers for the conventional SOX quality 
markers determined by RT-qPCR. Expression of the master chondrogenic promoter gene 
SOX-9 was affected by nearly all variables in the culture system. The literature suggested 
that the primary reason behind loss of SOX-9 expression was through the formation of actin 
stress filament formation (A Woods et al., 2005) which occurs during cell spreading which, 
in turn, is linked to fibronectin and seed density concentrations. The findings here agree that 
lower concentrations 0.5µg/cm2 of fibronectin promote higher transcript expression however 
the same is not true of high seed densities, which, have been suggested as a method of 
reducing cell spreading. The highest SOX-9 expression was obtained with a seed density of 
1500 cells/cm2. The magnitude of the seed density effect on SOX-9 expression was found to 
be in the region of approximately double of that observed for the effect of fibronectin 
concentration on transcript expression. The seed density effect was also found to be roughly 
proportional to the chondrogenic rescuer TGF-β1which elicited the highest transcript 
expression response at its higher level of 10ng/mL. Weighing up the cost-benefit of TGF-β1, 
a reasonable conclusion would be to remove it from the expansion medium. FGF-2 was 
determined to be the strongest promoter of SOX-9 transcript expression which is consistent 
with the literature (S Murkakami et al., 2000) although was found to be only weakly 
mitogenic relative to EGF and PDGF-BB. The use of FGF-2 can serve to counteract the 
negative effect on SOX-9 expression associated with higher seed densities while benefiting 
from the boost in growth rate observed in high-density cultures. SOX-6 expression was 
predominately driven by EGF, which was also identified as one of the more potent mitogens. 
Additionally, recombinant EGF is relatively cheap and so its use in the culture of clonal 
chondrocytes is recommended. A significant two-way interaction between glucose and ITS 
was recorded with the positive effect obtained when both factors were at their higher levels of 
1g/L and 20ml/L. It was noted that the single effects were not significant which clouds if this 
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is a genuine two-factor interaction. With that said, the same interaction was recorded for 
SOX-5 transcript expression, along with significant effects for both glucose and ITS.  The 
conclusion then is that the expression of both SOX-6 and 5 can be enhanced using glucose 
and ITS concentrations of 1g/L and 20ml/L, respectively. This also hints that SOX-6 and 5 
transcript expression may be linked to glucose metabolism pathways. 
A further problem at this stage is the uncertainty of the shape of many of the 
relationships. As the experiment was only conducted at two levels and significant curvature 
was often detected the effect of altering dosages between the levels is not well understood, 
furthermore, nothing as of yet is known about extending doses beyond the highest level of the 
design. This was addressed by investigating the effect of two factors on growth rate further. 
FGF-2 and EGF were chosen based on the rationale that they, between them, are potent 
promoters of SOX-9 and 6 as well as being significant mitogens. A noted weakness of the 
fractional factorial design was that a number of runs were lost due to assay failure resulting in 
the loss of orthogonality in the design. Consequently, the power to resolve some two-factor 
interactions were lost. 
To understand the effect of concentration of both growth factors on growth rate 
beyond the two levels a seven stage concentration series was employed.  EGF did not affect 
growth rate in a dose-dependent manner when added as a single bolus dose at the start of the 
culture, with the five-day growth rate obtained from using a 100ng/mL been comparable to 
1ng/mL dose. The growth rate as measured from 24h to 72h showed an overall higher rate of 
growth was achieved earlier in the culture hinting that lack of dose-response maybe owed, at 
least in part, to a short half-life of the EGF protein (Adrian J L Clark, 1985). FGF-2, in 
contrast, did show a dose-response pattern in both 72h and 120h growth rates although. A one 
way ANOVA suggested the difference in obtained growth rates across the concentrations was 
significant although post hoc testing failed to pinpoint exactly where the significance lay. It is 
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proposed that FGF-2 is more stable under culture conditions which is also supported by the 
literature (G Chen et al., 2013) and so, as a result, persists longer. Previous data suggested 
FGF-2 to be a weaker mitogen so again the issue of protein stability and half-life is a 
plausible explanation. One observation of note was the surprising effect of 1ng/mL compared 
to higher concentrations, especially on the 72h growth rate. The lower level of the fractional 
factorial experiment for the growth factors was set at zero. Inefficient or incomplete mixing 
of the 1ng/mL dose may have led the effective concentration to be zero. It was suspected that 
maybe a two-factor interaction between the growth factors existed that adversely affected 
growth rate that could have been missed due to the incomplete design of the previous 
experiment.  
A time-dose experiment was set up to study the effect of introducing the recombinant 
proteins at specific time points as oppose to bolus dosing on growth rate and SOX-9,6 and 5 
gene expression. Twenty-four-hour dosing of EGF (20ng/mL) significantly increased the 
five-day specific growth rate compared to a single bolus dose. Interestingly, however, so too 
did the EGF negative control in both five day and seventy-two-hour specific growth rates. 
The results suggest that EGF does have a profound effect on proliferation but its effect can be 
hindered by its relatively short half-life in culture (Adrian J L Clark, 1985). Furthermore, 
there is evidence now of at least a two-factor interaction between EGF and FGF-2 that results 
in an extended lag phase. The SOX transcript expression results showed no benefit of 
increased EGF-dosing compared to bolus dosing and again it is proposed this is due to the 
protein half-life. Timed dosing of FGF-2 revealed that SOX-9 transcript expression was 
significantly higher when the protein was introduced at the time of seeding, with twenty-four 
hour and forty-eight-hour dosing not significantly more effective at upregulating transcript 
expression than the FGF-2 negative control.  SOX-6 transcript expression, as discovered 
earlier, is decreased by FGF-2 addition in a dose-dependent fashion with the lowest average 
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transcript expression recorded in the twenty-four-hour dose group. SOX-5 transcript 
expression is best served with using a bolus dose at the time of seeding, however, continued 
dosing appears to be detrimental to expression with the lowest number of transcripts counted 
in the twenty-four-hour dose group.  
The data returned here reinforces the earlier point that culture parameters that promote 
proliferation can be counter to the conditions that promote SOX gene expression profiles 
meaning the ideal culture conditions are a trade-off between the two. It should be noted 
though that no absolute threshold for SOX transcript expression that translates directly to an 
efficient expression of the in vivo chondrogenic phenotype was established here. A great deal 
of further work is required in order to provide a comprehensive culture regime. The role of 
PDGF-BB dosing as of yet remains unexplored along with the role of pH in the culture 
system. Outside of the parameters explored here, a great number of other factors and quality 
markers that were not investigated due to cost constraints remain of high interest. Factors that 
could replace the use of growth factors are of the highest priority, namely oxygen tension, 
due to the potential for achieving similar physiological effects without the high cost and 
possible manufacturing variation.  
 
2.0 General Conclusion 
Recommending a comprehensive medium composition is problematic as it would 
appear factors that favour proliferation do not necessarily favour upregulation of the 
chondrogenic promoter genes.  A careful balance needs to be considered as to which to give 
priority to. With the evidence collected in this thesis, a cautionary approach to an optimised 
and part modulated nutritional regime is presented in table 1. 
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Component Amount Rationale 
Glucose 5.5 mM A trade-off aimed at enhancing proliferation while promoting 
SOX-9 transcript expression. 
 
                Glutamine 
 
5mM 
Higher glutamine levels were associated with decreased 
SOX-9 expression and increased ammonia production. The 
latter may be relieved by switching to a stabilised form of 
glutamine. 
 
ITS 
 
20 mL/L 
Higher concentrations of ITS supplement did not affect 
proliferation or metabolic behaviour but was associated with 
enhanced SOX-5 transcript expression. 
 
Seed Density 
 
1500 cell/cm2 
The lower seed densities returned higher SOX-9 transcript 
levels but slower growth rates. The slower growth rates 
maybe acceptable when weighed against the higher 
expansion factor obtainable when using low seed densities. 
 
Fibronectin 
 
0.5µg/cm2 
The lower concentration of Fibronectin will significantly 
reduce the cost of a run and promote SOX-9 transcript 
expression. This will come at the tradeoff of decreased 
growth rate. 
 
 
 
FGF-2 
 
 
20ng/mL added as a single 
dose at the start of the 
culture 
FGF-2 significantly increased SOX-9 and 5 transcript 
expression when introduced as a single dose at the start of the 
culture. Further dosing did not affect growth rate or SOX 
transcript expression and was detrimental to SOX-6 transcript 
expression. Larger doses appears to correlate with increased 
growth rate but the effect on the gene transcript remains 
unknown. 
 
EGF 
20 ng/mL introduced 
every twenty-four hours 
Timed dosing of EGF did not affect SOX-9,6 and 5 transcript 
expression over five-day culture but did increase growth rate 
Table 1. Conclusions drawn from the various studies in this thesis on how to maximise growth 
rate whilst promoting the expression of SOX-9,6 and 5. 
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after the initial forty-eight 
hours of culture 
with the contradiction that this only happened when added 
when the addition to the culture was separated from FGF-2. 
 
 
PDGF-BB 
 
10ng/mL added as a single 
dose at the start of the 
culture 
The dose-response range and the effect of time dosing was 
not investigated. The potential interaction with EGF and 
FGF-2 remains of high interest. The recommended dose is 
based on the observed mitogenic effect derived from the 
study in chapter C. 
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3.0 Future Work 
A few notable limitations of the studies in this thesis mean the recommendations 
listed in table 1 need further investigation to increase their robustness. The resolution of the 
effects of timed dosing of PDGF-BB on the outputs, the possible interaction EGF and FGF-2, 
as well as its dose-response ceiling all require investigation. Factors not included in the 
studies offer a source of further optimisations; Oxygen tension and pH are of particular note. 
The literature provides a strong pretext for the role of oxygen tension in promoting SOX-9 
gene expression and would likely prove to be more cost-effective than using recombinant 
proteins. Studying cell behaviour under true hypoxic conditions is difficult to achieve and 
requires specialised workstations in order to avoid reintroducing an oxygenated atmosphere 
when manipulating the cells or administrating diagnostic tests. The work here used bovine 
chondrocytes due to their accessibility compared to non arthritic human chondrocytes. The 
consequence of this is that a bridging study between human and bovine cells would be 
needed if that results here are to be confidently accepted as valid when advancing 
manufacturing understanding in human chondrocyte lines. A significant but unexplored 
avenue here is the use of serum in the explant and cryopreservation stages. The bulk of the 
later work was conducted using serum-free medium but the long-term impact on the cells 
from the initial exposure to serum remains unknown. To this end, developing a serum-free 
explant and cryopreservation protocol would be an avenue worth exploring.  
 The cell culture period was limited to five days in the bulk of the experiments here 
which means the conclusions drawn here are only valid for that duration. A cell culture 
platform that uses technology that negates the need for passaging, such as packed bed or 
microcarrier, would be an ideal platform to further test the robustness of the 
recommendations here. On top of this, a platform that allows more substrate to be added 
would open up bioreactor runs well beyond five days. How the growth kinetics and cell 
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phenotype alter beyond five-day culture is an important question in need of addressing. 
Further work is needed on assessing the “quality” of the cells. The studies here were limited 
to only three gene transcripts but in reality, these alone are not enough to sufficiently define 
the term “quality”. Building a robust quality specification may require additional gene 
transcript profiling as well as extensive cell proteome profiling, cell subpopulation tracking 
via cell surface antigen and genetic stability via karyotypic analysis and telomerase 
expression. Once the theoretical quality specification and cells can be confidently replicated 
progression to in vitro models and eventually patient trials.  The greater challenge, however, 
lies in the development of novel measurement systems that can capture the appropriate 
metric, either directly or indirectly through surrogate markers, in a low-cost high throughput 
fashion. The lack of appropriate measurements systems is a major rate-limiting step in the 
progression of the commericailastion of all indication “more-than-minimally manipulated” 
cell therapies. It’s envisaged that the majority of the limitations discussed here would need to 
be addressed in order to provide a total manufacturing platform for the cost-efficient and 
effective expansion of clinically relevant chondrocytes. 
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